

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48192 A1

- (51) International Patent Classification⁷: **C12N 15/11**
- (21) International Application Number: PCT/NZ00/00256
- (22) International Filing Date:
21 December 2000 (21.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/171,678 23 December 1999 (23.12.1999) US
09/724,864 28 November 2000 (28.11.2000) US
- (71) Applicant (for all designated States except US): **GENESIS RESEARCH & DEVELOPMENT CORPORATION LIMITED** [NZ/NZ]; 1 Fox Street, Parnell, Auckland (NZ).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **WATSON, James, D.** [NZ/NZ]; 769 Riddell Road, St Heliers, Auckland (NZ). **MURISON, James, Greg** [NZ/NZ]; 24 Calgary Street, Sandringham, Auckland (NZ).
- (74) Agents: **HAWKINS, Michael, Howard** et al.; Baldwin Shelston Waters, P.O. Box 852, Wellington (NZ).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: POLYNUCLEOTIDES, POLYPEPTIDES EXPRESSED BY THE POLYNUCLEOTIDES AND METHODS FOR THEIR USE

(57) Abstract: Novel polynucleotides including partial and extended sequences, and open reading frames, are provided, together with probes and primers, DNA constructs comprising the polynucleotides, biological materials and organisms incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for using the polynucleotides and polypeptides.



WO 01/48192 A1

POLYNUCLEOTIDES, POLYPEPTIDES EXPRESSED BY THE POLYNUCLEOTIDES AND METHODS FOR THEIR USE

5 Technical Field of the Invention

 This invention relates to polynucleotides believed to be novel, including partial, extended and full length sequences, as well as probes and primers, genetic constructs comprising the polynucleotides, biological materials incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for
10 using the polynucleotides and polypeptides.

Background of the Invention

 Sequencing of the genomes, or portions of the genomes, of numerous biological materials, including humans, animals, microorganisms and various
15 plant varieties, has been and is being carried out on a large scale. Polynucleotides identified using sequencing techniques may be partial or full-length genes, and may contain open reading frames, or portions of open reading frames, that encode polypeptides. Putative polypeptides may be determined based on polynucleotide sequences. The sequencing data relating to polynucleotides thus represents
20 valuable and useful information.

 Polynucleotides may be analyzed for various degrees of novelty by comparing identified sequences to sequences published in various public domain databases, such as EMBL. Newly identified polynucleotides and putative polypeptides may also be compared to polynucleotides and polypeptides
25 contained in public domain information to ascertain homology to known polynucleotides and polypeptides. In this way, the degree of similarity, identity or homology of polynucleotides and polypeptides of unknown function may be determined relative to polynucleotides and polypeptides having known functions.

 Information relating to the sequences of isolated polynucleotides may be
30 used in a variety of ways. Specified polynucleotides having a particular sequence may be isolated, or synthesized, for use in *in vivo* or *in vitro* experimentation as

probes or primers. Alternatively, collections of sequences of isolated polynucleotides may be stored using magnetic or optical storage medium, and analyzed or manipulated using computer hardware and software, as well as other types of tools.

5

Summary of the Invention

The present invention relates to polynucleotide sequences identified in the attached Sequence Listing as SEQ ID NOS: 1-35, variants of those sequences, extended sequences comprising the sequences set out in SEQ ID NOS: 1-35 and
10 their variants, probes and primers corresponding to the sequences set out in SEQ ID NOS: 1-35 and their variants, polynucleotides comprising at least a specified number of contiguous residues of any of the polynucleotides identified as SEQ ID NOS: 1-35 (x-mers), and extended sequences comprising portions of the sequences set out in SEQ ID NOS: 1-35, all of which are referred to herein,
15 collectively, as “polynucleotides of the present invention.”

The polynucleotide sequences identified as SEQ ID NOS: 1-35 were derived from mammalian sources, namely, from mouse airways induced eosinophilia, rat dermal papilla and mouse stromal cells. Some of the polynucleotides of the present invention are “partial” sequences, in that they do
20 not represent a full-length gene encoding a full-length polypeptide. Such partial sequences may be extended by further analyzing and sequencing the EST clones from which the sequences were obtained, or by analyzing and sequencing various DNA libraries (e.g. cDNA or genomic) using primers and/or probes and well known hybridization and/or PCR techniques. The partial sequences identified as
25 SEQ ID NOS: 1-35 may thus be extended until an open reading frame encoding a polypeptide, a full-length polynucleotide and/or gene capable of expressing a polypeptide, or another useful portion of the genome is identified. Such extended sequences, including full-length polynucleotides and genes, are described as “corresponding to” a sequence identified as one of the sequences of SEQ ID NOS:
30 1-35 or a variant thereof, or a portion of one of the sequences of SEQ ID NOS: 1-35 or a variant thereof, when the extended polynucleotide comprises an identified

sequence or its variant, or an identified contiguous portion (x-mer) of one of the sequences of SEQ ID NOS: 1-35 or a variant thereof.

The polynucleotides identified as SEQ ID NOS: 1-35 were isolated from mouse and rat cDNA clones and represent sequences that are expressed in the tissue from which the cDNA was prepared. The sequence information may be used to isolate or synthesize expressible DNA molecules, such as open reading frames or full-length genes, that can then be used as expressible or otherwise functional DNA in transgenic mammals and other organisms. Similarly, RNA sequences, reverse sequences, complementary sequences, anti-sense sequences and the like, corresponding to the polynucleotides of the present invention, may be routinely ascertained and obtained using the cDNA sequences identified as SEQ ID NOS: 1-35.

In a first aspect, the present invention provides isolated polynucleotide sequences comprising a polynucleotide selected from the group consisting of: (a) sequences recited in SEQ ID NO: 1-35; (b) complements of the sequences recited in SEQ ID NO: 1-35; (c) reverse complements of the sequences recited in SEQ ID NO: 1-35; (d) reverse sequences of the sequences recited in SEQ ID NO: 1-35; (e) sequences having either 40%, 60%, 75% or 90% identical nucleotides, as defined herein, to a sequence of (a) – (d); probes and primers corresponding to the sequences set out in SEQ ID NO: 1-35; polynucleotides comprising at least a specified number of contiguous residues of any of the polynucleotides identified as SEQ ID NO: 1-35; and extended sequences comprising portions of the sequences set out in SEQ ID NO: 1-35; all of which are referred to herein as “polynucleotides of the present invention”. The present invention also provides isolated polypeptide sequences identified in the attached Sequence Listing as SEQ ID NO: 36-65; polypeptide variants of those sequences; and polypeptides comprising the isolated polypeptide sequences and variants of those sequences.

In another aspect, the present invention provides genetic constructs comprising a polynucleotide of the present invention, either alone, or in combination with one or more additional polynucleotides of the present invention,

or in combination with one or more known polynucleotides, together with cells and target organisms comprising such constructs.

The polynucleotides identified as SEQ ID NOS: 1-35 may contain open reading frames ("ORFs") or partial open reading frames encoding polypeptides. Additionally, open reading frames encoding polypeptides may be identified in extended or full-length sequences corresponding to the sequences set out as SEQ ID NOS: 1-35. Open reading frames may be identified using techniques that are well known in the art. These techniques include, for example, analysis for the location of known start and stop codons, most likely reading frame identification based on codon frequencies, etc. Suitable tools and software for ORF analysis are available, for example, on the Internet at <http://www.ncbi.nlm.nih.gov/gorf/gorf.html>. Open reading frames and portions of open reading frames may be identified in the polynucleotides of the present invention. Once a partial open reading frame is identified, the polynucleotide may be extended in the area of the partial open reading frame using techniques that are well known in the art until the polynucleotide for the full open reading frame is identified. Thus, polynucleotides and open reading frames encoding polypeptides may be identified using the polynucleotides of the present invention.

Once open reading frames are identified in the polynucleotides of the present invention, the open reading frames may be isolated and/or synthesized. Expressible DNA constructs may then be constructed that comprise the open reading frames and suitable promoters, initiators, terminators, etc., which are well known in the art. Such DNA constructs may be introduced into a host cell to express the polypeptide encoded by the open reading frame. Suitable host cells may include various prokaryotic and eukaryotic cells.

Polypeptides encoded by the polynucleotides of the present invention may be expressed and used in various assays to determine their biological activity. Such polypeptides may be used to raise antibodies, to isolate corresponding interacting proteins or other compounds, and to quantitatively determine levels of interacting proteins or other compounds.

In another aspect, the present invention provides isolated polypeptides encoded, or partially encoded, by the above polynucleotides. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins, wherein the amino acid residues are linked by covalent peptide bonds. The term "polypeptide encoded by a polynucleotide" as used herein, includes polypeptides encoded by a polynucleotide that comprises an isolated polynucleotide sequence or variant provided herein. Polypeptides of the present invention may be naturally purified products, or may be produced partially or wholly using recombinant techniques. Such polypeptides may be glycosylated with bacterial, fungal, mammalian or other eukaryotic carbohydrates or may be non-glycosylated. In specific embodiments, the inventive polypeptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 36-65.

Polypeptides of the present invention may be produced recombinantly by inserting a polynucleotide sequence that encodes the polypeptide into a genetic construct and expressing the polypeptide in an appropriate host. Any of a variety of genetic constructs known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with a genetic construct containing a polynucleotide that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, and higher eukaryotic cells. Preferably, the host cells employed are *Escherichia coli*, insect, yeast, or a mammalian cell line such as COS or CHO. The polynucleotide sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof.

In a related aspect, polypeptides are provided that comprise at least a functional portion of a polypeptide having an amino acid sequence encoded by a polynucleotide of the present invention. As used herein, the "functional portion" of a polypeptide is that portion which contains the active site essential for affecting the function of the polypeptide, for example, the portion of the molecule that is capable of binding one or more reactants. The active site may be made up

of separate portions present on one or more polypeptide chains and will generally exhibit high binding affinity.

Functional portions of a polypeptide may be identified by first preparing fragments of the polypeptide by either chemical or enzymatic digestion of the polypeptide, or by mutation analysis of the polynucleotide that encodes the polypeptide and subsequent expression of the resulting mutant polypeptides. The polypeptide fragments or mutant polypeptides are then tested to determine which portions retain biological activity, using, for example, the representative assays provided below.

Portions and other variants of the inventive polypeptides may also be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2154, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems, Inc. (Foster City, California), and may be operated according to the manufacturer's instructions. Variants of a native polypeptide may be prepared using standard mutagenesis techniques, such as oligonucleotide-directed, site-specific mutagenesis (Kunkel, *Proc. Natl. Acad. Sci. USA* 82:488-492, 1985). Sections of polynucleotide sequence may also be removed using standard techniques to permit preparation of truncated polypeptides.

In general, the polypeptides disclosed herein are prepared in an isolated, substantially pure, form. Preferably, the polypeptides are at least about 80% pure, more preferably at least about 90% pure, and most preferably at least about 99% pure. In certain embodiments, described in detail below, the isolated polypeptides are incorporated into pharmaceutical compositions or vaccines.

The present invention also contemplates methods for modulating the polynucleotide and/or polypeptide content and composition of an organism, such methods involving stably incorporating into the genome of the organism a construct containing DNA of the present invention. In one embodiment, the target
5 organism is a mammal, preferably a human, for example for human gene therapy. In a related aspect, a method for producing an organism having an altered genotype or phenotype is provided, the method comprising transforming a cell with a DNA construct of the present invention to provide a transgenic cell, and cultivating the transgenic cell under conditions conducive to regeneration and
10 mature organism growth.

The isolated polynucleotides of the present invention have utility in genome mapping, in physical mapping, and in positional cloning of genes. Additionally, the polynucleotide sequences identified as SEQ ID NOS: 1-35 and their variants may be used to design oligonucleotide probes and primers.
15 Oligonucleotide probes and primers have sequences that are substantially complementary to the polynucleotide of interest over a certain portion of the polynucleotide. Oligonucleotide probes designed using the polynucleotides of the present invention may be used to detect the presence and examine the expression patterns of genes in any organism having sufficiently similar DNA and RNA
20 sequences in their cells using techniques that are well known in the art, such as slot blot DNA hybridization techniques. Oligonucleotide primers designed using the polynucleotides of the present invention may be used for PCR amplifications. Oligonucleotide probes and primers designed using the polynucleotides of the present invention may also be used in connection with various microarray
25 technologies, including the microarray technology of Affymetrix (Santa Clara, CA).

The polynucleotides of the present invention may also be used to tag or identify an organism or reproductive material therefrom. Such tagging may be accomplished, for example, by stably introducing a non-disruptive non-functional
30 heterologous polynucleotide identifier into an organism, the polynucleotide comprising one of the polynucleotides of the present invention.

Detailed Description

Polynucleotides were isolated by high throughput sequencing of cDNA libraries prepared from mouse airway-induced eosinophilia, rat dermal papilla and mouse stromal cells as described below, in Example 1. Isolated polynucleotides of the present invention include the polynucleotides identified as SEQ ID NOS: 1-35; isolated polynucleotides comprising a polynucleotide sequence selected from the group consisting of SEQ ID NOS: 1-35; isolated polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of the polynucleotides identified as SEQ ID NOS: 1-35; polynucleotides complementary to any of the above polynucleotides; anti-sense sequences corresponding to any of the above polynucleotides; and variants of any of the above polynucleotides, as that term is described in this specification. The present invention also provides isolated polypeptide sequences identified in the attached Sequence Listing as SEQ ID NO: 36-65; polypeptide variants of those sequences; and polypeptides comprising the isolated polypeptide sequences and variants of those sequences.

The correspondence of isolated polynucleotides encoding isolated polypeptides of the present invention, and the functionality of the polypeptides, are shown, below, in Table 1.

Table 1

SEQ ID NO Poly-nucleotides	SEQ ID NO Poly-peptides	Activity Category	Functionality
1	36	Secretory molecule	Hypothetical 131.1 kDa protein
2	37	Secretory molecule/cytokine/cell signaling	ZCYTO7 belongs to a family of IL-17-related cytokines differing in patterns of expression and proinflammatory responses that may be transduced through a cognate set of cell surface receptors. IL-17 is a T cell-derived cytokine that may play an important role in the initiation or maintenance of the proinflammatory response. Whereas expression of IL-17 is restricted to activated T cells, the IL-17 receptor is found to be

			widely expressed, a finding consistent with the pleiotropic activities of IL-17.
3	38	Secretory molecule	Novel
4	39	Receptor/cytokine/ cell signaling	Tumor endothelial marker 1 precursor
5	40	Secretory molecule	ERO1-L (ERO1-like protein) is involved in oxidative endoplasmic reticulum (ER) protein folding in mammalian cells. Oxidizing conditions must be maintained in the ER to allow the formation of disulfide bonds in secretory proteins. A family of conserved genes, termed ERO for ER oxidoreductins, plays a key role in this process. ERO1-L is a type II integral membrane protein.
6	41	Secretory molecule	Novel
7	42	Receptor/transcription factor	EMR2 is an EGF-like module that is part of the epidermal growth factor (EGF)-TM7 proteins, which also include EMR1, (EGF-like molecule containing mucin-like hormone receptor 1) F4/80, and CD97. These proteins constitute a recently defined class B GPCR subfamily and are predominantly expressed on leukocytes. These molecules possess N-terminal EGF-like domains coupled to a seven-span transmembrane (7TM) moiety via a mucin-like spacer domain. EMR2 contains a total of five tandem EGF-like domains and expresses similar protein isoforms consisting of various numbers of EGF-like domains as a result of alternative RNA splicing. EMR2 share many characteristics with CD97, including highly homologous EGF-like domains and identical gene organization, indicating that both genes are the products of a recent gene duplication event. Both EMR2 and CD97 are highly expressed in immune tissues; however, unlike

			CD97, which is ubiquitously expressed in most cell types, EMR2 expression is restricted to monocytes, macrophages
8	43	Secretory molecule/ cell structure/motility, extracellular matrix	Bone/cartilage proteoglycan I (BGN) is also known as biglycan or PG-S1. BGN is found in the extracellular matrices of several connective tissues, especially in articular cartilages. The two glycosaminoglycan chains attached to BGN can be either chondroitin sulfate or dermatan sulfate. BGN belongs to the small interstitial proteoglycans family. BGN is a small leucine-rich proteoglycan and is a nonfibrillar extracellular matrix component with functions that include the positive regulation of bone formation. It is synthesized as a precursor with an NH(2)-terminal propeptide that is cleaved to yield the mature form found in vertebrate tissues. Bone morphogenetic protein-1 (BMP-1) cleaves proBGN at a single site, removing the propeptide and producing BGN. Soluble BGN purified from rat thymic myoid cells had hemopoietic activity capable of inducing preferential growth and differentiation of monocytic lineage cells from various hemopoietic sources, including brain microglial cells. The haemopoietic BGN plays an important role in generating brain-specific circumstances for development of microglial/monocytic cells
9	44	Secretory molecule	Tubulointerstitial nephritis antigen (TIN-ag) is a basement membrane glycoprotein reactive with autoantibodies in some forms of immunologically mediated human tubulointerstitial nephritis. TIN1 and TIN2 are alternatively spliced products of the TIN-Ag gene. The

			open reading frames of TIN1 and TIN2 indicates the presence of a signal peptide and putative pre-propeptide and both forms contain putative calcium-binding sites. TIN1 additionally contains a characteristic laminin-like epidermal growth factor (EGF) motif and significant homology within the carboxy terminus with the cysteine proteinase family of enzymes. The EGF motif bears important similarities in the positions of cysteines with two motifs in the propeptide of von Willebrand factor. The EGF motif and part of the region that is homologous with the cysteine proteinase family are removed from the TIN2 cDNA. The rest of the TIN1 and TIN2 sequences are identical. TIN-ag is expressed mainly in the kidney and in the intestinal epithelium.
10		Receptor-like molecule	Novel
11	45	Secretory molecule/ gene/protein expression, RNA synthesis, transcription factors	Toso is a cell surface, specific regulator of Fas-induced apoptosis in T cells. Fas is a surface receptor that can transmit signals for apoptosis. Toso is expressed in lymphoid cells and expression is enhanced after cell-specific activation processes in T cells. Toso appeared limited to inhibition of apoptosis mediated by members of the TNF receptor family and was capable of inhibiting T cell self-killing induced by TCR activation processes that up-regulate Fas ligand. Toso inhibits caspase-8 processing, the most upstream caspase activity in Fas-mediated signaling, potentially through activation of cFLIP. Toso therefore serves as a novel regulator of Fas-mediated apoptosis and may act as a regulator of cell fate in T cells and

			other hematopoietic lineages.
12	46	Secretory molecule/ gene/protein expression, RNA synthesis, transcription factors	<p>Surface glycoprotein CD59 is a phosphatidyl-inositol-glycan-anchored glycoprotein involved in T-cell activation and restriction of complement-mediated lysis. It is also known as protectin, and is ubiquitously expressed on benign and malignant cells. CD59 inhibits complement (C)-mediated lysis of target cells by preventing the formation of the membrane attack complex, in the terminal step of C-activation. Recent experimental evidence demonstrates that CD59 is the main restriction factor of C-mediated lysis of malignant cells of different histotypes. Additionally, a soluble form of CD59, that retains its anchoring ability and functional properties, has been identified in body fluids and in culture supernatants of different malignant cells. CD59 may protect neoplastic cells from C-mediated lysis, contributing to their escape from innate C-control and to tumor progression. The expression of CD59 by neoplastic cells may contribute to impair the therapeutic efficacy of C-activating monoclonal antibodies (mAb) directed to tumor-associated antigens. CD59 can be utilized to improve the therapeutic efficacy of clinical approaches of humoral immunotherapy with C-activating mAb in human malignancies.</p>
13	47	Secretory molecules/cell or organism defense, homeostasis, detoxification	<p>Cytochrome B561 (cyb561) is a secretory vesicle-specific electron transport protein unique to neuroendocrine secretory vesicles. It binds two heme groups non-covalently and is an integral membrane protein. It acts as an electron channel and mediates</p>

			equilibration of ascorbate-semidehydroascorbate inside the secretory vesicle with the ascorbate redox pair in the cytoplasm. The role for this function is to regenerate ascorbate inside the secretory vesicle for use by monooxygenases. The secretory vesicles contain catecholamines and amidated peptides. Cyb561 belongs to the eukaryotic b561 family.
14	48	Secretory molecule	Novel
15	49	Receptor-like molecule/ gene or protein expression, RNA synthesis, transcription factor	High affinity immunoglobulin epsilon receptor beta-subunit (FCER1) is also known as IgE Fc receptor, beta-subunit, FCER1b or FCE1b. FCER1 binds to the Fc region of immunoglobulins epsilon and is a high affinity receptor. FCER1 plays a role in initiating the allergic response where binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators, such as histamine. FCER1 is responsible for the manifestations of allergy and induces the secretion of important lymphokines. It functions as a tetramer consisting of an alpha chain, a beta chain, and two disulfide-linked gamma chains and is an integral membrane protein. Variants of the FCER1B gene have been identified, which are associated with an increased risk of developing atopy and bronchial asthma. Atopic dermatitis is a common skin disease frequently associated with allergic disorders such as allergic rhinitis and asthma.
16	50	Receptor-like molecule	Hypothetical 10.3 kDa protein
17	51	Secretory molecule/antigen processing	Lysosomal thiol reductase IP30 catalyzes disulfide bond reduction both <i>in vitro</i> and <i>in vivo</i> and is optimally active at acidic pH. IP30

			is important in disulfide bond reduction of proteins delivered to MHC class II-containing compartments and consequently in antigen processing. IP30 can be mediated by multiple lysosomal proteases. Proteins internalized into the endocytic pathway are usually degraded. Efficient proteolysis requires denaturation, induced by acidic conditions within lysosomes, and reduction of inter- and intrachain disulfide bonds. The active site, determined by mutagenesis, consists of a pair of cysteine residues separated by two amino acids, similar to other enzymes of the thioredoxin family.
18		Receptor-like molecule	RNA binding protein.
19	52	Secretory molecule/cellular	Notch4-like protein (ZNEU1) is part of the NOTCH4 family that encodes receptors responsible for cell fate decisions during development. These Notch receptors and their ligands, Delta and Jagged, have been implicated in several diseases. When truncated, constitutively active mutant forms of the Notch receptor appear to be involved in T-cell leukemia, mammary carcinomas and a tumorous germline phenotype. Notch4 genes are expressed specifically in endothelial cells.
20	53	Secretory molecule	Novel
21	54	Secretory molecule/transporter	Serotransferrin (siderophilin) (Tf) or beta-1-metal binding globulin is part of the transferrin family. Transferrins are iron binding transport proteins which can bind two atoms of ferric iron in association with the binding of an anion, usually bicarbonate. Tf is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and

			utilization. Serum transferrin also has a further role in stimulating cell proliferation. Tf gene expression is modulated by vitamin A, testosterone, and peptide hormones.
22	55	Secretory molecule/ gene or protein expression, RNA synthesis, transcription factor	Insulin-like growth factor binding protein 5 protease (IGFBP-5) modulates the effects of insulin growth factors (IGFs) on cells. IGFBP-5 is synthesized by smooth muscle cells and binds to the extracellular matrix. It is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs. IGFBP-5 protease belongs to a family of serine-metallo proteases.
23	56	Secretory molecule/cellular development	Major epididymis-specific protein E4 is also known as epididymal protein BE-20. It belongs to WAP-type 'four-disulfide core' family and plays a role in the maturation of spermatozoa during its movement through the epididymis and the capacity of sperm to fertilize ova. Expression of E4 was located to the epithelial cells of the cauda epididymis and proximal segment of the ductus deferens by in situ hybridization. No expression was found in sections of the corpus and caput epididymis, testis, and liver.
24		Secretory molecule/cell signaling	TNFR-related death receptor-6 DR6 contains an extracellular region containing varying numbers of cysteine-rich domains and an intracellular region that contains the death domain. Death receptors are activated in a ligand-dependent or independent manner and transduce apoptotic signals via their respective intracellular death domains.
25	57	Receptor-like molecule	Novel

26	58	Secretory molecule/regulation	Channel inducing factor precursor (CHIF) or corticosteroid-induced protein induces a potassium channel when expressed in <i>Xenopus</i> oocytes and activates endogenous oocyte transport proteins. It is a type I membrane protein selectively present in the distal parts of the nephron (medullary and papillary collecting ducts and end portions of cortical collecting tubule) and in the epithelial cells of the distal colon. No expression is found in renal proximal tubule, loop of Henle and distal tubule, proximal colon, small intestine, lung, choroid plexus, salivary glands, or brain. CHIF belongs to the ATP1G1 /PLM / Mat-8 family and exhibits significant homologies with proteins that are putatively regulatory (phospholemman, gamma-subunit of Na(+)-K(+)-ATPase, Mat-8).
27	59	Secretory molecule	Hepatocellular carcinoma-associated antigen 112.
28	60	Receptor-like molecule/homeostasis	Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is a major receptor for hyaluronan (HA) on the lymph vessel wall molecule that binds both soluble and immobilized HA. LYVE-1 plays a role in the control of the HA pathway. The extracellular matrix glycosaminoglycan hyaluronan (HA) is an abundant component of skin and mesenchymal tissues where it facilitates cell migration during wound healing, inflammation, and embryonic morphogenesis. Both during normal tissue homeostasis and particularly after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver. LYVE-1 is similar to the

			CD44 HA receptor, but in contrast to CD44, LYVE-1 colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels.
29	61	Receptor-like molecule/cell signaling	G protein-coupled receptor GPR35 is an integral membrane protein that belongs to family 1 of G-protein coupled receptors (GPCR). The GPCR family shares a structural motif of seven transmembrane segments with large numbers of conserved residues in those regions.
30	62	Receptor-like molecule	Tumor-associated glycoprotein E4 is also known as Taa1 or Tage4 and belongs to the immunoglobulin superfamily. This family contains cell adhesion molecules which have wide-ranging functions and mediate a variety of homotypic and heterotypic cellular interactions playing a general role in cell surface recognition. The Tage4 gene product is closely related to the hepatocellular carcinoma antigen TuAg.1. Tage4 is a glycoprotein expressed at the surface of colon carcinoma cell lines, but at a very low level in normal adult colon and lung tissue and not in normal tissues tested.
31	63	Secretory molecule	Hypothetical 28.6 kDa protein is also known as plunc, for palate, lung, and nasal epithelium clone. Expression of plunc is associated with the palate, nasal septum, and nasal conchae. It is also expressed strongly in the trachea and bronchi of the adult lung. No significant homologies with known genes were observed at the nucleotide level and limited amino acid homology with two salivary gland-specific proteins was noted. The amino acid sequence revealed consensus sequences for N-glycosylation, protein kinase C and

			casein kinase phosphorylation, as well as a leucine zipper. In addition, an unique amino acid sequence repeat sequence is located near the amino-terminal portion of the protein.
32	64	Secretory molecule	<p>Claudin-18 (Cldn18) is a component of tight junction (TJ) strands and belongs to the claudin family. Claudins are integral membrane protein component of tight junctions, a structure controlling cell-to-cell adhesion and, consequently, regulating paracellular and transcellular transport of solutes across epithelia and endothelia. The claudin family also includes occludin and 17 other distinct claudins. Claudin family members are tetra-span transmembrane proteins that are localized in cell-specific TJs. In multicellular organisms, various compositionally distinct fluid compartments are established by epithelial and endothelial cellular sheets. For these cells to function as barriers, TJs are considered to create a primary barrier for the diffusion of solutes through the paracellular pathway. Claudins are therefore responsible for TJ-specific obliteration of the intercellular space.</p>
33		Secretory molecule	<p>Glutamine repeat protein 1 (GRP-1) contains simple tandem repeats of the trinucleotide sequence CAG that encode homopolymeric stretches of glutamine. Although polyglutamine has been identified in diverse proteins, it is present predominantly in transcription factors. Greater than two-thirds of GRP-1 are only two amino acids, namely glutamine (50%) and histidine (18%). There are four polyglutamine motifs interspersed with histidine-rich regions. There is also a putative</p>

			<p>nuclear localization signal flanked by sites for possible serine phosphorylation. GRP-1 mRNA was expressed constitutively in some macrophage cell lines and B and T cell lines. Interferon-gamma or lipopolysaccharide augmented GRP-1 mRNA expression in the mouse macrophage cell line ANA-1. Because polyglutamine motifs can cause protein oligomerization and can function as transcriptional activation domains, GRP-1 is a transcription factor associated with interferon-gamma- or lipopolysaccharide-induced activation of macrophages.</p>
34		Secretory molecule	Alpha-1 collagen
35	65	Receptor-like molecule/Cell signaling	<p>Gdnf family receptor alpha 4, transmembrane isoform (Gfra4) is a members of the Gdnf protein family that signal through receptors consisting of a GPI-linked GFRalpha subunit and the transmembrane tyrosine kinase Ret. Gfra4 is expressed in many tissues, including nervous system, in which intron retention leads to a putative intracellular or secreted GFRalpha4 protein. Efficient splicing occurs only in thyroid, parathyroid, and pituitary and less in adrenal glands. A splice form that leads to a GPI-linked GFRalpha4 receptor is expressed in juvenile thyroid and parathyroid glands. In newborn and mature thyroid as well as in parathyroid and pituitary glands major transcripts encode for a putative transmembrane isoform of GFRalpha4. GFRalpha4 expression may restrict the inherited cancer syndrome multiple endocrine neoplasia type 2, associated with mutations in RET, to these cells.</p>

The word "polynucleotide(s)," as used herein, means a polymeric collection of nucleotides and includes DNA and corresponding RNA molecules and both single and double stranded molecules, including HnRNA and mRNA molecules, sense and anti-sense strands of DNA and RNA molecules, and comprehends cDNA, genomic DNA, and wholly or partially synthesized polynucleotides. An HnRNA molecule contains introns and "corresponds to" a DNA molecule in a generally one-to-one manner. An mRNA molecule "corresponds to" an HnRNA and DNA molecule from which the introns have been excised. A polynucleotide of the present invention may be an entire gene, or any portion thereof. A gene is a DNA sequence which codes for a functional protein or RNA molecule. Operable anti-sense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all operable anti-sense fragments. Anti-sense polynucleotides and techniques involving anti-sense polynucleotides are well known in the art and are described, for example, in Robinson-Benion *et al.*, *Methods in Enzymol.* 254(23): 363-375, 1995 and Kawasaki *et al.*, *Artific. Organs* 20 (8): 836-848, 1996.

Identification of genomic DNA and heterologous species DNA can be accomplished by standard DNA/DNA hybridization techniques, under appropriately stringent conditions, using all or part of a cDNA sequence as a probe to screen an appropriate library. Alternatively, PCR techniques using oligonucleotide primers that are designed based on known genomic DNA, cDNA and/or protein sequences can be used to amplify and identify genomic and cDNA sequences. Synthetic DNA corresponding to the identified sequences and variants may be produced by conventional synthesis methods. All of the polynucleotides described herein are isolated and purified, as those terms are commonly used in the art.

As used herein, the term "oligonucleotide" refers to a relatively short segment of a polynucleotide sequence, generally comprising between 6 and 60 nucleotides, and comprehends both probes for use in hybridization assays and primers for use in the amplification of DNA by polymerase chain reaction.

As used herein, the term "x-mer," with reference to a specific value of "x," refers to a polynucleotide comprising at least a specified number ("x") of contiguous residues of any of the polynucleotides identified as SEQ ID NOS: 1-35. The value of x may be from about 20 to about 600, depending upon the specific sequence.

As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins, wherein amino acid residues are linked by covalent peptide bonds. Polypeptides of the present invention may be naturally purified products, or may be produced partially or wholly using recombinant techniques. Such polypeptides may be glycosylated with mammalian or other eukaryotic carbohydrates or may be non-glycosylated.

According to one embodiment, "variants" of the polynucleotides of the present invention, including the polynucleotides set forth as SEQ ID NOS: 1-35, as that term is used herein, comprehends polynucleotides producing an "E" value of 0.01 or less, as described below, or having at least a specified percentage identity to a polynucleotide of the present invention, as described below. Polynucleotide variants of the present invention may be naturally occurring allelic variants, or non-naturally occurring variants.

Polynucleotide and polypeptide sequences may be aligned, and percentages of identical residues in a specified region may be determined against another polynucleotide or polypeptide, using computer algorithms that are publicly available. Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms. Polynucleotides may also be analyzed using the BLASTX algorithm, which compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database. The percentage identity of polypeptide sequences may be examined using the BLASTP algorithm. The BLASTN, BLASTP and BLASTX algorithms are available on the NCBI anonymous FTP server (<ftp://ncbi.nlm.nih.gov>) under /blast/executables/ and are available from the National Center for Biotechnology Information (NCBI), National Library of Medicine, Building 38A, Room 8N805, Bethesda, MD 20894,

USA. The BLASTN algorithm Version 2.0.11 [Jan-20-2000], set to the parameters described below, is preferred for use in the determination of polynucleotide variants according to the present invention. The BLASTP algorithm, set to the parameters described below, is preferred for use in the determination of polypeptide variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN, BLASTP and BLASTX, is described at NCBI's website at URL <http://www.ncbi.nlm.nih.gov/BLAST/newblast.html> and in the publication of Altschul, *et al.*, *Nucleic Acids Res.* 25: 3389-3402, 1997.

The FASTA and FASTX algorithms are available on the Internet at the ftp site <ftp://ftp.virginia.edu/pub/>, and from the University of Virginia by contacting David Hudson, Vice Provost for Research, University of Virginia, P.O. Box 9025, Charlottesville, VA 22906-9025, USA. The FASTA algorithm, set to the default parameters described in the documentation and distributed with the algorithm, may be used in the determination of polynucleotide variants. The readme files for FASTA and FASTX Version 1.0x that are distributed with the algorithms describe the use of the algorithms and describe the default parameters. The use of the FASTA and FASTX algorithms is described in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444-2448, 1988; and Pearson, *Methods in Enzymol.* 183:63-98, 1990. The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity: Unix running command with default parameter values thus: `blastall -p blastn -d embldb -e 10 -G 0 -E 0 -r 1 -v 30 -b 30 -i queryseq -o results`; the Parameters are : -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -r Reward for a nucleotide match (BLASTN only) [Integer]; -v Number of one-line descriptions (V) [Integer]; -b Number of alignments to show (B) [Integer]; -i Query File [File In]; -o BLAST report Output File [File Out] Optional.

The "hits" to one or more database sequences by a queried sequence produced by BLASTN or FASTA or a similar algorithm align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally represent an overlap over only a fraction of the sequence length of the queried sequence.

The BLASTN and FASTA algorithms produce "Expect" values for alignments. The Expect value (E) indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database, such as the preferred EMBL database, indicates true similarity. For example, an E value of 0.1 assigned to a hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a similar score simply by chance. The aligned and matched portions of the sequences, then, have a probability of 90% of being the same by this criterion. For sequences having an E value of 0.01 or less over aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN or FASTA algorithm.

According to one embodiment, "variant" polynucleotides, with reference to each of the polynucleotides of the present invention, preferably comprise sequences having the same number or fewer nucleic acids than each of the polynucleotides of the present invention and producing an E value of 0.01 or less when compared to the polynucleotide of the present invention. That is, a variant polynucleotide is any sequence that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters. According to a preferred embodiment, a variant polynucleotide is a sequence having the same number or fewer nucleic acids than a polynucleotide of the present invention that has at least a 99% probability of being the same as the

polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters.

Alternatively, variant polynucleotides of the present invention may comprise a sequence exhibiting at least about 40%, more preferably at least about 5 60%, more preferably yet at least about 75%, and most preferably at least about 90% similarity to a polynucleotide of the present invention, determined as described below. The percentage similarity is determined by aligning sequences using one of the BLASTN or FASTA algorithms, set at default parameters, and identifying the number of identical nucleic acids over the best aligned portion; 10 dividing the number of identical nucleic acids by the total number of nucleic acids of the polynucleotide of the present invention; and then multiplying by 100 to determine the percentage similarity. For example, a polynucleotide of the present invention having 220 nucleic acids has a hit to a polynucleotide sequence in the EMBL database having 520 nucleic acids over a stretch of 23 nucleotides in the 15 alignment produced by the BLASTN algorithm using the default parameters. The 23 nucleotide hit includes 21 identical nucleotides, one gap and one different nucleotide. The percentage similarity of the polynucleotide of the present invention to the hit in the EMBL library is thus $21/220$ times 100, or 9.5%. The polynucleotide sequence in the EMBL database is thus not a variant of a 20 polynucleotide of the present invention.

Alternatively, variant polynucleotides of the present invention hybridize to a polynucleotide of the present invention under stringent hybridization conditions. As used herein, "stringent conditions" mean prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65°C, 6X SSC, 0.2% SDS overnight; followed by two 25 washes of 30 minutes each in 1X SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65°C.

The present invention also encompasses allelic variants of the disclosed sequences, together with DNA sequences that differ from the disclosed sequences but which, due to the degeneracy of the genetic code, encode a polypeptide which 30 is the same as that encoded by a DNA sequence disclosed herein. Thus, polynucleotides comprising sequences that differ from the polynucleotide

sequences recited in SEQ ID NOS: 1-35, or complements, reverse sequences, or reverse complements of those sequences as a result of conservative substitutions are contemplated by and encompassed within the present invention. Additionally, polynucleotides comprising sequences that differ from the polynucleotide sequences recited in SEQ ID NOS: 1-35, or complements, reverse complements, 5 or reverse sequences as a result of deletions and/or insertions totaling less than 10% of the total sequence length are also contemplated by and encompassed within the present invention.

The polynucleotides of the present invention may be isolated from various DNA libraries, or may be synthesized using techniques that are well known in the 10 art. The polynucleotides may be synthesized, for example, using automated oligonucleotide synthesizers (e.g. Beckman Oligo 1000M DNA Synthesizer) to obtain polynucleotide segments of up to 50 or more nucleic acids. A plurality of such polynucleotide segments may then be ligated using standard DNA 15 manipulation techniques that are well known in the art of molecular biology. One conventional and exemplary polynucleotide synthesis technique involves synthesis of a single stranded polynucleotide segment having, for example, 80 nucleic acids, and hybridizing that segment to a synthesized complementary 85 nucleic acid segment to produce a 5-nucleotide overhang. The next segment may then be synthesized in a similar fashion, with a 5-nucleotide overhang on the 20 opposite strand. The "sticky" ends ensure proper ligation when the two portions are hybridized. In this way, a complete polynucleotide of the present invention may be synthesized entirely *in vitro*.

SEQ ID NOS: 2, 3, 5, 7-9, 11, 12, 14, 15, 17, 19-21, 23, 26, 28 and 30-32 25 are full-length sequences. The remaining polynucleotides are referred to as "partial" sequences, in that they may not represent the full coding portion of a gene encoding a naturally occurring polypeptide. The partial polynucleotide sequences disclosed herein may be employed to obtain the corresponding full-length genes for various species and organisms by, for example, screening DNA 30 expression libraries using hybridization probes based on the polynucleotides of the present invention, or using PCR amplification with primers based upon the

polynucleotides of the present invention. In this way one can, using methods well known in the art, extend a polynucleotide of the present invention upstream and downstream of the corresponding mRNA, as well as identify the corresponding genomic DNA, including the promoter and enhancer regions, of the complete gene. The present invention thus comprehends isolated polynucleotides comprising a sequence identified in SEQ ID NOS: 1-35, or a variant of one of the specified sequences, that encode a functional polypeptide, including full-length genes. Such extended polynucleotides may have a length of from about 50 to about 4,000 nucleic acids or base pairs, and preferably have a length of less than about 4,000 nucleic acids or base pairs, more preferably yet a length of less than about 3,000 nucleic acids or base pairs, more preferably yet a length of less than about 2,000 nucleic acids or base pairs. Under some circumstances, extended polynucleotides of the present invention may have a length of less than about 1,800 nucleic acids or base pairs, preferably less than about 1,600 nucleic acids or base pairs, more preferably less than about 1,400 nucleic acids or base pairs, more preferably yet less than about 1,200 nucleic acids or base pairs, and most preferably less than about 1,000 nucleic acids or base pairs.

Polynucleotides of the present invention comprehend polynucleotides comprising at least a specified number of contiguous residues (x -mers) of any of the polynucleotides identified as SEQ ID NOS: 1-35 or their variants. According to preferred embodiments, the value of x is preferably at least 20, more preferably at least 40, more preferably yet at least 60, and most preferably at least 80. Thus, polynucleotides of the present invention include polynucleotides comprising a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer, a 220-mer, a 250-mer, or a 300-mer, 400-mer, 500-mer or 600-mer of a polynucleotide identified as SEQ ID NOS: 1-35 or a variant of one of the polynucleotides identified as SEQ ID NOS: 1-35.

Polynucleotide probes and primers complementary to and/or corresponding to SEQ ID NOS: 1-35, and variants of those sequences, are also comprehended by the present invention. Such oligonucleotide probes and primers are substantially complementary to the polynucleotide of interest. An

oligonucleotide probe or primer is described as "corresponding to" a polynucleotide of the present invention, including one of the sequences set out as SEQ ID NOS: 1-35 or a variant, if the oligonucleotide probe or primer, or its complement, is contained within one of the sequences set out as SEQ ID NOS: 1-35 or a variant of one of the specified sequences.

Two single stranded sequences are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared using, for example, the BLAST algorithm as described above, with the appropriate nucleotide insertions and/or deletions, pair with at least 80%, preferably at least 90% to 95%, and more preferably at least 98% to 100%, of the nucleotides of the other strand. Alternatively, substantial complementarity exists when a first DNA strand will selectively hybridize to a second DNA strand under stringent hybridization conditions. Stringent hybridization conditions for determining complementarity include salt conditions of less than about 1 M, more usually less than about 500 mM and preferably less than about 200 mM. Hybridization temperatures can be as low as 5°C, but are generally greater than about 22°C, more preferably greater than about 30°C and most preferably greater than about 37°C. Longer DNA fragments may require higher hybridization temperatures for specific hybridization. Since the stringency of hybridization may be affected by other factors such as probe composition, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one alone. The DNA from plants or samples or products containing plant material can be either genomic DNA or DNA derived by preparing cDNA from the RNA present in the sample.

In addition to DNA-DNA hybridization, DNA-RNA or RNA-RNA hybridization assays are also possible. In the case of DNA-RNA hybridization, the mRNA from expressed genes would then be detected instead of genomic DNA or cDNA derived from mRNA of the sample. In the case of RNA-RNA hybridization, RNA probes could be used. In addition, artificial analogs of DNA hybridizing specifically to target sequences could also be employed.

In specific embodiments, the oligonucleotide probes and/or primers comprise at least about 6 contiguous residues, more preferably at least about 10 contiguous residues, and most preferably at least about 20 contiguous residues complementary to a polynucleotide sequence of the present invention. Probes and
5 primers of the present invention may be from about 8 to 100 base pairs in length or, preferably from about 10 to 50 base pairs in length or, more preferably from about 15 to 40 base pairs in length. The probes can be easily selected using procedures well known in the art, taking into account DNA-DNA hybridization stringencies, annealing and melting temperatures, potential for formation of loops
10 and other factors, which are well known in the art. Tools and software suitable for designing probes, and especially suitable for designing PCR primers, are available on the Internet, for example, URL <http://www.horizonpress.com/pcr/>. Preferred techniques for designing PCR primers are also disclosed in Dieffenbach and Dyksler, *PCR primer: a laboratory manual*. Cold Spring Harbor Laboratory
15 Press, Cold Spring Harbor, NY, 1995.

A plurality of oligonucleotide probes or primers corresponding to a polynucleotide of the present invention may be provided in a kit form. Such kits generally comprise multiple DNA or oligonucleotide probes, each probe being specific for a polynucleotide sequence. Kits of the present invention may
20 comprise one or more probes or primers corresponding to a polynucleotide of the present invention, including a polynucleotide sequence identified in SEQ ID NOS: 1-35.

In one embodiment useful for high-throughput assays, the oligonucleotide probe kits of the present invention comprise multiple probes in an array format,
25 wherein each probe is immobilized in a predefined, spatially addressable location on the surface of a solid substrate. Array formats which may be usefully employed in the present invention are disclosed, for example, in U.S. Patents No. 5,412,087, 5,545,531, and PCT Publication No. WO 95/00530, the disclosures of which are hereby incorporated by reference.

30 Oligonucleotide probes for use in the present invention may be constructed synthetically prior to immobilization on an array, using techniques well known in

the art (see, for example, *Oligonucleotide Synthesis: A Practical Approach*, Gait, ed., IRL Press, Oxford, 1984). Automated equipment for the synthesis of oligonucleotides is available commercially from such companies as Perkin Elmer/Applied Biosystems Division (Foster City, CA) and may be operated
5 according to the manufacturer's instructions. Alternatively, the probes may be constructed directly on the surface of the array using techniques taught, for example, in PCT Publication No. WO 95/00530.

The solid substrate and the surface thereof preferably form a rigid support and are generally formed from the same material. Examples of materials from
10 which the solid substrate may be constructed include polymers, plastics, resins, membranes, polysaccharides, silica or silica-based materials, carbon, metals and inorganic glasses. Synthetically prepared probes may be immobilized on the surface of the solid substrate using techniques well known in the art, such as those disclosed in U.S. Patent No. 5,412,087.

15 In one such technique, compounds having protected functional groups, such as thiols protected with photochemically removable protecting groups, are attached to the surface of the substrate. Selected regions of the surface are then irradiated with a light source, preferably a laser, to provide reactive thiol groups. This irradiation step is generally performed using a mask having apertures at
20 predefined locations using photolithographic techniques well known in the art of semiconductors. The reactive thiol groups are then incubated with the oligonucleotide probe to be immobilized. The precise conditions for incubation, such as temperature, time and pH, depend on the specific probe and can be easily determined by one of skill in the art. The surface of the substrate is washed free of
25 unbound probe and the irradiation step is repeated using a second mask having a different pattern of apertures. The surface is subsequently incubated with a second, different, probe. Each oligonucleotide probe is typically immobilized in a discrete area of less than about 1 mm². Preferably each discrete area is less than about 10,000 mm², more preferably less than about 100 mm². In this manner, a
30 multitude of oligonucleotide probes may be immobilized at predefined locations on the array.

The resulting array may be employed to screen for differences in organisms or samples or products containing genetic material as follows. Genomic or cDNA libraries are prepared using techniques well known in the art. The resulting target DNA is then labeled with a suitable marker, such as a radiolabel, chromophore, fluorophore or chemiluminescent agent, using protocols well known for those skilled in the art. A solution of the labeled target DNA is contacted with the surface of the array and incubated for a suitable period of time.

The surface of the array is then washed free of unbound target DNA and the probes to which the target DNA hybridized are determined by identifying those regions of the array to which the markers are attached. When the marker is a radiolabel, such as ^{32}P , autoradiography is employed as the detection method. In one embodiment, the marker is a fluorophore, such as fluorescein, and the location of bound target DNA is determined by means of fluorescence spectroscopy. Automated equipment for use in fluorescence scanning of oligonucleotide probe arrays is available from Affymetrix, Inc. (Santa Clara, CA) and may be operated according to the manufacturer's instructions. Such equipment may be employed to determine the intensity of fluorescence at each predefined location on the array, thereby providing a measure of the amount of target DNA bound at each location. Such an assay would be able to indicate not only the absence and presence of the marker probe in the target, but also the quantitative amount as well.

In this manner, oligonucleotide probe kits of the present invention may be employed to examine the presence/absence (or relative amounts in case of mixtures) of polynucleotides in different samples or products containing different materials rapidly and in a cost-effective manner.

Another aspect of the present invention involves collections of a plurality of polynucleotides of the present invention. A collection of a plurality of the polynucleotides of the present invention, particularly the polynucleotides identified as SEQ ID NOS: 1-35, may be recorded and/or stored on a storage medium and subsequently accessed for purposes of analysis, comparison, etc. One utility for such sets of sequences is the analysis of the set, either alone or together with other sequences sets, for single nucleotide polymorphisms (SNPs)

between sequences from different tissues and/or individuals for genetic studies, mapping and fingerprinting purposes. Suitable storage media include magnetic media such as magnetic diskettes, magnetic tapes, CD-ROM storage media, optical storage media, and the like. Suitable storage media and methods for
5 recording and storing information, as well as accessing information such as polynucleotide sequences recorded on such media, are well known in the art. The polynucleotide information stored on the storage medium is preferably computer-readable and may be used for analysis and comparison of the polynucleotide information.

10 Another aspect of the present invention thus involves storage medium on which are recorded a collection of the polynucleotides of the present invention, particularly a collection of the polynucleotides identified as SEQ ID NOS: 1-35. According to one embodiment, the storage medium includes a collection of at least 20, preferably at least 50, more preferably at least 100, and most preferably
15 at least 200 of the polynucleotides of the present invention, preferably the polynucleotides identified as SEQ ID NOS: 1-35, or variants of those polynucleotides.

Another aspect of the present invention involves a combination of polynucleotides, the combination containing at least 5, preferably at least 10, more
20 preferably at least 20, and most preferably at least 50 different polynucleotides of the present invention, including polynucleotides selected from SEQ ID NOS: 1-35, or variants of these polynucleotides.

In another aspect, the present invention provides DNA constructs comprising, in the 5'-3' direction, a gene promoter sequence; an open reading
25 frame coding for at least a functional portion of a polypeptide encoded by a polynucleotide of the present invention; and a gene termination sequence. The open reading frame may be orientated in either a sense or antisense direction. DNA constructs comprising a non-coding region of a gene coding for an enzyme encoded by the above DNA sequences or a nucleotide sequence complementary to
30 a non-coding region, together with a gene promoter sequence and a gene termination sequence, are also provided. Preferably, the gene promoter and

termination sequences are functional in a host cell. More preferably, the gene promoter and termination sequences are common to those of the polynucleotide being introduced. Other promoter and termination sequences generally used in the art, such as the Cauliflower Mosaic Virus (CMV) promoter, with or without
5 enhancers, such as the Kozak sequence or Omega enhancer, and *Agrobacterium tumefaciens* nopal synthase terminator may be usefully employed in the present invention. Tissue-specific promoters may be employed in order to target expression to one or more desired tissues. The DNA construct may further include a marker for the identification of transformed cells.

10 Techniques for operatively linking the components of the DNA constructs are well known in the art and include the use of synthetic linkers containing one or more restriction endonuclease sites as described, for example, by Sambrook *et al.*, *Molecular Cloning: a laboratory manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The DNA constructs of the present invention
15 may be linked to a vector having at least one replication system, for example, *Escherichia coli*, whereby after each manipulation, the resulting construct can be cloned and sequenced and the correctness of the manipulation determined.

Transgenic cells comprising the DNA constructs of the present invention are provided, together with organisms comprising such transgenic cells.
20 Techniques for stably incorporating DNA constructs into the genome of target organisms, such as mammals, are well known in the art and include electroporation, protoplast fusion, injection into reproductive organs, injection into immature embryos, high velocity projectile introduction and the like. The choice of technique will depend upon the target organism to be transformed. In
25 one embodiment, naked DNA is injected or delivered orally. Once the cells are transformed, cells having the DNA construct incorporated in their genome are selected. Transgenic cells may then be cultured in an appropriate medium, using techniques well known in the art.

In yet a further aspect, the present invention provides methods for
30 modifying the level (concentration) or activity of a polypeptide in a host organism, comprising stably incorporating into the genome of the organism a

DNA construct of the present invention. The DNA constructs of the present invention may be used to transform a variety of organisms, including mammals, for example to make experimental gene knock out or transgenic animals.

Further, the polynucleotides of the present invention have particular application for use as non-disruptive tags for marking organisms, including commercially valuable animals, fish, bacteria and yeasts. DNA constructs comprising polynucleotides of the present invention may be stably introduced into an organism as heterologous, non-functional, non-disruptive tags. It is then possible to identify the origin or source of the organism at a later date by determining the presence or absence of the tag(s) in a sample of material.

Detection of the tag(s) may be accomplished using a variety of conventional techniques, and will generally involve the use of nucleic acid probes. Sensitivity in assaying the presence of probe can be usefully increased by using branched oligonucleotides, as described by Horn *et al.*, *Nucleic Acids Res.* 25(23):4842-4849, 1997, enabling to detect as few as 50 DNA molecules in the sample.

In particular, the polynucleotides of the present invention encode polypeptides that have important roles in processes such as induction of growth, differentiation of tissue-specific cells, cell migration, cell proliferation, and cell-cell interaction. These polypeptides are important in the maintenance of tissue integrity, and thus are important in processes such as wound healing. Some of these polypeptides act as modulators of immune responses, such as immunologically active polypeptides for the benefit of offspring. In addition, many polypeptides are immunologically active, making them important therapeutic targets in a whole range of disease states. Antibodies to the polypeptides of the present invention and small molecule inhibitors related to the polypeptides of the present invention may also be used for modulating immune responses and for treatment of diseases according to the present invention.

SEQ ID NOS: 1; 2; 4; 5; 6; 8; 9; 11; 12; 14; 17; 19-24; 26; 27; 31-34 encode secreted polypeptides. SEQ ID NOS: 10; 15; 16; 18; 25; 28; 30; and 35 encode polypeptides acting as receptors. SEQ ID NOS: 2; 4; 24; 29 and 35

encode polypeptides with cell signaling activity, which may be either intracellular or extracellular. Kinase genes, for example, encode polypeptides that phosphorylate specific substrates during cell-to-cell signaling. While some kinases are involved in normal metabolism and nucleotide production, others are significant for altering the activity of many cellular processes through the phosphorylation of specific proteins. Polypeptides encoded by these genes are important in the transmission of intracellular signals resulting from the binding of extracellular ligands such as hormones, growth factors or cytokines to membrane-bound receptors. The utility of polynucleotides encoding kinases resides in the manipulation of their signaling activities and downstream effects for the diagnosis and treatment of mammalian diseases that may be a consequence of inappropriate expression of these kinase genes.

SEQ ID NOS: 2 and 4 encode polypeptides with cytokine activity. Cytokine or growth factor polynucleotides encode polypeptides involved in intercellular signaling and represent another important class of molecules. Polynucleotides encoding such genes have utility in the diagnosis and treatment of disease.

SEQ ID NOS: 7; 11; 12; 15 and 22 encode polypeptides with transcription factor activity. These polynucleotides encode polypeptides required for the control of synthesis of proteins in tissue specific manner and have utility for the modification of protein synthesis for the control of disease.

SEQ ID NOS: 8 encode polypeptides acting in the extracellular matrix.

SEQ ID NOS: 11; 12; 15 and 22 encode polypeptides with RNA synthesis activities.

SEQ ID NO: 12 encodes a polypeptide having CD antigen activity. Such polynucleotides have utility as modulators of the composition, expression level and class of CD antigen expressed, which influence immune responses to self-antigens, neo-antigens and infectious agents.

Further exemplary specific utilities, for exemplary polynucleotides of the present invention, are specified in the Table below.

SEQ ID NO:	UTILITY
2	Promoting immune response as part of a vaccine or anti-cancer treatment. Inhibitors of this molecule can be useful as anti-inflammatory treatment, e.g. for autoimmune diseases or allergies.
11; 19	Utility as a target for cancer treatment and as an immunoregulatory and anti-inflammatory molecule
12	Diagnostic for specific types of cancer and for development of an anti-cancer treatment.
15	As a target for antagonists in the treatment of diseases such as asthma and allergy.
22	Useful to inhibit or enhance the activity of the soluble molecule that binds this protein.
28	Useful to promote or block cell trafficking and therefore in the treatment as anti-inflammatory and/or vaccine adjuvant where it can promoter inflammation.
35	Useful for tissue and neural regeneration.

The following examples are offered by way of illustration and not by way of limitation.

5

Example 1

ISOLATION OF CDNA SEQUENCES FROM MAMMALIAN EXPRESSION LIBRARIES

The cDNA sequences of the present invention were obtained by high-throughput sequencing of cDNA expression libraries constructed mouse airways-induced eosinophilia, rat dermal papilla and mouse stromal cells. The cDNA
10 libraries were prepared as follows.

cDNA Library from Dermal Papilla (DEPA)

Dermal papilla cells from rat hair vibrissae (whiskers) were grown in
15 culture and the total RNA extracted from these cells using established protocols. Total RNA, isolated using TRIzol Reagent (BRL Life Technologies, Gaithersburg, MD), was used to obtain mRNA using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA), according to the manufacturer's

specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit (Stratagene).

5 *cDNA library from mouse airway-induced eosinophilia (MALA)*

Airway eosinophilia were induced in BALB/cByJ mice by administering 2 µg ovalbumin in 2 mg alum adjuvant intraperitoneally on day 0 and day 14, and subsequently 100 µg ovalbumin in 50 µl phosphate buffered saline (PBS) intranasally route on day 28. The accumulated eosinophils in the lungs were
10 detected by washing the airways of the anesthetized mice with saline, collecting the washings (broncheolar lavage or BAL), and counting the numbers of eosinophils. The mice were sacrificed and total RNA was isolated from whole lung tissue using TRIzol Reagent (BRL Life Technologies). mRNA was isolated by using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA),
15 according to the manufacturer's specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit (Stratagene).

cDNA Expression Library from Peripheral Lymph Node Stromal Cells (MLSA)

20 The peripheral axillary and brachial lymph nodes of BALB/cByJ mice with the flaky skin (*fsn*) mutation (Jackson Laboratories, Bar Harbour, MN) were dissected out. Single cell suspensions were obtained from the lymph nodes and cultured in tissue culture flasks at 10^7 cells /ml in 20% fetal calf serum and Dulbecco's Minimum Essential Medium. After 2 days the non-adherent cells were
25 removed. The adherent cells were cultured for a further 2 days and then treated with 0.25 g/100ml Trypsin (ICN, Aurora, OH) and re-cultured. After a further 4 days, non-adherent cells were discarded and adherent cells removed by trypsinization. Remaining adherent cells were physically removed by scraping with a rubber policeman. All adherent stromal cells were pooled.

cDNA Expression Library from Flaky skin lymph node stromal cells in pBK-CMV (MLSA)

Stromal cells from Flaky skin mice lymph nodes were grown in culture and the total RNA extracted from these cells using established protocols. Total
5 RNA, isolated using TRIzol Reagent (BRL Life Technologies, Gaithersburg, MD), was used to obtain mRNA using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA), according to the manufacturer's specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit
10 (Stratagene).

cDNA sequences were obtained by high-throughput sequencing of the cDNA libraries described above using a Prism 377 sequencer (Perkin Elmer/Applied Biosystems Division, Foster City CA), and are provided in SEQ ID NO: 1-35, with corresponding polypeptide sequences in SEQ ID NOS: 36-65.

15

EXAMPLE 2

Analysis of cDNA sequences using BLAST algorithms

BLASTN Polynucleotide analysis

20 The isolated cDNA sequences were compared to sequences in the EMBL DNA database using the computer algorithm BLASTN. Comparisons of DNA sequences provided in SEQ ID NOS: 1-35, to sequences in the EMBL DNA database (using BLASTN) were made as of November, 2000, using Version 2.0.11 [Jan-20-2000], and the following Unix running command: blastall -p
25 blastn -d embldb -e 10 -G0 -E0 -r 1 -v 30 -b 30 -i queryseq -o.

The sequences of SEQ ID NOS: 1, 3, 4, 6-11, 13, 18, 21, 22, 24, 25, 28-30, 33 and 34 were determined to have less than 50% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above. The sequences of SEQ ID NOS: 2, 12,
30 14-16, 20 and 35 were determined to have less than 75% identity, determined as described above, to sequences in the EMBL database using the computer

algorithm BLASTN, as described above. The sequences of SEQ ID NOS: 17, 19, 23 and 27 were determined to have less than 90% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above. Finally, the sequences of SEQ ID NOS: 5, 26 and 32 were determined to have less than 98% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above.

BLASTP Polypeptide analysis

10 The sequences of SEQ ID NOS: 37, 41, 42, 44, 46-50, 55, 56 and 59 were determined to have less than 50% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. The sequences of SEQ ID NOS: 36, 38, 43, 45 and 60 were determined to have less than 75% identity, determined as described above, to
15 sequences in the SwissProt database using the computer algorithm BLASTP, as described above. The sequences of SEQ ID NOS: 39, 54 and 58 were determined to have less than 90% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. Finally, the sequences of SEQ ID NOS: 53, 57, 62 and 65 were determined to
20 have less than 98% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above.

BLASTX Polynucleotide Analysis

25 The sequences of SEQ ID NOS: 2-4, 6-16, 18, 22-24, 26-30 and 33-35 were determined to have less than 50% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTX, as described above. The sequences of SEQ ID NOS: 1, 19, 20, 25 and 32 were determined to have less than 75% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTX, as
30 described above. Finally, the sequences of SEQ ID NOS: 5, 17, 21 and 31 were determined to have less than 90% identity, determined as described above, to

sequences in the SwissProt database using the computer algorithm BLASTX, as described above.

5

Example 2

ISOLATION AND CHARACTERIZATION OF THE HUMAN HOMOLOG OF muKS1

This example demonstrates that an isolated cDNA may be used to isolate its homologue from a different species, the corresponding polypeptide may be expressed and the function of the polypeptide can be determined, starting the whole process from an isolated cDNA obtained as described above.

10

Analysis of RNA transcripts by Northern Blotting

Northern analysis to determine the size and distribution of mRNA for the clone muKS1 (SEQ ID NO: 66; isolated from a mouse keratinocyte stem cell cDNA library using high-throughput sequencing as described above) was performed by probing murine tissue mRNA blots with a probe consisting of nucleotides 268-499 of muKS1, radioactively labeled with [α^{32} P]-dCTP. Prehybridization, hybridization, washing and probe labeling were performed as described in Sambrook *et al.*, *Ibid.* mRNA for muKS1 was 1.6 kb in size and was observed to be most abundant in brain, lung, muscle and heart. Expression could also be detected in lower intestine, skin and kidney. No detectable signal was found in testis, spleen, liver, thymus and stomach.

15

25 *Human homologue of muKS1*

MuKS1 (SEQ ID NO: 66) was used to search the EMBL database (Release 50 plus updates to June, 1998) to identify human EST homologues. The top three homologies were to the following ESTs: accession numbers AA643952, HS1301003 and AA865643. These showed 92.63% identity over 285 nucleotides, 93.64% over 283 nucleotides and 94.035% over 285 nucleotides, respectively. Frame shifts were identified in AA643952 and HS1301003 when

30

translated. Combination of all three ESTs identified the human homologue huKS1 (SEQ ID NO: 67) and translated polypeptide SEQ ID NO: 67. Alignment of muKS1 and huKS1 polypeptides indicated 95% identity over 96 amino acids.

5 *Bacterial expression and purification of muKS1 and huKS1*

Polynucleotides 269-502 of muKS1 (SEQ ID NO: 69), encoding amino acids 23-99 of polypeptide muKS1 (SEQ ID NO: 70), and polynucleotides 55-288 of huKS1 (SEQ ID NO: 71), encoding amino acids 19-95 of polypeptide huKS1 (SEQ ID NO: 72), were cloned into the bacterial expression vector pET-16b
10 (Novagen, Madison, WI), which contains a bacterial leader sequence and N-terminal 6xHistidine tag. These constructs were transformed into competent *E. coli* BL21(DE3) (Novagen) as described in Sambrook *et al.*, *Ibid*.

Starter cultures of recombinant *E. coli* BL21(DE3) (Novagen) transformed with bacterial expression vector pET16b containing SEQ ID NO: 69 (muKS1a) and SEQ ID NO: 71 (huKS1a) were grown in NZY broth containing 100 µg/ml
15 ampicillin (Gibco-BRL Life Technologies) at 37°C. Cultures were spun down and used to inoculate 800 ml of NZY broth and 100 µg/ml ampicillin. Cultures were grown until the OD₅₉₅ of the cells was between 0.4 and 0.8. Bacterial expression was induced for 3 hours with 1 mM IPTG. Bacterial expression produced an
20 induced band of approximately 15 kDa for muKS1a and huKS1a.

MuKS1a and huKS1a were expressed in insoluble inclusion bodies. In order to purify the polypeptides, bacterial cell pellets were re-suspended in lysis buffer (20 mM Tris-HCl pH 8.0, 10 mM β-Mercaptoethanol, 1 mM PMSF). To the lysed cells, 1% NP-40 was added and the mix incubated on ice for 10 minutes.
25 Lysates were further disrupted by sonication on ice at 95 W for 4 x 15 seconds and then centrifuged for 10 minutes at 18,000 rpm to pellet the inclusion bodies.

The pellet containing the inclusion bodies was re-suspended in lysis buffer containing 0.5% w/v CHAPS and sonicated for 5-10 seconds. This mix was stored on ice for 1 hour, centrifuged at 14,000 rpm for 15 minutes at 4°C and the
30 supernatant discarded. The pellet was once more re-suspended in lysis buffer

containing 0.5% w/v CHAPS, sonicated, centrifuged and the supernatant removed as before. The pellet was re-suspended in solubilizing buffer (6 M guanidine HCl, 0.5 M NaCl, 20 mM Tris-HCl pH 8.0), sonicated at 95 W for 4 x 15 sec and centrifuged for 10 minutes at 18,000 rpm and 4°C to remove debris. The supernatant was stored at 4°C. MuKS1a and huKS1a were purified by virtue of the N-terminal 6x histidine tag contained within the bacterial leader sequence, using a Nickel-Chelating sepharose column (Amersham Pharmacia, Uppsala, Sweden) and following the manufacturer's protocol. Proteins were purified twice over the column to reduce endotoxin contamination. In order to re-fold the proteins once purified, the protein solution was dialysed in a 4 M-2 M urea gradient in 20 mM Tris-HCl pH 7.5 containing 10% glycerol overnight at 4°C. The protein was then further dialysed 2x against 2 litres of 20 mM Tris-HCl pH 7.5 containing 10% glycerol.

Injection of bacterially expressed muKS1a into nude mice

Two nude mice were anaesthetised intraperitoneally with 75 µl of 1/10 dilution of Hypnorm (Janssen Pharmaceuticals, Buckinghamshire, England) in phosphate buffered saline. 20 µg of bacterially expressed muKS1a (SEQ ID NO: 70) was injected subcutaneously in the left hind foot, ear and left hand side of the back. The same volume of phosphate buffered saline was injected in the same sites but on the right hand side of the same animal. Mice were left for 18 hours and then examined for inflammation. Both mice showed a red swelling in the ear and foot sites injected with the bacterially expressed protein. No obvious inflammation could be identified in either back site. Mice were culled and biopsies taken from the ear, back and foot sites and fixed in 3.7% formol saline. Biopsies were embedded, sectioned and stained with Haemotoxylin and eosin. Sites injected with muKS1a had a marked increase in polymorphonuclear granulocytes, whereas sites injected with phosphate buffered saline had a low background infiltrate of polymorphonuclear granulocytes.

Chemokines are a large superfamily of highly basic secreted proteins with a broad number of functions (Baggiolini *et al.*, *Annu. Rev. Immunol.* 15:675-705, 1997; Ward *et al.*, *Immunity* 9:1-11, 1998; Horuk, *Nature* 393:524-525, 1998). The polypeptide sequences of muKS1 and huKS1 have similarity to CXC chemokines, suggesting that this protein will act like other CXC chemokines. The *in vivo* data from nude mice supports this hypothesis. This chemokine-like protein may therefore be expected to stimulate leukocyte, epithelial, stromal and neuronal cell migration, promote angiogenesis and vascular development, promote neuronal patterning, hematopoietic stem cell mobilization, keratinocyte and epithelial stem cell patterning and development, activation and proliferation of leukocytes, and promotion of migration in wound healing events. It has recently been shown that receptors to chemokines act as co-receptors for HIV-1 infection of CD4+ cells (Cairns *et al.*, *Nature Medicine* 4:563-568, 1998) and that high circulating levels of chemokines can render a degree of immunity to those exposed to the HIV virus (Zagury *et al.*, *Proc. Natl. Acad. Sci. USA* 95:3857-3861, 1998). This novel gene and its encoded protein may thus be usefully employed as regulators of epithelial, lymphoid, myeloid, stromal and neuronal cells migration and cancers; as agents for the treatment of cancers, neuro-degenerative diseases, inflammatory autoimmune diseases such as psoriasis, asthma and Crohns disease; for use in wound healing; and as agents for the prevention of HIV-1 binding and infection of leukocytes.

SEQ ID NOS: 1-72 are set out in the attached Sequence Listing. The codes for nucleotide sequences used in the attached Sequence Listing, including the symbol "n," conform to WIPO Standard ST.25 (1998), Appendix 2, Table 1.

All references cited herein, including patent references and non-patent publications, are hereby incorporated by reference in their entireties.

While in the foregoing specification this invention has been described in relation to certain preferred embodiments, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details

described herein may be varied considerably without departing from the basic principles of the invention.

We claim:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of: (1) sequences recited in SEQ ID NOS: 1-35; (2) complements of the sequences recited in SEQ ID NOS: 1-35; (3) reverse
5 complements of the sequences recited in SEQ ID NOS: 1-35; (4) reverse sequences of the sequences recited in SEQ ID NOS: 1-35 (5) sequences having at least a 99% probability of being the same as a sequence recited in (1) – (4) above as determined using computer algorithm BLASTN; (6) sequences having at least
10 50% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (7) sequences having at least 75% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (8) sequences having at least 90% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (9) sequences having at least 95% identity to a nucleotide sequence
15 recited in (1) – (4) above determined using computer algorithm BLASTN; (10) nucleotide sequences that hybridize to a sequence recited in (1) – (4) above under stringent hybridization conditions; (11) nucleotide sequences that are 200-mers of a sequence recited in (1) – (4) above; (12) nucleotide sequences that are 100-mers of a sequence recited in (1) – (4) above; (13) nucleotide sequences that are 40-
20 mers of a sequence recited in (1) – (4) above; (14) nucleotide sequences that are 20-mers of a sequence recited in (1) – (4) above; and (15) nucleotide sequences that are degeneratively equivalent to a sequence recited in (1) – (4) above.

2. An oligonucleotide comprising at least 10 contiguous residues
25 complementary to 10 contiguous residues of a nucleotide sequence recited in claim 1.

3. A genetic construct comprising an isolated polynucleotide of claim
1.

4. A host cell transformed with a genetic construct of claim 3.
5. An isolated polypeptide encoded by a polynucleotide of claim 1.
- 5 6. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOS: 36-65; (b) sequences having at least a 99% probability of being the same as a sequence of SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (c) sequences having at least 50% identity to a sequence provided in
10 SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (d) sequences having at least 75% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (e) sequences having at least 90% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; and (f) sequences having at
15 least 95% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP.
7. An isolated polynucleotide encoding a polypeptide of claim 6.
- 20 8. An isolated polypeptide comprising at least a functional portion of a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOS: 36-65; (b) sequences having at least a 99% probability of being the same as a sequence of SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (c) sequences
25 having at least 50% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (d) sequences having at least 75% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (e) sequences having at least 90% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer
30 algorithm BLASTP and (f) sequences having at least 95% identity to a sequence

provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP.

5 9. A composition comprising a polypeptide according to any one of claims 6 and 8 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

10 10. A composition comprising a polynucleotide according to claim 1 and at least one component selected from the group consisting of pharmaceutically acceptable carriers and immunostimulants.

 11. A method for treating a disorder in a mammal comprising administering a composition according to claim 9.

15 12. A method for treating a disorder in a mammal comprising administering a composition according to claim 10.

 13. A diagnostic kit comprising at least one oligonucleotide according to claim 2.
20

 14. An organism comprising a host cell according to claim 4.

SEQUENCE LISTING

<110> Watson, James D
Murison, James G

<120> Polynucleotides, polypeptides expressed
by the polynucleotides and methods for their use.

<130> 1050U1PCT

<160> 74

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2401

<212> DNA

<213> Rat

<400> 1

gaggccacag	ttatcaccac	ggagaagaga	gagaggccag	cgccccctag	agagctcctg	60
gtaccccagg	cagaagtgac	agcacgtagc	ctccggctcc	agtgggtccc	tggcagcgat	120
ggggcctccc	cgatccggta	ctttaccgtg	caggtgcgag	agctgccggg	tggagaatgg	180
cagacctact	cctogtctat	cagccacgag	gccacactct	gtgctggtga	aaggctgagg	240
cctttcacct	cctacaagct	gcgcctgaag	gccaccaacg	acattgggga	cagtgacttc	300
agtgcagaaa	cagaggctgt	gaccacactg	caagatgttc	caggagagcc	accaggatct	360
gtctcagcca	caccgcacac	cacgtcctca	gttctgatcc	agtggcagcc	tccccgggat	420
gagagcttga	atggccttct	gcaaggctac	aggatctact	accgtgagct	ggagtccgag	480
acaggcctga	gccctgaacc	caagacactc	aagagccctt	ctgccttacg	tgctgaactc	540
acggctcaaa	gcagcttcaa	gaccgtgaac	agcagctcca	cattaacgac	ctatgaatta	600
acacatctga	agaagtaccg	gcgctatgaa	gtcatcatga	ctgcctataa	catcattggg	660
gagagcccag	ccagtgtacc	agtggaggtc	ttcgttgggtg	aggctgcccc	agcaatggcc	720
ccacagaaca	tccaggtgac	cccactcaca	gccagccagc	tggaggtoac	atgggacccg	780
ccacccccag	agagccagaa	tgggaacatc	caaggttaca	aggtttacta	ctgggaggca	840
gacagtcgta	atgagacgga	gaaaatgaag	gtcctctttc	tccctgagcc	tgtggtaaaag	900
attaaggatc	tcaccagcca	cacaaagtac	ctggtcagca	tctcagcctt	caacgctgct	960
ggtgacgggc	ccagaagtga	cccatgccag	ggacgcacac	accaggcagc	tccagggccc	1020
ccaagcttct	tgggaattctc	agaaataaca	tctaccacac	tcaacgtatc	ctggggggag	1080
ccatcggcag	ccaacggcat	cctacagggc	tatcgagtgg	tgtatgaacc	cttagcacca	1140
gtgcaaggcg	tgagcaaggt	ggtgaccgtg	gatgtgaaag	ggaactggca	acggtggctg	1200
aaggtgcggg	acctcaccaa	gggagtgacc	tatttcttcc	gtgttcaggc	gcgaaccatc	1260
gcctacgggc	cagaactcca	agccaatgtc	actgcagggc	cagccgaggg	gtccccagga	1320
tctccaagaa	atgtccttgt	caccaaattct	gcctctgagc	tgacccttca	gtggacagaa	1380
gggaacacag	ggaacacacc	cactacaggc	tacgtcatag	aagccagacc	atcagatgaa	1440
ggcttatggg	acatgtttgc	aaaggacatt	cccaggagtg	ctacgtcata	caccgtgggt	1500
ctggacaagc	tgcggaagc	ggtgacctac	gagttccggg	tgggtggccgt	gaacaaggca	1560
ggctttgggg	aacccagccg	cccttccatt	gcagtgtcag	cacaagctga	agccccgttc	1620
tatgaggagt	ggtggttctt	gctggtgata	gcgtctctca	gcctcctcct	cgtcctcctg	1680
gtggtcttct	tgctggtcct	gcatgggcaa	agcaagaagt	acaagaactg	tggctcaggt	1740
aagggcatct	ccaacatgga	ggagacagtg	accctggata	atggaggggt	tgccgccttg	1800
gaactcaaca	gtcgtcacct	caatgtcaag	agcaccttct	caaagaagaa	cggaaccaga	1860
tccccacccc	gaccaagccc	cggaggctctg	cactactctg	acgaagacat	ctgcaacaaa	1920
tacaacgggtg	cgggtgctgac	agagagtgtg	aacctcaagg	agaaatcggt	ggatgggtcg	1980
gaatcggagg	cttctgactc	agactacgag	gaagccctgc	ccaagcactc	ctttgtcaac	2040
cactacatga	gcgacccccc	ctactacaac	ttttggaagc	ggcgtccccc	tgccgcagca	2100

ccgcacaggt	acgagggcgg	ggcagggggc	gaagctggcc	cgcacctgca	cacagtcatc	2160
accacacaga	gcgcggggcg	agtttacaca	ccagctggcc	ccggagcccg	ggccccctc	2220
accggcttct	cctccttcgt	gtgacgtcac	gcctccatca	gggtagacgg	gtgcagaact	2280
tctggagtct	atTTTTgtta	agacaatcaa	ctccgataac	tgagctgaat	TTTTTTgtt	2340
taaaaaata	ataataatTT	tgataagcga	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2400
a						2401

<210> 2

<211> 1258

<212> DNA

<213> Mouse

<400> 2

cacacgcccc	gcgtgtgcgg	agcccttatt	tacttcgcag	aagagccttc	agacccccctc	60
ctaacaagtg	tggaaagcat	cacggcgacg	cgatgttggg	gacactggtc	tggatgctcg	120
cggtcggctt	cctgctggca	ctggcgccgg	gccgcgcggc	gggcgcgctg	aggaccggga	180
ggcgcgccgg	gcggcccgcg	gactgcgcgg	accggccgga	ggagctcctg	gagcagctgt	240
acgggcggct	ggcggccggc	gtgctcagcg	ccttccacca	cacgctgcag	ctcggggccgc	300
gcgagcaggc	gcgcaatgcc	agctgcccg	ccgggggcag	ggccgcgcgac	cgcgccttc	360
ggccacccac	caacctgcgc	agcgtgtcgc	cctgggcgta	caggatttcc	tacgaccctg	420
ctcgcttttc	gaggtacctg	cccgaagcct	actgcctgtg	ccgaggctgc	ctgaccgggc	480
tctacgggga	ggaggacttc	cgccttccga	gcacaccgt	cttctctcca	gccgtggtgc	540
tgccgcgcac	agcgccctgc	gcgggcggcc	gctctgtgta	cgccgaacac	tacatcacca	600
tcccgggtgg	ctgcacctgc	gtgcccgagc	cggacaagtc	cgccgacagt	gcgaactcca	660
gcatggacaa	gctgctgctg	gggcccgccg	acaggcctgc	ggggcgctga	tgccggggac	720
tgcccggcat	ggcccagctt	cctgcatgca	tcagggtccc	tggccctgac	aaaaccaccc	780
ccatgatccc	tggccgctgc	ctaatttttc	caaaaggaca	gctacataag	ctttaaatat	840
atTTTTcaaa	gtagacacta	catatctaca	actatTTTga	atagtggcag	aaactatTTT	900
catattagta	atTTtagagca	agcatgttgt	TTTTaaactt	ctttgatata	caagcacatc	960
acacacatcc	cgtTTTTcctc	tagtaggatt	cttgagtgc	taattgtagt	gctcagatga	1020
acttccttct	gctgcaactgt	gcctgtctcc	tgagtctctc	ctgtggccca	agcttactaa	1080
ggtgataatg	agtgtcccg	atctgggcac	ctaaggctct	cagggtccctg	gagagggagg	1140
gatgtggggg	ggctaggaac	caagcgcccc	tttgttcttt	agcttatgga	tggtcttaac	1200
tttataaaga	ttaaagtTTT	tggtgttatt	ctttcaaaaa	aaaaaaaaaa	aaaaaaaaaa	1258

<210> 3

<211> 3043

<212> DNA

<213> Mouse

<400> 3

cgcgtctccc	gccgcaccca	cccgtcgtcg	tatcaagcaa	aagcgaaagg	aagccgagcg	60
gtcccgcgtg	gcgtggcggt	ggcggggagg	tggctgcgcg	ctctagctcc	gcgggaccag	120
gctgccgctt	tgtgacttca	ccggtttcgc	aacaagccag	gaccgcccgc	gccccaccca	180
cccggctgcc	cgtccgccct	ccgccctcgg	gtctctgagc	gcttccctcc	ctccggggct	240
gggcctgtcc	cggccgtccc	ggagtctctg	tcccgcgcgc	ccgttagctg	tctgtgtctt	300
ggccaccgcc	tccaggcagt	ccgcagcaag	ccagcttctt	ggtcgcagca	gctcagcgcc	360
ctctcaccgc	gatgctgtgc	ttcctcaggg	gaatggcttt	cgtcccttcc	ctcctggtga	420
cttggctcgc	cgcagccttc	atcatctcct	acgtggctgc	ggtgctctct	gggcacgtca	480
acccctttct	cccctatatc	agtgcacacg	gaacaactcc	tccagagagt	ggtatTTTTg	540
gattcatgat	aaacttctct	gcatttcttg	gcgcagctac	gatgtacaca	agatacaaga	600
tagtgagaaa	gcagaatgag	acctgctact	tcagcactcc	cgtTTTTaac	ttggtgtcct	660
tggcgcttgg	attggtggga	tgcatcggaa	tgggcacgtg	agccaaactc	caggagttag	720
ccgtgcctgt	ggtccatgat	ggcgggtgcg	ttctggcttt	cgtctgcggg	gtggtgtaca	780
cgtccttgca	atcgatcatc	tcctacaaa	cctgtcccca	gtggaacagt	ctcaccacgt	840
gccatgtcag	gatggccatc	tccgctgttt	cgtgcgcagc	tgctgtcccc	atgattgcct	900
gtgcttcaact	catTTctata	accaagctgg	aatggaatcc	aaaagaaaag	gattatatat	960

atcacgtggt	gagcgccatc	tgtgagtgga	cogtggcctt	tggttttatt	ttctattttcc	1020
taacattcat	ccaagatttc	cagagtgtca	ctctaaggat	atccacagaa	atcaatgacg	1080
acttttgaaa	gacgagaat	cctgtctcat	tcagggagtg	tcgcagacag	tttctggaag	1140
tggacagagg	acggacgggc	ttggatgtca	ccctgatggg	gactttatct	gtggcacatc	1200
cgggacttga	atttcattaa	gagttcctag	tagttcaatt	tacaaaggta	tgtttccctg	1260
gaggatggat	agcaccaacg	acactgtagc	aatatTTTTa	tattttctaa	aacaatcttt	1320
tatgaacaaa	ttcatatgca	aagaagacga	ggcattgcag	aaaggggagg	attattcttg	1380
tatagattct	ttagactttt	tatgtaataa	tgatttatga	aaatacacta	agagaaaaaa	1440
atgttaagtt	tagtactttt	tattaaagaa	gccaaatcag	ggcatattca	ctttaaaatt	1500
tcatttttta	aatacagtga	cctgcataca	ttttcatcac	aagagcactt	atacaattca	1560
attcatagt	attatatacc	ctaattggtat	agatttaggt	aataaacgaa	cacttttaaag	1620
cactctgaat	tttcagtgtc	ttaaacaatt	gcttttatag	tgaaggactc	aaaaccattt	1680
acagtgcaca	ttaaccagcg	aatgtggaag	acctcggttc	gaaaatttag	ccccctcatt	1740
tacttctcca	agggaccac	agctttactg	ccgctgttaa	tgggtgggcc	gggaactaat	1800
tccaggtagg	atgggctcat	caggccagct	tagaaatgat	caaactgcc	ttctctgtga	1860
ccgggcagca	caagttcaat	tcacttctca	gtttccctgt	aagccaaaga	gaatgcagat	1920
ccaagtcagg	gagaaaggag	agcgctcata	gaaacttcca	gatgtgggct	gctgcctatc	1980
tgctcctatc	aatgcctgtg	ggccactata	agggagtcag	gccctttccg	aagcaaggcc	2040
tggagactct	acctttcatg	cagttcacca	atggcaaaga	aacgccagct	gttgtggagg	2100
aagaagtgga	taacaagacc	ccccagtctg	ggccagtagg	agctgcccc	agggcacggt	2160
ccaaggacag	agaccatttg	gacagcctta	gtgaaagggt	acctggcgat	gaaggggcac	2220
acagcagctg	ctcctttggc	tgctaagtga	agggtgctgc	tcagcaggca	cttctgccat	2280
gacatcctgt	gtcttcttcc	tcagtgtgca	gtgggtggcaa	ccaacgtcca	tttctgagtc	2340
ccctgttaact	tttcacagta	ccgaacatgc	ccattgtaac	actggaacag	aaagacagtg	2400
gctgtcattc	tgatgagtga	gagaggagtc	gatacatttc	ctgtggaagc	tggggcgagc	2460
tgaatgcatg	ctgttctttg	ctttgagcgg	gagccttggt	tgatgccttc	ccagaatgca	2520
cttggctctc	ttcgcttcca	ctggagaccc	gaccacgtgc	ctttacccat	agtggaacac	2580
agtgccttgt	ggcatgcaat	aggtgcttaa	taaatactca	ttgaatgtat	gcacgcataa	2640
atggatgaac	aagtaacgac	tagggatggt	tgaggtgcta	agggtttttt	ttactctagt	2700
tcacgggtat	tctaagggtc	acagctagtc	tgtgccaat	agtaatgttg	tctgttttgc	2760
tttgtgaact	attctcggtt	ccacctgttc	cagctgtgtg	agcttcatga	ttgtgtgaca	2820
actctctcct	ggacagatag	cacagaaatt	gttacatggg	ctaaacctgt	cttggcaaac	2880
cgaggaggcc	cccaaatac	actctgcaga	ttccatgcga	cttctagttt	tatccctgtt	2940
ttgggtgttat	ttttaatttc	tacaaatatg	tatttccttg	gactttgtac	ccgagaaagt	3000
aaaataaaat	atttctttat	tttaaaaaaa	aaaaaaaaaa	aaa		3043

<210> 4

<211> 2515

<212> DNA

<213> Mouse

<400> 4

gctgcgcctg	ctgctggcct	gggtggccgc	ggtgcccgca	ctggggccagg	tcccctggac	60
gccggagcct	cgagccgcgt	gcggccccag	cagctgctac	gcgctctttc	cccggcgccg	120
cacattcctg	gaagcttggc	ggcgctgccg	cgaattgggg	ggcaacctgg	ccacaccgcg	180
gacccagag	gaggccagc	gtgtggacag	cctgggtggg	gtcgggcccg	ccaacgggct	240
gctatggatt	gggttgcagc	ggcaggctag	gcaatgccag	cgcagcgcc	cactgcgggg	300
cttcatatgg	accacgggag	accaggacac	cgcccttacc	aactggggcc	agccggctac	360
ggaaggaccc	tgcccgccc	agcgctgtgc	agcccttgag	gccagcgagg	agcatcgctg	420
gctcgaaggc	togtgcacac	tggctgtcga	cggctacctc	tgccagtttg	gttttgaggg	480
tgccctgccct	gccttgccgc	ttgaggtggg	tcaggccggt	cccgtgtct	acaccacacc	540
cttcaacctg	gtttccagcg	agttcgaatg	gctgcccttt	ggctccgtgg	cagctgtgca	600
gtgccaaagt	ggcaggggag	cttctctgct	gtgcgtgaaa	cagccttcag	gtggcggtgg	660
ctggctccag	actggccccg	tgtgcccgag	gactggctgt	ggtcctgaca	atggggggtg	720
cgaacatgag	tgtgtggaag	aggtggacgg	tgcgtgtctc	tgccgctgca	gtgaaggctt	780
ccgtctagca	gcagatgggc	acagttgtga	agacccctgt	gcccaggccc	cctgtgagca	840
gcagtggtgaa	cctggagggc	cacaaggcta	tagctgccac	tgtcgccttg	gcttccggcc	900

agctgaggat	gatccacacc	gctgcgtgga	cacggatgag	tgccagattg	ctgggtgtgtg	960
ccagcagatg	tgtgtcaact	atggttggtg	ctttgagtgt	tactgcagcg	aggggtcacga	1020
gcttgaggca	gatggtatca	gctgtagccc	tgccaggagcc	atgggtgccc	aggcttccca	1080
ggatctcaga	gatgagttgc	tggtatgatg	agaagaagg	gaggatgaag	aggagccctg	1140
ggagactttt	gatggcacct	ggacagagga	acaggggatc	ctatggctgg	cacctacaca	1200
tccacctgac	tttggcctgc	cctataggcc	caacttccca	caggatggag	agcctcagag	1260
attgcacctg	gagcctacct	ggccaccccc	acttaaggcc	cccaagggcc	cccaacaacc	1320
cccaaggggg	gccgccaaaa	cgcccaagg	gaaccccgcc	aacccaaccc	acactacctt	1380
ctgcccacaa	gacctctgtt	atttcagcta	cacgcccacc	cctgagccct	gtccacccac	1440
ctgccatggc	ccctgccaca	cctccagctg	tgttctctga	gcaccagatc	cccaaaatca	1500
aggccaatta	tccagacctg	cottttggcc	acaagcctgg	gataacctcg	gccactcacc	1560
cagcacggcc	tcctccgtac	cagcccccca	ttatctcaac	caactatccc	caagtcttcc	1620
ctccccacca	ggccccctatg	tctccagata	cccacactat	cacttatttg	cctccagtcc	1680
cccctcacct	tgatcctggg	gataccactt	ctaaagccca	tcaacacctt	ttgctcccag	1740
atgctccagg	tatcagaacc	caggcccccc	agctttctgt	ctcagctctc	cagccccctc	1800
ttcctaccaa	ctccaggtct	tctgtccatg	aaactcctgt	gcctgctgcc	aaccagcccc	1860
cagccttccc	ttctttctccc	ctccccctc	agaggccac	taaccagacc	tcacttatca	1920
gccctacaca	ttcctattcc	agagcccctc	tagtcccaag	ggaaggagtt	cccagtccca	1980
aatcagtgcc	acagctgccc	tcgggtgccct	ccacagcagc	tccaacagcc	ctggcagagt	2040
caggtccttg	aggccaaaagc	caaaggggatg	accgctggct	gctgggtggca	ctcctggtgc	2100
caacatgtgt	cttcttggtg	gtgctgcttg	ccctgggcat	tgtgtactgc	actcgctgtg	2160
gctcccacgc	acccaacaag	cggatcacgg	actgctatcg	ctgggtcaca	catgctggga	2220
acaagagctc	aacagaaacc	atgcccccca	gaggcagcct	tacaggggta	cagacctgta	2280
gaaccagtgt	gtgatggggt	gcagatgccc	ctttgtggga	tagaagaaaa	ggacttgctt	2340
tggaacacatg	gctgagacca	caccaaggac	ttatgggggc	tgcccagctg	acagaggagg	2400
ttctgttctt	tgagcccagc	atccatggca	aaggacacac	caggactcca	ggacctcaag	2460
gggtgggtgc	tgggatcttc	tccaataaat	ggggtgcca	cctctaaaaa	aaaaa	2515

<210> 5

<211> 1587

<212> DNA

<213> Mouse

<400> 5

gcggcgcggg	tagagggcgg	tgggcggcga	gcggcgatgg	gcggcgccctg	gggcttgctc	60
gttggactcc	tgggcgtcgt	gtggctgctg	cgcttgggccc	acggcgagga	gcggcgggccg	120
gagacagcgg	cacagcgctg	cttctgccag	gttagtggtt	acctggacga	ctgtacctgt	180
gatgtcgaga	ccatcgataa	gtttaataac	tacagacttt	tcccaagact	acaaaagctt	240
cttgaaagtg	actacttttag	atattacaag	gtgaacttga	agaagccttg	tcctttctgg	300
aatgacatca	accagtgtgg	aagaagagac	tgtgcggtca	aacctgcca	ttctgatgaa	360
gttcctgatg	gaattaagtc	tgcgagctac	aagtattctg	aggaagccaa	ccgcattgaa	420
gaatgtgagc	aagctgagcg	acttgagacc	gtggatgagt	ctctgagtga	ggagaccag	480
aaagctgtac	ttcagtggac	caagcatgat	gattcgctcag	acagcttctg	cgaaattgac	540
gatatacagt	cccccgatgc	tgagtatgtg	gacttactcc	ttaacctga	gcgctacaca	600
ggctacaagg	ggccagacgc	ttggaggata	tggagtgtca	tctatgaaga	aaactgtttt	660
aagccacaga	caattcaaag	gcctttggct	tctgggcgag	gaaaaagtaa	agagaacaca	720
ttttacaact	ggctagaagg	cctctgtgta	gaaaagagag	cattctacag	acttatatct	780
ggcctgcacg	caagcattaa	tgtgcatttg	agtgcagggt	atcttttaca	agatacttgg	840
ctggaaaaga	aatggggtca	caatgtcaca	gagttccagc	agcgctttga	tgggattctg	900
actgaaggag	aaggccacgc	aaggctgagg	aacttgtact	tcctgtacct	gatagagtta	960
agggtctctt	ccaaagtgtc	tccatttttt	gagcgtccag	attttcagct	cttactggg	1020
aataaagtcc	aggatgcaga	aaacaaagcg	ttacttctgg	agatacttca	tgaaatcaag	1080
tcatttcctt	tgcacttcga	tgagaattct	ttttttgctg	gggataaaaa	cgaagcacat	1140
aaactaaagg	aggacttccg	gctacacttt	aggaacattt	caagaatcat	ggactgtgtt	1200
ggctgcttca	agtgccgcct	gtggggcaag	cttcagacgc	aggggctggg	cactgctctg	1260
aagatcttgt	tttccgaaaa	actgatcgca	aatatgccgg	aaagcggacc	aagttatgag	1320
ttccagctaa	ccagacaaga	aatagtatca	ctgtttaatg	catttggaag	gatttccaca	1380

agtgtgagag	aactagagaa	cttcaggcac	ttgttacaga	atgttcactg	aggaggacgg	1440
ttggaatgtg	cctgtttctg	cacaggggaa	tttgaagggc	aaaatctctt	ttagcccat	1500
ggttgcaatg	tactgtccta	agcccaacgt	ttatataaac	ctgcttttgt	taaagaaaaa	1560
aaaaaaaaaa	aaaaaaaaaa	aaaaaaa				1587

<210> 6

<211> 2494

<212> DNA

<213> Rat

<400> 6

acttgaactg	gcagataaaa	aagtatgaca	ccaaggcagc	ttactgccag	agcaagttgg	60
ctgttgcct	cttcaccaag	gagctgagtc	gccggctgca	aggcactggt	gtgactgtca	120
atgcgctgca	ccctggcgctg	gccaggacgg	agctggggcg	acatacaggc	atgcacaact	180
ctgcgttctc	tggcttcatg	cttggggccct	tcttctggct	gctgttcaag	agtccccagc	240
tggcggccca	gcccagcaca	tacctggctg	tggcagagga	actggagagt	gtctctggga	300
agtactttga	tggactcaga	gagaaggctc	catctcctga	ggctgaagat	gaggaagtag	360
cccggaggct	ttggactgaa	agtgcccat	tggtagggctt	ggacatggct	catgggtcct	420
ctgggagagg	acattccatc	tccagataaac	cttcagaaat	ccagatggag	cctcatcatc	480
ctctaggggc	agtgttggta	ttgttagaat	ctcaagactg	tggatgttgg	ctgccatgac	540
cctcatcatc	ctctaggagc	agtgttgtac	tactcgaact	gaagactgtg	gatgctggct	600
gccatcctct	gggtggctgt	gttggtccta	gcattattgt	tagctggctg	ctttggtttg	660
gaccacggga	tggcaggcac	atgtactcct	ttggttactg	gggagatagt	ccattgggtgc	720
ctcctacagg	aatctaaaag	cggggaagct	gatggaggag	tcagtcactc	tagttatggg	780
cagtgtccaa	agacagtggg	caccaaagct	gcagtagtgg	actgattgat	ccactgtgaa	840
agagcaagta	atcagacaaa	tatggctgta	gagctttgtg	ggcccttgca	catgtctgcc	900
tcctctctga	cttggctgtt	gttctagtgt	gctttctgtt	gctgtgataa	ataccatgac	960
caaaatcaac	ttgggggagga	aaagggtcta	tttaacttac	aggttatagt	ttaccatgga	1020
agagggaaac	caggggaagga	actcaggaca	agaacttgaa	gcagatacca	gatacaacgg	1080
aggtttgctc	ccaggcatatc	atcagatacc	tttattttat	ttttattatt	gttatttttt	1140
tatagagagg	gtctcacttt	gtaaccctgg	cctccctgga	acttgctatg	tagatcaggc	1200
tggcctcaaa	ctcacagaga	cctgccttct	gggattaaag	gcttgaatta	ttaggcttgg	1260
cccaggtacc	agtgcagcct	acctgccag	ggatggcacc	atctgcagtg	gggttctacc	1320
tcccatatca	actagcaatc	aagaaaatgc	tccacaaaca	ttccctcagg	gcagtctggt	1380
ctaagcagtt	cttcaggcga	gggtctgtct	gtctatcttc	taggtatgcc	aggttgacaa	1440
acaaatgaac	cagacggctc	ttgattgcaa	actgcaaagg	gtgtctgcta	cctcagggat	1500
ggtgtgggccc	tgaagctctt	gcccactca	gtaaagggca	gctgtggaca	cttgtgtact	1560
ggacactggc	tgaggggctg	ggatccagtg	gaaaccctgg	cctttgttag	ccctgaagta	1620
atcaggacag	aatggagtga	aaagctgcta	gctgctgctc	cagaaaatga	gtgtgacctg	1680
ggatcacgat	ctctccagtt	cctgtgtaat	tttaacctta	gcctctcaag	catgttgttt	1740
gattataata	acaagctaga	tagaggtagt	ggcacacttc	agtagctcca	gcacttaaga	1800
gggagaggca	ggagtatcaa	aagtccaagg	tcattccgagg	ccagcctggg	ctatatgaga	1860
ttctgccgaa	acaaagcaaa	acggtgagat	ctccaaatgg	ctgattcata	gatttaaaat	1920
aaagacatac	atcttagtgtg	cgagtgtgta	tactatgtgt	gtgtatgtgt	acgggtatgt	1980
gcacgtgccc	ttgtatgtgc	attacatgat	ggaggtcaga	ggacaacctg	tgggaatcag	2040
ttctctcttc	gtgaatcccg	aggatccaac	tcagtttgtc	aggcttggtg	gcaagggcct	2100
tcacctctga	accatagtgc	cagccctgag	tcataagggtt	tttttttata	ctttctgtat	2160
gggattttatt	ccacatacaa	cttattcttt	attcctttta	agaaactaag	acattccaatt	2220
gttgacaaga	caatgatttt	ccaacaactc	cctcgtattt	ctcatctatc	ctgttctgct	2280
taaattaggg	tagatcaact	tcccccttcc	cccccttctt	tgttttgaga	cagagtttca	2340
ctctatagat	caggctaaac	ttgggctctc	aggctccttg	tctaagcctc	tggagtcag	2400
agatgacggg	tctgccacac	cctgcgttta	caatcagtgt	ttacaatcaa	ataaatggaa	2460
ataaacatth	ctatcaaaaa	aaaaaaaaaa	aaaa			2494

<210> 7

<211> 1859

<212> DNA

<213> Mouse

<400> 7

gctcaaagtg	gccaactaca	gcaactcagg	cagattcaag	aagaggttca	tgtatcctgt	60
aggatatggg	cttcctgctt	ttattgttgc	tgcattgctgc	aatagctggc	cacaagaatt	120
atggaacaca	caaccactgc	tggctcagcc	ttcatcgagg	attcatctgg	agcttcttgg	180
ggccagcggc	agccattatc	ttgataaacc	tgggtgttcta	ctttctaata	atatggattt	240
tgagaagcaa	actttcttct	ctcaataaag	aagtttctac	acttcaagac	acaaaggtta	300
tgacatttaa	agccattgtc	cagttatttg	tgttgggatg	ttcttggggc	attggcttgt	360
ttatttttcat	tgaagttggg	aagacagtga	gactgatcgt	tgcctatctg	ttcaccatca	420
tcaatgtcct	gcagggtgtt	ttgataattta	tggtagattg	tctgcttaat	cgccagggtgc	480
ggatggaata	taagaagtgg	tttcatagac	tgcggaagga	agttgaaagt	gaaagcactg	540
aagtgtctca	ttctactact	cacacaaaaa	tgggtctttc	tctgaacctg	gaaaatttct	600
gccaacacag	aaacctccat	gatccttctg	actccatcct	tccaagtact	gaagtagcag	660
gtgtatatct	aagcacaccc	aggtctcaca	tgggtgctga	ggatgtgaac	tcaggtagctc	720
acgcttactg	gagcagaact	attagtgtat	gaatcagctc	cttcccccaa	gcctcttaca	780
gtacatttta	acttgtactg	tgccatgcac	atgaagctat	aattgctagt	ctggtaaaac	840
aactgttgca	tattccatga	tcatttcatt	ttatctctac	ttgcaaaagt	tagcttttctt	900
tttatatcat	ttttattttct	ctttcttttg	tttatatata	gcttcagttg	agtgggtttc	960
tagtcttaat	gttctagatc	actatttttct	tttcagttta	cctttatttg	tatttagttc	1020
ctgtgtagtg	tataccactg	gaataattttt	atttctttta	ttttgagggt	aaaatatagt	1080
tacatcattt	ttcctttttt	tctttcccac	aatcctcctg	tatacttttt	ccctgggtgtc	1140
tattttattg	tttctacatg	catatatatt	ttatgcaaaa	catatatatg	tataaatata	1200
aatatatatt	cttatatgca	tgaaaacccat	ctacttcac	caaataatgt	tccttctatg	1260
tatgttttca	ggacagggac	aacaatagct	atggtagcat	ggcaggggaa	agcccacagg	1320
acctcagcct	tatacaaaga	atcagaggca	actgaggagt	gctgagttga	aggaattgtc	1380
ttaccacagg	gagggcacat	taattgggtta	tctaatacaa	aatgttcagc	cccaaaaactg	1440
ttaagataaa	agcctatatg	catcttagga	agtatctacc	ttgatacacc	tttattggaa	1500
tatcatccac	atgtttattg	tgtgttctga	agagggtctg	ttgaatttct	aagggttgat	1560
cagtttaatt	gtgccatttt	atattcaggg	tgtttggctt	tgttgtagtg	aataatgcta	1620
tatttccctg	tatgtgtcat	ctttgactgt	tattttttcc	tggcaatact	ttattcaaca	1680
agaacctaga	gccttggttt	attacttttt	cttccataga	aaaactattt	gtcttccagg	1740
attagatatg	atcaatat	cttatatgca	tgtatcaaat	atcatgatga	aatatattac	1800
tgtgtataat	taataactgg	caataaagtc	caagggaaaa	ggaaaaaaa	aaaaaaaaa	1859

<210> 8

<211> 2305

<212> DNA

<213> Mouse

<400> 8

gaatctgtgg	aagcagttta	ttccagtatc	acccaggagc	agccacacag	aggctggtag	60
gagggctgga	tttttgttct	ctttttttct	tttcttttaa	tgtaacactt	ctttattttt	120
tcttcttgaa	gagtcttgag	gatacttaca	ttgcagttta	gtagtacagg	gtggataaat	180
tctactttga	agaaaaactt	tctcctctga	caagggttga	cttgtacaca	ggccagcatg	240
aaggagtatg	tgatgctact	gcttttggct	gtgtgctctg	ccaaaacctt	cttttagccct	300
tcccacacag	cactgaagaa	tatgatgttg	aaggatatgg	aagacacaga	tgatgacgat	360
aacgatgatg	acgacaactc	tctttttcca	acgaaagagc	cagtgaacct	ttttttccct	420
ttcgatttgg	ttccaacatg	tccatttggg	tgccaatgtt	actctcgagt	tgttcaactgc	480
tctgatctag	gtctgacatc	ggttccaaac	aacattccat	ttgatactcg	aatggttgac	540
cttcaaaaata	ataaaatcaa	ggaaattaaa	gaaaatgact	ttaaaggact	cacttcaactt	600
tatgctctga	ttctgaacaa	caacaagcta	acaaagattc	acccaaaaac	ctttctaacc	660
acaaagaaat	tgagaaggct	atatttatcc	cacaaccaac	taagtgaat	tccacttaat	720
cttcccaaat	cattagcaga	actcagaatt	catgataata	aagttaagaa	gatacaaaa	780
gacacgttca	agggaaatgaa	tgcctttacat	gttttgaaa	tgagtgcaca	ccctcttgag	840
aacaacggga	tagaaccagg	ggcatttgaa	gggtgacag	tattccatat	caggatcgct	900
gaagcaaaaac	taacctcaat	tccaaaaggc	ctaccaccaa	ctttgctgga	gcttcattta	960

caggctggcg	gaagccccc	gatatcacag	cgggaactgg	gaagggccct	gtttggaaac	1680
tgcaggagg	atagacagat	tccagggtccc	tgggtcagcca	ggccaagacc	acaggagcta	1740
agacaccccc	acctcatcac	cctcctaccc	accctctctc	tcatcttctt	tttgatgaat	1800
tctgtccatc	tccctagcct	ccatttttgg	tgtaccttcc	cattctcagt	actgctttct	1860
tattcttttaa	agatatttat	ttttcttttc	attaaaataa	aaccaaagta	ttgataaaaa	1920
aaaaaaaaaa						1930

<210> 10
 <211> 2617
 <212> DNA
 <213> Mouse

<400> 10						
ggcggcggga	agatgcggtt	gagggtccta	gcgctggcgg	cgcccggtgt	gctgggtccg	60
gccccggaag	tctgtggtgc	tctcaatgtc	acggtgtccc	caggacctgt	ggtggactac	120
ttggaagggg	aaaatgccac	cctcctctgc	cacgtctccc	agaagagacg	gaaggacagc	180
tgctggccgt	gcgctgggtc	ttcgccccctg	acggctccca	ggaggccttg	atggtgaaga	240
tgacgaagct	ccggataaatt	cagtactatg	ggaacttcag	ccggactgcc	aaccagcaga	300
ggctacgcct	gctcgaggag	cgctcgagggg	tgctgtacag	gctgtctgtc	ctgacgctcc	360
ggccacaga	tcaagggcag	tatgtctgca	aagtgcaga	aatcagcaag	caccgcaaca	420
agtggacagc	ctggtccaat	ggctcctcgg	cgacggaaat	gagagtgatc	tccctcaaag	480
ctggcggaaga	ttcatcattt	gagaaaaaga	aggtgacttg	ggcatttttt	gaagatctct	540
atgtgtacgc	tgctccttgg	tgctgcgtgg	ggatcctcag	tgctctgtct	ttcacctcgg	600
tcattgcctg	cagtctgtgt	ttcacaagag	gaaatcaaga	gtgagacatt	atgtggtgaa	660
gtgccctcag	aacagctcag	gggagactgt	caccagtgtg	accagcttgg	ccccactgca	720
gccacagaag	ggtaagaggc	agaagaagaa	ggtagatgtt	ccacctgcag	tccctgcca	780
agcgccgata	gccaccactt	tccacaaaacc	aaagctgctg	aaaccacaga	ggaaagtccg	840
cctgccccag	atcacccagg	aaaacttgac	ctatgccgag	ctggagctga	tcaaaccaca	900
cagggtgcc	aaaggcgtcc	ccaccagcac	cgtgtatgca	cagatcctct	tcgaggagaa	960
ccagctgtag	cgataacctc	tctctggctg	tcattgtgtc	tcccagttgt	ttatgacact	1020
cagaaacaaa	ctccctagtt	ttgtattttc	acccgtgcct	tcagtgtgat	ggggagcccc	1080
ttcccacagc	gttctgatgt	cttctaagag	gtacacactt	cccagaagag	aagggaccag	1140
ctcttgccca	tgccctccca	gataagaggc	ccctggcctg	attctgagca	caaggactct	1200
gcttctgaga	gcattgtctg	gccaaaccgt	ccaacttctc	ctctttctta	gccttaaagt	1260
tttgagggaa	aaatcaaata	ttaattttta	tcagcccccc	ttgttctgta	taacaagcat	1320
ccagtttata	gccacaggaa	atgctgtaaa	ggtcacagag	agaaatggga	tatatggact	1380
gacaagttct	ctaaggctct	gggacaccca	ggacagagca	aacccttgg	ggtggtggca	1440
ggagccactt	atgatgacat	ccattgcttt	taatagatgc	tctgaaactg	gccatgtgag	1500
ggcagagatg	tgctgggttg	aaagccggag	atctggctca	gaaaattctg	gtcttatgtc	1560
tttagagcca	tacttcacca	gggctgtaga	tctacaagaa	cacccttgta	aagtgtttgt	1620
ccccctttag	cagaatggac	ctagagagac	atattgttct	ctcttttcca	aagacttgag	1680
tatggctcca	gtgggtacat	cgggtaagtg	agcaaagcat	gcaagctcag	tcaactccat	1740
tcaagataga	gtggagcctt	tcaccattcc	ctcagcagag	aatgaaagc	acaaggcatg	1800
ccgggaaact	atgtccagga	ggactcaacc	cttggcaagt	gctttgaccg	tctcaatctt	1860
ggatgagaac	catgattgcc	ttgggtggat	gtcaggggac	catgggacat	aagtccgtgg	1920
ggaagtgact	ctgtggacct	aaacaatgta	caaaaatgtc	agacttaatg	gaagtaagag	1980
agtcaccttg	atctccgcag	tgctattgat	gcttcttgat	gtatactctg	gtggccactt	2040
actgcacttt	ataaacattg	tctggctttg	taattttaca	atgtatatat	gataaattat	2100
ctatttttaa	cacagctagg	gtgtgcattg	tgccctctgt	ctcactgtgg	gacttgagtt	2160
ttttattacc	ttaaacttga	tcacagctac	acaagtgtgt	ggaatggggg	aacctactga	2220
acattgcctt	ttaatgggga	atagaagcct	cacagcatcc	ctgcccagct	tgtctctctg	2280
actttttcaa	agggaaaccg	cagcagcacc	ctcagagcag	ggacaatgag	cagtttgtac	2340
ctgggtgctt	tttgaagtaa	catatttttg	ggttcttgat	cagaaaaatg	gtctagtccg	2400
tcttccttta	ccacatagac	cactaacctg	gaattgacat	ttctgaagct	aagtgaggag	2460
aagcatccat	catctggaaa	gtgcaaaagg	ttcttcttgc	gacaaggcat	caataggagc	2520
ggtgatgtaa	tcactgagta	gttccccaaa	tggcagctgt	cttcagtggt	tccatgcaat	2580
taaagcaagc	atgacctcaa	aaaaagaaaa	aaaaaaa			2617

gattttaata	aaatttcaac	ggtggaactt	gaagatctta	aacggtacag	ggaactgcaa	1020
aggctgggtc	ttggaaacaa	cagaatcaca	gataattgaaa	atggaacttt	tgctaataata	1080
ccacgtgtga	gagagataca	cttggaaacac	aataaaactaa	aaaaaatccc	ttcaggattaa	1140
caggagttga	aataacctcca	gataatcttc	cttcattata	attcaattgc	aaaagtgga	1200
gtgaatgact	tctgtccaac	agtgccaaaag	atgaagaaat	ctttatacag	tgcaataagt	1260
ttattcaaca	acccaatgaa	gtactgggaa	atacaacctg	caacatttcg	ttgtgttctt	1320
ggcagaatga	gtgttcagct	tgggaatgtt	ggaaaataat	tcatgacatc	cattaaatat	1380
aaaattcaaa	aatgtatata	tttggaaatac	ttgaaactgtc	ctagtaatgg	tagtattata	1440
cacataagca	aaattctatt	ctatatggtc	aatgacaaaa	aatttcaaca	gaattttgcc	1500
taattattga	tgctcagaat	aaatttctat	tgcaagtgtcc	ttctgcacat	gaatgattct	1560
tgcgtaaatc	ttttgcttga	acatttcttt	tttcggcaaa	aaaagatatt	tagtatttaa	1620
cccttcatta	tcaagtcagt	caaacagaat	tgtactgtaa	acagaatgct	tgacttagta	1680
acatttgtgt	catatctttg	ctgttagaaa	aacaaaactg	gcaagaacag	cattttgaaag	1740
agtacatata	tttttagtag	ttttttaaaaa	aaaacttgga	cagtactgta	atgtttccaa	1800
taatgttggga	atacatatag	tttgacagaa	tcaaaattct	caactcataa	taaagcttca	1860
agtattcaca	gataaatattc	atcagagttg	gtttgggcta	taacacatga	atatcttttt	1920
taaattatta	actggctata	aaattgtaaa	aatataatga	ctgctaatat	aaaatctata	1980
atgtgcattt	tatgatcagt	tatataagct	ttgaagaaca	cagtaactgt	taggttacat	2040
agtgttatta	cttcaactag	gaatatattca	ggatatccct	ttggaacagt	atggacgcca	2100
atcaatttta	tatcaactta	tctcttcaaa	tatgcacatt	gggtaatgoc	tggaacata	2160
gctaaggtga	caaaaactga	aaactgaaca	aaacttaata	gtactttcat	gtgttttttt	2220
taaactgata	ttcattatga	attaagttaa	aagtgacaat	aaggaaaaca	ttaaatactg	2280
gttttcaata	aaaaaaaaaa	aaaaa				2305

<210> 9

<211> 1930

<212> DNA

<213> Mouse

<400> 9

gcggaggcgc	gcagggcagc	ctgggtccag	cccacacccc	tcaccaggag	gcaccatgtg	60
gggatgttgg	ctggggctgc	tcttgctgct	gctggctggc	caggctgccc	tgaggcccg	120
gcggagtcgt	tggcgcaggg	agctggcgcc	agggctgcac	ctgcggggca	tccgggacgc	180
cgggtggcaga	tactgccaag	agcaggacat	gtgctgtcga	ggcctgtctg	acgagtgtgc	240
cctgccctac	ctgggagcca	cctgttactg	tgacctcttc	tgcaaccgca	ccgtctctga	300
ctgctgcccc	gacttctggg	acttctgcct	cgggattcca	cccccttcc	ctcccgcca	360
aggggtgcatg	catggggggc	ggatctaccc	agtcttcgga	acctactggg	acaactgcaa	420
tcgatgcacc	tgccatgagg	gagggcattg	ggagtgcgac	caggagccgt	gtctagtgga	480
cccagacatg	attaaagcca	tcaaccgagg	caactacggg	tggcaggctg	ggaaccacag	540
tgccctctgg	ggcatgaccc	tggatgaggg	cattcgctac	cgccggggca	caatccgccc	600
atcctccaact	gtcatgaata	tgaatgagat	ttatacgggtg	ctgggccaag	gggaagtgtc	660
acccactgcc	tttgaagctt	cagagaagtg	gccaacctg	atccacgagc	cattggacca	720
gggcaattgt	gcaggttcct	gggctttctc	cacagcagct	gtcgcatctg	atcgctctc	780
tatccattct	ttgggacaca	tgacacccat	cctatcaccg	caaaacctgc	tgctcgtgtg	840
taccacccac	cagcagggct	gccgaggtgg	gcgtcttgat	ggcgcttggg	ggttcctgcg	900
gcgcgcgggg	gtggtgtctg	acaactgtta	ccattctctc	ggcgtgagc	agaacgaggc	960
cagccccact	cctcgttgta	tgatgcacag	ccgcgccatg	gggcggggca	agcgccaagc	1020
cacttcccgc	tgccccaatg	gtcaggttga	ttccaacgac	atctaccagg	tcacgcctgc	1080
ctaccgcctg	ggctctgatg	agaaggagat	catgaaggag	ctaattggaaa	acggccctgt	1140
tcaagcactc	atggaagtac	acgaggactt	cttcttgtac	cagcgtggca	tctacagcca	1200
cacacctgta	agccagggga	ggccggagca	gtaccgcaga	catgggactc	actcagtcaa	1260
gatcactggg	tggggagaag	agacgctgcc	agacggaagg	accattaagt	actggactgc	1320
tgccaactcg	tggggcccat	ggtgggggtga	aaggggcccac	ttccggatcg	tgctggcac	1380
caacgagtgc	gacatcgaga	ccttcgtgct	gggcgtctgg	ggtcgcgtgg	gaatggagga	1440
catggggcac	cactgagtct	cagccactag	gcgaggtggg	atccacagcc	acagaagagg	1500
ccttgggggc	catgcccgat	gaagccttgt	gtgcacttcg	ggaccagggtg	ctaactctta	1560
cagactcaga	tccgcgcgtg	cgcgctaagg	cagaatccca	cctaggagac	aaagatgcac	1620

<210> 11
 <211> 1480
 <212> DNA
 <213> Mouse

<400> 11
 gggctcccag gtgatcgggtg tgtgtcagcc tctctccagg gcctccaggg aaccatggac 60
 ttttggcttt ggttacttta ctctctgcca gtgtctgggg ccctgagagt cctcccagaa 120
 gtacagctga atgtagagtg ggggtggatcc attatcatcg aatgccact ccctcaacta 180
 cacgtaagga tgtatctgtg tcggcagatg gccaaacctg ggatatgctc cactgtgggtg 240
 tccaacacct ttgtcaagaa ggaatatgaa aggcgagtc caactgacgc atgcttggat 300
 aagaagctat tcctagtggg gatgacacag ctgacggaaa atgacgatgg aatctatgcc 360
 tgtgtgtgtg gcatgaagac agacaaaggc aagaccaga aaatcaccct gaatgtccat 420
 aatgaatacc cagaaccatt ctgggaagat gaatggacct ctgagcggcc aagatggttg 480
 cacagatttc tgcagcacca gatgccctgg ctccacggga gtgaacatcc cagctcttct 540
 ggagtcatag ccaaagttac cacgccagct tcaaagactg agggccctcc ggttcaccag 600
 ccctccagca tcacttcagt aacccaacat ccagagttt acagagcatt ttctgtgtca 660
 gctaccaagt cccagcgcct cctgccagca accacagcct caaagacttc cactcagcaa 720
 gcaatcaggc ccctagaggc cagctacagc caccacacca gacttcatga gcaaaggaca 780
 cgccaccatg gccacacta tgggagagaa gaccgagggc ttcacatccc catcccagaa 840
 tttcacatcc tgattccgac ctctctgggc tttctcttgc tggttctttt gggactgggtg 900
 gtaaaaagag ccattcaaag gaggagagcc tcctccagac gtgcgggccc actggcgatg 960
 aggaggcgag gccggggggc ttcccgcccg ttcccccac acgcgcggga tgccccgcag 1020
 aggcgcgcgt cgcagaacaa cgtctacagc gcctgcccc ggcgcgcacg gggaccagac 1080
 agcttgggtc cagcggaggc tccgctcctc aacgccccag cctcagcgtc ccccgcttct 1140
 ccgcaggtac ttgaagctcc ttggccccac acccatctc tgaagatgag ctgtgaatac 1200
 gtgagcttgg gctaccagcc tgctgtcaac ctggaagacc ctgattcaga tgattacatc 1260
 aatattcctg acccatctca tctccctagc tatgccccag ggcccagatc ttcattgcaa 1320
 tgagttctgc ctgtttgtgc atgtctagca cgttttcctt ataggatccc tgcattggcg 1380
 tatgtcctat accctaagtc gactctcacc tgactatctg aatgccttga gaatgatcaa 1440
 ttacaggcta atttttcacc ccaaaaaaaaa aaaaaaaaaa 1480

<210> 12
 <211> 802
 <212> DNA
 <213> Mouse

<400> 12
 gctgagccag gatgaaggct ctgagggtg tcctcctgat cttgtacta agtggacagc 60
 cagggagtgg ctgggcacaa gaagatggtg atgcggaccc ggagccagag aactacaact 120
 acgatgatga cgatgatgaa gaggaagagg aggagaccaa catgatccct ggaagcaggg 180
 acagagcacc totacaatgc tacttctgtc aagtgttca cagcggggag agctgcaatc 240
 agacacagag ctgctccagc agcaaaccct tctgcatcac gctcgtctcc cacagcggaa 300
 ccgacaaaagg ttacctgact acctactcca tgtgtgtgac tgatacctgc cagcccatca 360
 tcaagacagt gggaggcacc cagatgactc agacctgttg ccagtccaca ctgtgcaata 420
 ttccaccctg gcagaacccc caagtccaga accctctggg tggccgggca gacagccccc 480
 tggaaagtgg gactagacat cctcagggtg gcaagtttag ccaccccag gttgtcaagg 540
 ctgctcatcc tcagagcgat ggggctaact tgcctaagag tggcaaggct aaccagcccc 600
 agggaaagtgg ggcaggatac ccttcaggct ggaccaaatt tggtaataata gccctcctgc 660
 tcagcttctt cacttgtctg tgggcgtcag gggcctgaag acccgttctc ctccaaccag 720
 gacgccctgg cctctccttc ctgacaacca gcttcagaga ataaacttga atgtcgtttg 780
 ccatctaaaa aaaaaaaaaa aa 802

<210> 13
 <211> 2112
 <212> DNA

<213> Mouse

<400> 13

gggtgctcag	acggtgaaaa	tcagagatca	ggccaccttt	ctgtgagcct	tcagctgagt	60
ctaaaggtgt	tattgatcag	aatggcttca	ggatggtttt	acctgtcctg	catgggtgctg	120
ggatcgctgg	gatcgatgtg	catcctcttc	actgcctact	ggatgcagta	ctggcgcggt	180
ggctttgcct	gggatggcac	ggtgctcatg	tttaactggc	acccagtgtc	catggttgcc	240
ggcatgggtg	tgctctatgg	agctgcctca	ctggtgtacc	gcctgccttc	atcgtgggtg	300
gggcccaggc	tgccctggaa	agttctccat	gcagcactgc	acctgctggc	cttcacctgc	360
actgtgggtg	ggctgattgc	cgtctttcgg	tttcacaacc	actcgagaat	cgcacacctc	420
tactccctgc	acagctggct	gggtatcacc	actgtagtcc	tcttcgcctg	ccagtgggtc	480
ctgggctttg	ctgtcttcc	cctgccctgg	gcatcccagt	ggctgcgaag	cctcctgaaa	540
cctctgcatg	tattctttgg	agcctgcac	ctttccctgt	ccatcacatc	tgttatttcc	600
ggcatcaatg	agaagctttt	ctttgttttg	aaaaatgcc	ccaagcccta	ctccagcctg	660
cctggtgagg	ctgtctttgc	caacagcaca	gggtctcttg	tggtggcttt	tggtctgctg	720
gttctctatg	ttcttctggc	ttcatcatgg	aagcgtccag	atccaggagc	tctgactgat	780
agacagcccc	tggtgcatga	cagggaatga	agcgggcagg	ggctcctggg	aacggtcagc	840
gatgcgggtc	ctgctccctc	agaagttctg	ctgtactggg	gctcctggct	ggtttcagca	900
acagacttct	cttggggccag	agacccaacc	ttgctactcc	agttgcaggc	tctcgtgtgc	960
cagccactag	ctgttccctc	gcttttcttg	tggtcttggc	ttattgccgt	tttttctgg	1020
tcctccattg	gcacaaagac	cttcttgcct	tggtcacaca	tgtctcttct	gctgggtctgc	1080
agatttgggc	tgctttcctt	accactccta	gggatgtggg	agaagccaaa	gctgggggtc	1140
aaatgcagtc	tacacgtgta	aaatacaaa	tctgctctct	gtgggagcat	ttgtcttagt	1200
taggtatgct	tccccctctg	ctctgtcctg	gatgtgtatt	tggttgggca	gttgcatatga	1260
ggggtcattc	atgggacagt	ggcagccgga	gaagcctctg	ctgtaaagtc	aggtgcccag	1320
tactctgctc	ttttcacttt	gatgtgctgt	attgtgtgga	ttgtgacctt	gtgattcccc	1380
ctcttctagc	tgctgtctca	gctgcttcc	ggatcccgc	ctttccctgt	gacttacatg	1440
cctgttcccc	tcaggtagca	tgacgagccg	ttaaacagtt	ctcccaagaa	cacatgtcct	1500
gtccctagag	tccctcccag	tgatgagtct	gaggtttctt	tggtcttcc	ttctgtccct	1560
ttgtgggtat	gggttttcc	gcctcctcta	gttatgctct	cccctgacag	ggcccagcc	1620
cactatgaaa	ttgaaaccag	cattatgaag	caatttgctg	ggagccattc	actgctgctg	1680
ccttcagaga	tggtcccttag	tgagttagtg	gtgcttctgt	tccccaaaag	gtcactcagc	1740
taccctctat	gctataccag	aatgtgagct	ttgctcttct	gaatagaaac	tggttagaga	1800
gggaggagtc	ttgccccact	cctttgtgtt	agccctgcc	ggtccctcaa	caggcaggca	1860
ggcaggcaag	caggcagaca	ggcaggcaga	gttgggttcc	tgaactctct	gcagacagtg	1920
gccaggctgc	cagacgttgg	gaggagggtc	ggcatggatt	tgctgactaa	atggaagcct	1980
gaacacatag	cgatgaactc	tggcaccac	atgaacatct	tcctggttca	ctcatgagtg	2040
ggtatttttac	ttcatgaatc	ttatttttat	taaatatgtt	tttaaaccatc	agaaaaaaaa	2100
aaaaaaaaaa	aa					2112

<210> 14

<211> 915

<212> DNA

<213> Mouse

<400> 14

ggaagtaagt	tcagaggcca	tgagactgcc	tctgccactg	ttgctactgt	tcgggtgcag	60
ggctatcctg	gggagcgccg	gggatagggt	ttccctctcg	gcttcggctc	ccacactgga	120
tgatgaagag	aagtactcgg	ctcatatgcc	ggctcacctg	cgctgcgatg	cctgccgggc	180
tgtggccttc	cagatggggc	aacgtctggc	gaaagcagag	gctaaatctc	acactccaga	240
cgccagtggg	ttgcaggagc	tgagtgaatc	cacgtacaca	gatgtcctgg	accagacctg	300
ctctcagaac	tggcagtcct	atggagtcca	tgaagtgaac	cagatgaagc	gtctcacggg	360
cccaggactt	agcaaggggc	cagagccaag	aatcagcgtg	atgatttctg	ggggctccctg	420
gcccataagg	ctctccaaga	cgtgtttcca	ctacctgggt	gagtttggag	aggaccagat	480
ctatgaagcc	taccgccaag	gccaagcgaa	tctggaggcg	ctgctctgtg	ggggcaccca	540
tgggcccctg	tcacaggaga	tcctggccca	gagagaagag	ctttagtcca	acctgctgca	600
cttctggatc	ttctctaatt	ttattattat	taatggctga	ttagaggcag	gctctcatca	660

tgtaggccag	gctggcctta	aacttgtcat	cctgctcagc	ctcgaaagtg	ctgcatttaa	720
gtcctgagcc	tttttgtgct	tgaccctcct	atataatatt	ttcaactgtg	gtgggtggga	780
ggggacaggg	aagcctgact	ctagctgtca	atcttctccc	tccacctctc	gatggggtac	840
tgggactgag	gctgcctttc	tactttcaaa	taaagctttg	aaagacaaaa	aaaaaaaaaa	900
aaaaaaaaaa	aaaaa					915

<210> 15

<211> 1308

<212> DNA

<213> Mouse

<400> 15

gtgagagctc	agctggaagt	gactgggtga	caaggcgcac	aggctcagcc	gtggaagctc	60
catcatgatt	ccacaagtag	tgaccagtga	gactgtcaca	gtgatttcac	caaattggaat	120
cagctttccc	caaacagaca	aacccagacc	ttcccaccag	agccaagaca	gactgaagaa	180
acatctaaag	gctgagatca	aagtgatggc	ggcaatccag	atcatgtgtg	ctgtgatggg	240
gttgagtctg	ggaatcattt	tggcatctgt	tccctccaat	ctacacttta	cctcagtgtt	300
ttccatcctg	ttagaatctg	gctacccatt	tgtaggagct	ttgttttttg	ccatctctgg	360
aattctgtct	attgtcacag	agaaaaagat	gactaagcct	ttggttcaca	gcagcctagc	420
cctgagcatc	ctgagtgtcc	tctctgctct	tacaggcatc	gctattctct	ctgtcagttt	480
ggctgcttta	gagcctgcct	tgcagcaatg	taagctggct	ttcacacaac	tagacacaac	540
ccaagacgct	tatcatttct	ttagccctga	gccattaaac	agctgcttcg	tggccaaagc	600
tgctctgact	ggagtctttt	cactgatgct	aatcagcagt	gtgttggagc	ttggcctggc	660
tgtcctcact	gccacactgt	ggtggaaaca	gagctcctct	gctttctctg	ggaatgtgat	720
tttctgtct	cagaactcaa	agaataaatc	cagtgtatct	tcagagtcac	tttgtaaccc	780
tacatatgaa	aacatattga	cttcataaga	attaagtaga	ggttatatag	cagaaaaatc	840
tgtctttaac	atgattttaga	aaagccattt	actgtgtgac	aacaatgctt	aatatcttaa	900
tatcttaatg	tgtgtattgg	ttaatcagca	accatgaaaa	acataactaac	tggctggggt	960
cagtagcacg	ctcttgattt	ggcgtcagtc	aaaacacaga	cctgtaaaatt	ccaatttatg	1020
tagtggctaa	agagcccca	ttattttctc	aaaaaactgg	aagaatgttt	cataggatca	1080
tgggtggagc	aatgggcaac	agttcttctt	atccttgtca	cttggctgca	ggaggtagctg	1140
actagggcct	gagatcatat	tctgtgtgcg	tggcatggac	ttcatggcat	ctattttatt	1200
cataagcaca	tgaaaacaag	tcatctctta	tgaagtctca	aagagcataa	aaaagtttagc	1260
ctccaaataa	agtcttttatg	taatcccaaa	aaaaaaaaaa	aaaaaaaaaa		1308

<210> 16

<211> 1288

<212> DNA

<213> Mouse

<400> 16

gctccagctc	ctccatcctg	tagtttacag	ggtgtaccct	atgtcgggac	caatgtgacc	60
ctgaactgca	agtccccaag	gagtaaacct	actgctcagt	accagtggga	gaggctggcc	120
ccatcctccc	aggtcttctt	tggaccagcc	ttagatgctg	ttcgtggatc	tttaaagctc	180
actaaccttt	ccattgccat	gtctggagtc	tatgtctgca	aggctcaaaa	cagagtgggc	240
tttgccaagt	gcaacgtgac	cttggacgtg	atgacaggtc	agtaaggggg	tccaaggctg	300
cagtggctgc	tggagcagtt	gtgggcactt	ttgttgggtt	ggtgctgata	gctgggctgg	360
tcctgttgta	ccagcgccgg	agcaagacct	tggaaagagc	ggccaatgat	atcaagggaag	420
atgccattgc	tccccggacc	ttgccttggg	ccaaaggctc	agacacaatc	tccaagaatg	480
ggacactttc	ttcgggtcac	tcagcacgag	ctctgcggcc	acccaaggct	gctcctccaa	540
gacctggcac	atttactccc	acaccagtg	tctctagcca	ggcctgtcc	tcaccaagac	600
tgcccagggg	agatgaaccc	ccacctcagg	cagtgtccct	gacccaggt	ggggtttctt	660
cttctgctct	gagccgcatg	ggtgctgtgc	ctgtgatggg	gcctgcacag	agtcaggctg	720
ggtctcttgt	gtgatagccc	aggcactcat	tagctacatc	tggatatctga	cctttctgta	780
aaggctctct	tgtggcacag	aggactcaat	cttgggagga	tgcccacatt	ctagacctcc	840
agtccttttg	toctacctcc	ttctattgtt	ggaatactgg	gcctcagtaa	gactaaaatc	900
tgggtcaaag	gacaaaagga	ggaaatggac	ctgaggtagg	gggttgggag	tgaggagggt	960

tcacttcctc	cctgcttctc	cctgaagcca	gatgaatgct	gcggaagatc	ggctaccctc	1020
caagggctct	ggaggagact	gccagtcagt	gatgccccctg	gctctgtgat	ctgtacaaca	1080
cccttatcta	atgctgtcct	ttgccgttcg	ctccatctcc	ctgtattaat	ataacctgtc	1140
ctgctggcctt	ggctggggtt	tggtgtagca	gggggatagg	aaagacattt	taaaatctga	1200
cttgaaattg	atgtttttgt	ttttattttg	caaattccaa	taaagataca	tcgcatttgc	1260
atggccaaaa	aaaaaaaaaa	aaaaaaaaa				1288

<210> 17

<211> 999

<212> DNA

<213> Mouse

<400> 17

gccagctttt	tcctccgcag	ccatgtcctg	gtctccgata	ctaccatttt	tgctcccttct	60
gcttctgctg	ttcccaactcg	aggttcccag	agcagccact	gcgtcccttt	cgcaagcatc	120
ctccgaaggc	acaaccacct	gcaaggtcca	cgatgtgtgc	ctcttggggc	cacgcccatt	180
gcccccttca	ccacctgtca	gagtcagcct	gtattatgag	tcctgtgtgtg	gagcttgtcg	240
ctacttcctc	gtccgggatt	tgttcccaac	ctggctgatg	gtgatggaaa	tcatgaacat	300
caccctgggtg	ccctacggga	atgcacagga	gagaaatgtc	agcggtagct	gggagttcac	360
gtgccagcac	ggggagctgg	agtgtagact	gaacatgggtg	gaggcctgtc	tgctggataa	420
gctgaaaaag	gaggcagcgt	tcctaaccat	cgtctgtatg	gaggagatgg	atgatatgga	480
gaagaaactg	ggaccgtgcc	tcgagggtga	tgctcctgag	gtgtcaccag	agagtatcat	540
ggagtgcgcc	acaggaaaac	ggggcacaca	gctcatgcat	gagaatgccc	agctcacaga	600
tgccctacac	ccaccccacg	agtatgtgcc	ctgggtgctg	gtcaatgaga	aacctttgaa	660
ggaccccagc	gagctcctga	gcatagtctg	tcagctggac	cagggaacgg	agaagccaga	720
catctgctcc	tcatttgccg	actccccag	gaaggtctgc	tataagtaaa	ggcataacct	780
caaactcgtc	ccagaaaact	gccagcttc	ttcaaattgc	caacotgcaa	gagctgctgc	840
ctcgctatga	aaaccttgca	catgtcccac	aaagcccaga	ctccagactt	ctcagagaca	900
aggatcttgc	cttatttttca	aatgggtgcta	aatttaaatt	catagaataa	atcatctata	960
ctcctgtgat	tccttttttcc	taaaaaaaaa	aaaaaaaaa			999

<210> 18

<211> 2123

<212> DNA

<213> Mouse

<400> 18

gctgtcccgt	gtcctgctgt	ggaaactgct	gcttcttcag	agctctgcag	tcctgtcctc	60
agggccttca	gggaccgcag	cagccagcaa	ctctctgggtg	tctgagtctg	tggtgagctt	120
ggcagccgga	acccaggctg	tgctacgctg	ccagagcccc	cgcattgggtg	ggacccaaga	180
ccggctgcat	gatcgccagc	gcgtgggtcca	ctgggacctc	agcggggacc	cgggcagcca	240
acggcgccga	cttgtggata	tgtattcggc	gggtgaacag	cgcgtgtacg	agccgcgcga	300
tcgcgaccgc	ctcctgctgt	cgccttctgc	tttccacgac	ggcaacttct	cgtgctcat	360
tcgcgctgtg	gagagaggcg	atgaaggggt	gtacacctgc	aacctgcacc	atcactactg	420
ccacctcgat	gagagcctgg	ctgtgcgctt	cgagggttaca	gacgatcccc	tattaagtcg	480
cgcatactgg	gacgggtgaga	aggaagtgtt	ggtgggtggcc	catggcgcg	cggcactgat	540
gacctgcac	aacogtgcgc	acgtgtggac	tgaccgccat	ttagaggagg	cgcagcaggt	600
ggtccattgg	gaccgacagc	tacctggagt	gtcacacgac	cgcgcgcgacc	gcctgcttga	660
cctgtatgca	tctggcgagc	gccgcgccta	tgggcgcgcc	ttcctgcgtg	atcgcgtgtc	720
agtgaacacc	aaogcttttg	cacgcgggtga	cttctcccta	cgcctcgatg	agctggagcg	780
agctgatgag	ggcatctatt	cctgccacct	gcaccatcac	tactgtggcc	tccacgagcg	840
ccgagtcttc	cacctacagg	tcacagagcc	tgccctttgag	ccaccagctc	gtgcttctcc	900
tggcaatggg	tctgggtcaca	gcagtgtctc	tagcccagat	cccaccctga	cccagggcca	960
cagcatcatc	aatgtcattg	tcccagagga	ccacacacat	ttcttccagc	aactgggcta	1020
cgtgttggcc	acogtgcctg	tcttcatctt	gctgctcatc	actgtagtcc	tggtacacg	1080
acatcgtaac	agcggaggat	gcaagacgtc	ggacaaaaaa	gctgggaagt	caaaggggaa	1140
ggatgtgaac	atggtggagt	ttgctgtagc	cacaagggat	caggctccat	ataggactga	1200

ggacatccag	ctagattaca	aaaacaacat	cctgaaggag	agggctgagc	tggcccatag	1260
tcctctgcct	gccaaggatg	tggatctgga	taaagagttc	aggaaggagt	actgcaaata	1320
aatggaccct	gagcttctgg	ctgggccagc	agctctgtat	caaaggacat	ctccctgacc	1380
ctcctgcggt	attcctggct	cttctcagcg	gctggtccga	cttacctaga	aacttggcct	1440
aaacttggca	gagcagctgc	ctgtactttg	cccttcctag	aatcgccacc	cctcatcttg	1500
gtgagcaact	gtgggttccc	tagagactct	ggtatagtac	gattgctgcc	cttcagtcac	1560
ctgtgcccac	tgatggtcgg	acccccaaat	taaacacaac	aaagatccct	tgtaaataatc	1620
caccaaattgc	aaagtccctc	gtggcctctt	actgctaggg	tcaggaagac	acttaaaaaat	1680
tccaggtaaa	actccctagc	caccagttaa	acacattagc	cattgtcctg	gggggggggg	1740
ggtcttcctg	agctgcatcg	tgcctgtgtc	ctgctcagag	ccctgctgtt	ataggttgtg	1800
actcatgggc	ccgccttget	gcttttggga	acttgaggct	agcccagggc	cctttctctg	1860
cttctgattc	ctttctgccc	aatgcctccc	aagagctaca	ccagcagttt	ctgggtaccg	1920
tatgaccctt	ggccttgaca	tccctcccta	ggctggagtc	tggggttggg	gccccatttg	1980
tcctctgttt	tggctgaaga	tgggggtgaag	atttggctga	gtggcctatg	ctgtcacatc	2040
aaacagctat	cattttactcc	tacttggaata	gttgtcatgt	gacaataaaa	gatacatttg	2100
acttttaaaa	aaaaaaaaaa	aaa				2123

<210> 19

<211> 1391

<212> DNA

<213> Mouse

<400> 19

gctggcaggc	tgctgtgcag	tccacgagga	aggcttcggt	cgacaggaca	ggcgtgcaga	60
cttcaggagg	gaccctgggc	agcagacatt	ccctggaagg	gcaggttgca	ttgcatgggt	120
ggctcatgga	ggcagcagag	gtggcctcag	ccaggcctgg	gcagcatcag	cccccgccag	180
cagcaagacg	ctggctgttc	cacctgcccc	caagaacagc	caccaccagt	accaggggga	240
tgactagcgg	ccggaccaca	ggccacaaaa	agaagaaggc	tacccccact	acagatgcag	300
accatgtggg	gctccggaga	actgcttgta	gcatggtttc	tagtggttggc	agcagatggt	360
actactgagc	atgtctacag	accagccgt	agagtgtgta	ctgtggggat	ttccggaggt	420
tccatctcgg	agacctttgt	gcagcgtgta	taccagcctt	acctcaccac	ttgcgacgga	480
cacagagcct	gcagcaccta	ccgaaccatc	taccggactg	cctatcgccg	tagccctggg	540
gtgactcccg	caaggcctcg	ctatgcttgc	tgccttggtt	ggaagaggac	cagtgggctc	600
cctggggctt	gtggagcagc	aatatgccag	cctccatgtg	ggaatggagg	gagttgcatc	660
cgcccaggac	actgcccgtg	ccctgtggga	tggcagggag	atacttgcca	gacagatggt	720
gatgaatgca	gtacaggaga	ggccagttgt	ccccagcgct	gtgtcaatac	tgtgggaagt	780
tactggtgcc	agggatggga	gggacaaagc	ccatctgcag	atgggacgcg	ctgcctgtct	840
aaggaggggc	cctccccggt	ggccccaac	cccacagcag	gagtggacag	catggcgaga	900
gaggaggtgt	acaggctgca	ggctcgggtt	gatgtgctag	aacagaaact	gcagttgggt	960
ctggcccccac	tgccacagct	ggcctctcgg	tccacagagc	atgggctaca	agatcctggc	1020
agcctgctgg	cccatctcct	ccagcagctg	gaccgaattg	attcactgag	tgagcagggt	1080
tccttctttg	aggaacatct	ggggtcctgc	tcctgcaaaa	aagatctgtg	ataacctctc	1140
accaccagag	ctggatagag	cagtcattccc	tagatccctt	gtagccagag	ttcaggcgct	1200
gtctgggtgt	gcctatgagc	agaaggccct	gcctcattgt	ccctctttct	taggaggttc	1260
ctaggacttg	ggcatgggga	gtgggtctct	gtgtgactct	tcagtggggc	tcctgtctta	1320
agtggtaagg	tggggattgt	ctccatcttt	gtcataataa	agctgagact	tgaaaaaaaaa	1380
aaaaaaaaaa	a					1391

<210> 20

<211> 1864

<212> DNA

<213> Mouse

<400> 20

ggcaccgcgc	gggcggctat	ggagcgagcc	tgaggcccg	caggatatga	attggctccc	60
tctgaccgcc	atttcagtg	ttgtaagtgt	gaggtcagca	actgcagcct	acagattgat	120
aactgtcgaa	cccacgaat	tgtggaggca	ctgcagtga	gaaatatgta	atcatggaat	180

ctccttgcta	atcgtcacca	cctgttccct	gtgataagcc	agccaggacg	tgggctgagg	240
agaaggaaaa	gaggccacca	tgaagctgaa	gcagcgagtt	gtgctgttag	caatactcct	300
cgtcattttt	atcttcacca	aagttttcct	gatagacaat	ttagatacat	cagctgccaa	360
ccgagaggac	cagagggtt	ttcacggaat	gatgactggc	ttgcgggtgg	agctgggtgcc	420
caagttggac	cataccctgc	agtctccttg	ggagattgca	gccagtgagg	tgggtgcccgc	480
ggaagtgtat	cctgaagaga	caccagagct	gggagcaatc	atgcatgcca	tggccactaa	540
gaaaatcatt	aaagctgacg	tgggtataaa	agggacacag	ctaaaagctt	tactgattct	600
tgaaggagga	cagaaagttg	tctttaagcc	taagcggtag	agcagagact	atgtggtaga	660
aggggagcca	tacgctgggt	atgacagaca	caatgcagag	gtggcggcct	tccatttgga	720
caggattctg	ggtttccgce	gagctccctt	ggtgggtggc	agatatgtta	atctgcgaac	780
agaagttaag	cctgttgcca	cggagcagct	gctgagcacc	ttcctaactg	tagggaacaa	840
tacttgtttc	tatgggaagt	gctactactg	ccgagaaaca	gagccagcat	gtgctgacgg	900
tgacatgatg	gagggtctctg	tcacactttg	gcttccagat	gtgtggcctc	tgcagaaaca	960
tcgacatccc	tggggcagga	cctaccgaga	aggcaaactg	gccagggtggg	aatatgatga	1020
gagctactgc	gatgctgtga	agaaaacatc	cccctatgac	tcaggcccgc	gtctcctgga	1080
catcattgac	acggctgtct	ttgattactt	gattggcaat	gctgatcgcc	atcaactacga	1140
gagctttcaa	gatgatgaag	gcgcgagcat	gcttattctt	cttgataatg	ccaaaagctt	1200
tggaaacccc	tcgctggatg	agagaagcat	tcttgcccct	ctctatcagt	gttgcacat	1260
tcgggtttca	acctggaata	gactgaatta	tctaaagaat	ggagtactaa	agtctgcctt	1320
aaaatctgcc	atggcccacg	accccatctc	ccctgtgctc	tccgatccac	acttggcac	1380
tgtggaccag	cggcttctga	atgtcttggc	caccatcaag	cagtgtactg	accagtttgg	1440
gacggatact	gtgctgggtg	aagacaggat	gccactctcc	cacttgtaat	tctcaatgcg	1500
aaacaagtgg	aactgatttt	acaaagatag	agaaacagca	caatcaattc	cgaatggcat	1560
gcgatggtct	gcagggtggc	acagtgggtg	ctggtggcag	aagacgggtg	cggccctggg	1620
agtgtcgggt	gttttctgca	gtgcaagcta	cggaccacag	ttcagctgcc	tcacctctca	1680
ggctgccagc	agcagctctg	ctcagtcctt	attcccacac	cagagggcga	gcagggtgtga	1740
cataggctaa	ggaagtgttt	ccagagtgtg	cgtctcgggt	gacccttgct	gtcttttctc	1800
tacacccatg	gattctctga	aaacactttg	cagttccttg	tgtcttaaaa	aaaaaaaaaa	1860
aaaa						1864

<210> 21

<211> 2324

<212> DNA

<213> Mouse

<400> 21

gggtctgtac	tccccgctcc	tcgccacaca	cacaccgaga	ggatgaggct	caccgtgggt	60
gccctgctgg	cctgcgcgcg	cctggggctg	tgtctggctg	tccccgacaa	aacgggtcaaa	120
tgggtgcgag	gttcagagca	cgagaataacc	aaatgcatca	gcttccgtga	ccacatgaag	180
accgtccttc	cgcctgatgg	cccccggtt	gcctgtgtga	agaaaaacct	ctatccggat	240
tgcataaagg	ccattttctgc	aagtgaagcc	gatgctatga	ccttggatgg	gggttgggtg	300
tacgatgccg	gcctgactcc	gaacaacctg	aagcccgtgg	cggcggagtt	ttatggatca	360
gtggaacatc	cacagacctc	ctactacgct	gtggctgtgg	taaagaaggg	aacagacttc	420
cagctgaacc	agctcgaagg	caagaagtcc	tgccacacag	gcctgggaag	gtctgcaggc	480
tgggtcatcc	ccattggctt	gctcttctgt	aagctgtcgg	agccccgcag	tcctcttgag	540
aaagctgtgt	ccagtttctt	ctcgggcagt	tgtgtccctt	gtgcagatcc	agtggccttc	600
cccaaatctg	gtcaactgtg	cccaggctgt	ggctgctcct	ccactcaacc	gttctttggc	660
tacgtaggcg	cattcaagtg	tctgaaagat	ggcgggtggg	atgtggcctt	tgtcaagcac	720
acaaccatat	ttgaggctct	gccggagaag	gctgacaggg	accaatatga	actgctctgc	780
cttgacaata	cccgaagcc	agtggatcag	tatgaggatt	gctacctggc	tcggatccct	840
tctcatgctg	ttgtggctcg	aaaaaacaat	ggcaagggaag	acttgatctg	ggagattctc	900
aaagtggcac	aggaacactt	tggcaaaggc	aaatcaaaag	acttccaact	gttcagctct	960
cctcttggga	aagacctgct	gtttaaagat	tctgcctttg	ggctgttaag	ggcccccca	1020
aggatggact	acaggctgta	ccttggccat	aactatgtca	ctgccattcg	gaatcagcag	1080
gaaggcgtgt	gccccgaggg	ctcgatcgac	aactcgccag	tgaagtgggtg	tgcactgagt	1140
cacctggaga	gaaccaagtg	tgacgagtgg	agcatcatca	gtgagggaaa	gatagagtgt	1200
gagtcagcag	agaccactga	ggactgcatt	gaaaagattg	tgaacggaga	agcggacgcc	1260

atgacttttg	atggaggaca	tgccctacatt	gcaggccagt	gtggcttagt	gcctgtcatg	1320
gcagagtact	acgagagctc	taattgtgcc	atcccatcac	aacaaggat	ctttcctaaa	1380
gggtattatg	ccgtggctgt	ggtgaaggca	tccgacacta	gcatacacctg	gaacaacctg	1440
aaaggcaaga	agtcctgcca	cactggggta	gacagaaccg	ctgggttgaa	catccctatg	1500
ggcatgctgt	acaacaggat	caaccactgc	aaattcgtatg	aatttttcag	tcaaggctgc	1560
gctcccgggt	atgagaagaa	ttccaccctc	tgtgacctgt	gtattggccc	actcaaattgt	1620
gctccgaaca	acaaagagga	atataatggt	tacacagggg	ctttcagggtg	tctcgttgag	1680
aaaggagatg	tagcctttgt	gaaacaccag	actgtcctgg	ataacaccga	aggaaagaac	1740
cctgccgaat	gggctaagaa	tctgaagcag	gaagacttcg	agttgctctg	ccctgatggc	1800
accaggaagc	ctgtgaaaga	ttttgccagc	tgccacctgg	cccaagctcc	aaacctatgtt	1860
gtggtctcac	gaaaagagaa	ggcagcccg	gttaaggctg	tactgactag	ccaggagact	1920
ttattttggg	gaagtgactg	caccggcaat	ttctgtttgt	tcaagtctac	caccaaggac	1980
cttctgttca	gggatgacac	caaattgttc	gttaaaacttc	cagagggtac	cacacctgaa	2040
aaatacttag	gagcggagta	catgcaatct	gtcggtaaca	tgagggaagt	ctcaacctca	2100
cgactcctgg	aagcctgcac	tttccacaaa	cattaaaatc	caagagggtg	gttgccactg	2160
tggtggagac	agatgctccc	tcccggtggc	catgggcttc	tcttggtctt	catgccctga	2220
ggggttgagg	ctaactggtg	tagtcttcgc	tgctgtgcct	taccacatac	acagagcaca	2280
aaataaaaaa	gactgctgac	tttaaaaaaa	aaaaaaaaaa	aaaa		2324

<210> 22

<211> 1859

<212> DNA

<213> Mouse

<400> 22

ggcgaccta	ccccagccta	tgtgctgctcc	gcaaggagaa	ccgagccgct	cgccagcggg	60
gctgctccc	ggctgtgcca	gtgcagaagg	gtgcctgcga	ggaagcagg	accacaagag	120
caggcggt	ccggagaaag	tacaacttca	tccgctcagt	ggtggagaag	gtggcgccgt	180
ctgtggtcca	cttgagctg	ttccgcagat	gacagacaca	cagggttcca	cactgatcta	240
aaggaggaga	caccatcctg	gaccagatc	tcagttgtgt	tcagaaaaga	tggccaggac	300
gagcttcagg	cagctcaca	agcacatgga	agtggatcac	ctctcaccaa	ccaggaaatc	360
ccttcctcca	gctgctctgg	gttcatagtg	tctgaggatg	ggctcattgt	caccaatgcc	420
cagctcctca	ccaaccagca	gaagatccag	gtagagctcc	agagcggggc	ccggtatgaa	480
gccaccgtca	aagacatcga	ccataaactg	gaccttgac	tgattaagat	cgagccagat	540
actgagcttc	cagtactgct	gctgggcccga	tcctctgacc	tccgggctgg	agagtttgtg	600
gtagcttttg	gcagcccatt	ttctctgcag	aacaccgtga	ctgcagggat	tgctcagacc	660
acacagagag	gctggcagaga	gctgggactg	aagaattcag	acatagacta	tatccagacg	720
gatgccatca	ttaaccatgg	aaattctggg	ggtccgctgg	tgaacttgga	tggcgacgtg	780
attgggtata	acactctgaa	ggtgactgca	gggatctctt	ttgogatccc	ctctgactcg	840
atcagacagt	tcctggaaga	ctatcatgag	cgccagttga	aaggcaaggc	ccctttgcag	900
aagaaatacc	tgggtcttcg	aatgctgcct	ctcactctga	acctccttca	ggaaatgaag	960
aggcaagatc	cagagttccc	tgatgtgagt	tctggagttt	ttgtatatga	agtgattcag	1020
ggatcggctg	ctgcaagctc	ggggttgaga	gaccatgatg	taattgtcag	cataaacggg	1080
caacctgtca	ccaccacaac	tgatgtcatt	gaagctgtta	aggacaatga	ctttctctcc	1140
atcattgtgc	ttcgaggaag	tcaaaccctg	tttctgacag	tcacacctga	aataatcaat	1200
taagtatctt	actttgagaa	actgcctagc	aaaaccagtt	atattacctg	gtttttgtatc	1260
gaagaggtgc	cagagatggc	agggtcttct	ggagatcaag	aaaaatggat	gctttaaatg	1320
cagaagtcca	tgtttggtg	catacatcaa	cacacacaca	cacacacaca	cactcatgga	1380
tcctgaggtt	gagagtgtct	ttctgcccga	aaaccttcc	aactcaaattg	gaaacagcta	1440
tggtgatctg	ataaaaactg	atgacagtaa	gaactggaaa	gcaggcaatt	cctaactaaa	1500
tcttgatagg	aaactttagt	tacctcctat	acagccacaa	actggatgtg	cacgcacatg	1560
tacacataat	tacctaccaa	atattaagaa	cctgaatctg	gagtaaagag	gtaatcacat	1620
tttaataaat	acctctttgt	atactgaatt	tcccagggtta	tatccactct	gggccagggt	1680
ttgtggatag	aaaggctcatc	acctataaga	catcttgtag	ctgatgacat	catactacca	1740
cacaggagtg	tgatcatttt	ggaggtagaa	acaatttcgg	accttttagag	tttctgagaa	1800
tgtcttctat	ttctattaaa	ataatttttc	gaaccgttaa	aaaaaaaaaa	aaaaaaaaaa	1859

<210> 23
 <211> 724
 <212> DNA
 <213> Mouse

<400> 23
 atgcctgcct gtcgcctctg cttgctggcc gctggcctcc tactagggtt gctactgttc 60
 acccccatct cagccacagg caccgatgca gagaaacccg gcgagtgcc ccagctcgaa 120
 ccaattacgg actgtgtgtt ggagtgcact ttggacaagg actgtgcgga caaccgcaag 180
 tgctgccagg cgggctgcag ctctgtctgc tccaagccta atggaccgag cgaaggagag 240
 ctctcaggga cagatactaa actctcagag actgggacta ctactcaatc agcgggcctt 300
 gaccacacta ctaaaccacc gggagggtcaa gtctccacga agccaccggc tgtgaccagg 360
 gaaggcttag gtgtccgaga aaagcagggc acctgcccc aacctggacat acccaagctc 420
 ggctctgtgt agaccagtg tcaggtggac agccagtgtt ctggcaacat gaaatgctgc 480
 cgcaatggat gtgggaagat ggctgcacc acacccaaat tctgagcttc agcctccagc 540
 agcctgagga acggagagag gttgtttctg ccgactgtg catctggagt cgttcctgtg 600
 gcctcctttc tctctgggtc ttgcatttct tcctgggtcc acgaaagcat ctcccttttc 660
 taaccaataa agtgatcggt ttcagcaatg gagaagctat aaaaaaaaaa aaaaaaaaaa 720
 aaaa 724

<210> 24
 <211> 2395
 <212> DNA
 <213> Mouse

<400> 24
 gaaagaatag agacagagaa ggagtttctg cattcttggg atcacaaacc agaccatgaa 60
 agctggcatt cagaatgcct gcctacaaaa agtctcagca aggcccagca agctccacag 120
 gatgcttttc aagggtggct ctgtgggtgtg ggtacggcca aagggtgggga aagccagtct 180
 ttgggagcag actcttttga ggagtctgac ctccctctt cccctgccc ctccactctg 240
 acagccacag gtggaatgat gagggcccaa atgtgggaca tctatgctca gatattaaac 300
 ctaagctcac gtaagaagtg ggcaaagact ggccctgggt tgtctgtaag agaccagag 360
 tttcccaacc cccctgccat gagctaggct atcacactaa tttgttgatg tttgctcctg 420
 tttgccttaa ggatagtgac ccttgcctga cgcagatgtc atgtttaggc attaatgtgc 480
 cataggtcat tccgtagggc atctagtaca cgtcggttca caaatctact tccaagacct 540
 tcagaatcct tcattaaagg gctgggcctg ggtgtctgaa tttctgatga gctccctgca 600
 atatggttaa atgcactata actggaggtc agagccttag aaccgggggg agcagagcca 660
 ccttgtaaat gttatcaggc taatcacaaat gagatggccc cactgctagc tacgtctcag 720
 cctccatcag ctcttgctgc ctcttcaca gctgcttaca tctgggacac ttgtgcccc 780
 ttcccaggcc atacaagcct ggaagggtgg ctggacagcc tcctccctga cctacatggg 840
 aaggctctct cttttcttcc cgcccttttt tctaattgtg atgcttccat taatcctctg 900
 tttctggagc cttggaagat ctgtcttcca ttcatctatc caccatcca tcattcaaca 960
 tgaatgggtc atgtcacgtg ttgggtgcaa gggatactct ttcaaaacaa tccctcacga 1020
 gactcacagt ctagtgaaga gcacacgcca gaaaccaatt agagaagcta ccaaccaaga 1080
 tggaacatca gggattcaaa acctcggggg gagaggggag ctactttctc tgtgttcttc 1140
 taagagccct gatggctctc gattgctctg aacagaggct cacttgggtc agtgctatca 1200
 tgggtagtgc ccacgagggt tcccagaga atactactgt agagcattct atactccca 1260
 caggagagaa ggaaaggatt cccagagcca tggctcttaa gatggctctc gaaggaaaat 1320
 ccagtcattt ccaagtgggc cctgaaccct gaggtatagg ggaggctctc agaagtcctg 1380
 gaagagtgc aacacccgag tcccaggagc tctgtgatgg caacctctc ccttgaacac 1440
 ccttttccat ttttgagcat cgagttggag aggtgattct gggacagggt gtgtatat 1500
 gtgttgttta aacacattca catgtaagct gcctgagggg aggggatgtt tgcctctagc 1560
 tcagtccagc tggagctggg gggatgatga gtctgagtgg ctttagggcc atcattgaca 1620
 ccacctcagt acaaacggac tcccctccct tcctccctct cttctatcct ctttccctc 1680
 cttcccttag cagggtgcc aaggtgatat gggacagcga cagggcaaac gatcacctgt 1740
 tgccttaatg aactttccac agctcactgc tggctaggtc gtagagtttc tccttgtctt 1800
 gtgaggccca aggaaggagg ccaatctaaa gtgtcctcca taccttcccc ttgggggctt 1860

ttctgtaata	cttgtttaaa	aattgtttctg	atgatcatga	tggaaacaga	cagaccacct	1920
tagaaccaga	ggcctgaaag	cctgacctga	ccagcacaga	ttcccacttc	agaaccccag	1980
ggctatggaa	gtgcccttgt	ccaacgctat	gggaatagtc	ctgtgggttg	tctctgcttg	2040
ccactgtggc	cagcattcca	gtgcctacag	ccacctgtgc	ctacagccac	ctgtgccatg	2100
agaagtgcct	ctcctgctct	atgccctgca	tttgggatgc	taagaagagg	tgagggtgtg	2160
agcgagaaca	gatccaccct	tctcctaggt	aggatcagct	ctcaattggt	gcttatcact	2220
agttatcaaa	gaacagcaga	gacagctgog	ttatccaaga	agcaagtatt	aggacaaaaa	2280
cctgttactg	tatttaaagg	aacttttagtt	tgcgtatctt	acatttttat	aaagtactgt	2340
aattcagggg	gtgggggtatg	caacagagac	agactaacc	atgtttgtca	tttgc	2395

<210> 25

<211> 881

<212> DNA

<213> Mouse

<400> 25

gtgaggaatg	gcgacctttt	ttttaaaaag	gtgcaggtcg	aggatggggg	tgtgtatacc	60
tggttacgcca	tgggggagac	tttcaacgag	acactgtctg	tggagttgaa	agtgtataac	120
ttcaccttgc	acggacacca	tgacaccctc	aacacagcct	acactaccct	ggtgggctgt	180
atcctcagtg	tggttctggt	cctcatatac	ttgtacctca	ccccttgccg	ctgctggtgt	240
cggggtgtgg	agaaaccttc	cagccacca	ggagatagcc	tcagctcttc	tatgctcagt	300
accacacca	accacgacct	tatggctggt	ggggacaaag	atgatggttt	tgaccggcgg	360
gtggccttcc	tggaaacctgc	tggaccgggg	cagggtcaaa	atggcaaact	caagccaggc	420
aacactctgc	cgggtgcccg	agctacaggc	aagggccaac	ggaggatgtc	cgatccagag	480
tcggtcagct	cgggtcttttc	tgatacacc	attgtggtgt	gagcagcgta	ggctgatggg	540
gaggttctgc	cccaggagag	gtacccttga	gggatatgac	aggggtggaag	agagggtcgg	600
atgcccaagg	gagtgggttc	ctcctgacca	ccagggaatc	ggtcacaggc	gccggaggag	660
gcaagacccc	agtgagggtg	tggatgctgc	gagtttcacc	tatggatatc	ctcaggcaga	720
tgccacaccc	ctacccaaag	ccttggctat	tctcagtggt	ggggaggggg	acaggaacga	780
ggaaagggcg	gaggggagga	gcaaattccc	taaacttttt	tgaggtcac	cctagctcct	840
taagagaaaa	ccatttgaaa	aacaaaaaaa	aaaaaaaaaa	a		881

<210> 26

<211> 556

<212> DNA

<213> Mouse

<400> 26

gcaccactcc	cctggctcga	gtcatctccc	gggacactga	aacacagaga	tattacctgc	60
taagtcacac	acctgcctgc	agtctcacc	tggtcctga	tatggaggaa	atcacctgtg	120
cctttctcct	gctgctagca	ggtctgccgg	ccttggaagc	cagtgaacca	gttgataaag	180
acagtccctt	ctactatgac	tgggagagcc	tgcagctggg	aggattgatt	tttggagggc	240
tcctgtgcat	cgctggaatt	gccatggccc	tgagtggcaa	gtgcaaattgt	aggcgtaacc	300
ataagcccag	ttccttaacct	ggaaaagcca	ctccactcat	cattccaggc	tctgccaata	360
cctgctgaac	tgaacacagg	accaagtttg	gaggcaggtt	tttgacaact	ttctgccgta	420
cttctcctct	ggagaccttc	ctctccagga	tggcttcctt	agaacatact	gttaagtctt	480
cattgacagg	aaaggggtgtg	gcaaagctga	ttttatatta	aactgggtctt	gctgctcaaa	540
aaaaaaaaaa	aaaaaa					556

<210> 27

<211> 750

<212> DNA

<213> Mouse

<400> 27

gctgagtgtg	gttctgggtg	gaaccctcta	cataggccat	tatttagcca	tgtattccga	60
aggcgcccc	ttctggactg	ggatcgtggc	tatgctggct	ggagctgttg	ccttccttca	120

caagaaacgg	ggtggtacct	gctgggcccct	gatgaggacc	cttcttgtgc	tggcaagttt	180
ctgcaccgct	gtggctgcca	tcgttatttg	gtctcgtgag	ttgaattatt	actggatttt	240
tctcggagat	gatgtctgtc	aaagagactc	ttcatatgga	tgggccacca	tgcctagaac	300
cactccagtt	cccgaagaag	ctgataggat	tgccttgtgc	atatactaca	caagcatgct	360
aaagaccctg	ctcatgagcc	tccaagctat	gctcttgggt	atctgggtgc	tgctgctcct	420
ggcttctctc	acccctgtat	gtgtctacat	ctggaaaaga	tttttcacaa	aggcggaac	480
agaggagaag	aaactgctgg	gtgcagctgt	gatctagcct	ttcctcttgc	tccgggcgtc	540
cctcctactg	aagcctgaaa	gaagaatcag	gcaggactaa	gaagaccctc	ccccactagc	600
agggccatgg	ccactgcctg	gttctgcccc	gcaccacagc	agctctcagc	agcacttgct	660
tgtctctcca	tccttcaccg	tcctatatcc	ctcctcaggc	agcaacttga	taataaaactc	720
tcctgttatt	gctggcaaaa	aaaaaaaaaa				750

<210> 28

<211> 1896

<212> DNA

<213> Mouse

<400> 28

gtgaacatct	gtctccctta	ctgcgggtgg	ccagccacag	tgccccggag	ggatctgcac	60
aatgctccag	cacactagcc	tgggtgttact	cctcgcctct	atttgacca	ctaggcacc	120
agtccaaggt	gccgacctog	tgcaagacct	ttccatttct	acatgcagaa	tcattggcgt	180
tgcccttgtg	ggcagaaaca	aaaaccacaca	gatgaatttc	acagaagcca	acgaggcctg	240
taagatgctg	ggactgactc	tggccagcag	ggaccaggta	gagtcagcgc	agaaatctgg	300
ctttgagact	tgcagctatg	gatgggttgg	agaacagttc	tctgtcatcc	ctcggatttt	360
ctcaaaccct	aggtgtggga	agaatggcaa	aggtgtcctg	atttggaatg	ctccctccag	420
ccaaaagtct	aaagcctatt	gccacaactc	atccgacacc	tgggttaact	cctgcattcc	480
agaaatcggt	accacatttt	accccggtgt	ggacactcaa	acaccgcgaa	cagagttttc	540
tgtcagcagc	agcgccctact	tggcttcatc	ccctgactcc	acaacacctg	tttctgccac	600
caccggggct	ccacctttga	cctccatggc	acggaagaca	aaaaagattt	gtatcacgga	660
agtttataca	gaacctatca	coatggctac	agaaacagaa	gcatttgttg	caagtggagc	720
agcattcaag	aacgaagcag	ctgggttttg	aggtgtcccc	accgcccctg	tgggtgctggc	780
tctcctcttc	tttgggtgctg	ccgctgtgct	ggctgtttgc	tacgtgaaaa	ggtatgtgaa	840
ggccttccct	ttcacaaaca	agaatcaaca	gaaggaaatg	atcgaaacca	aggttgtaaa	900
ggaagagaag	gctgatgacg	tcaacgctaa	tgaagaatca	aagaaaacca	ttaaaaacc	960
agaggaggcc	aagagtccac	ccaaaactac	ggtgcgatgc	ttagaagctg	aagtttagat	1020
gcaagagagt	ggagaagggtg	cacacgaggc	aagtttcatg	ccccgggaac	caaagaagca	1080
agccactgtc	agttcctgca	gaaaaagact	gcagagttca	ccagaaggag	ccctctcctt	1140
actgcagtct	tctctggact	ctaccctctg	gcctccaacc	ttcccacagc	ctccctaacc	1200
cttctgtggc	tcacagcaga	ccagagagta	gaggagctt	tcaaagtacc	aggtcctaaa	1260
acagctccta	agctcacact	cagagacagg	cttccagggt	gcctgacccc	catgaaaggc	1320
cagagtccct	gagacatggc	cagccccata	gttcaaaatc	ttcccacagg	gaaatacacc	1380
acctggccgt	gctcttttga	accaggcaca	tgtaaaataa	ggaaaggaaa	acaacagaag	1440
gtcatggaga	gcctgggtga	cttgagactt	aatctctgga	aagccaaaat	aaacagagca	1500
tgagatggga	gctggggcca	cagatagcag	ccttggttggc	tgagactgta	aatacaggct	1560
ggggctgaga	agcctctcgg	ttaattgatc	tgcagcacgt	agacagactt	tcttttcttt	1620
ttactgtttg	tgggtgttctc	tagagacaaa	tacacgttta	taagaaacct	aaaagcagga	1680
gagcccagga	gctgactcag	tggtaaagca	cttgcccggc	atgtacaaac	aaggcttcca	1740
gtccaatccc	cagaatccac	tgacccacaca	cacacaaaga	aacaaacaca	agtatgcatt	1800
tccatttttt	acttgaatta	caggacccat	ggctgagaaa	ataactgtgt	taaaagggtta	1860
aaaaaaagga	gaaaagtaca	aaaaaaaaaa	aaaaaa			1896

<210> 29

<211> 1854

<212> DNA

<213> Mouse

<400> 29

gcccacatgg	tctggggccaa	cttgggtgtg	tttgtcatct	gcttcctgcc	cttgcattgtg	60
gtcctgaccg	tgcaggtctc	cctgaacctc	aatacctgtg	ctgccccgaga	caccttcagc	120
cgtgccctgt	ccatcacagg	taaactctca	gacaccaact	gctgcctgga	tgccactgt	180
tactactaca	tggccagaga	gttccaggaa	gcgtccaagc	cagccacgtc	ttccaacaca	240
ccccacaaga	gccaagattc	ccagatcctg	agcctcacct	agaagaagtg	aacacatgcc	300
aaggggccaga	ggaacctgtg	atgtgagcaa	ggagccctgg	atcagcctga	acctcctgtg	360
gggtctgagc	actctaggag	acctagttgg	actagagagg	ctgcatctgc	tccctgaaa	420
ggaccagagg	actcaggctc	taacgtccga	cctgaggggac	cctggaacaa	gaccacatat	480
ctcccatctc	agatctagaa	acctggggca	ccagaatggg	gccttgatgg	ctagccactg	540
agtttaggat	acacccctcc	ccagagttgg	tcctggcaag	gtcctctgtc	acctagatgc	600
aagtgatgag	agataaagga	cagacatacg	gctcagagaa	ccaggagaca	tctttccaga	660
ggacctcaa	atggcttctt	ccttttagga	cctttaaac	tcatgccaca	tgtagggttg	720
ttgctccagc	tctgtattat	gggtctggcag	gctgtcctcc	aaggcccatg	actgtcactg	780
gttgagcaat	cggacctgag	cctcttctgg	ttattttccat	tctatagtgg	gactgttgat	840
tcctgaggac	agtggctatg	gtagagggtc	ctggagttta	ttgtgaggaa	gattgctgtt	900
tggtattcat	gctctctgag	gatgtggccc	caggcttcga	ggatctctgg	agtaaaggat	960
gagccacaaa	gccagctttg	agtcaggagc	acatttgagg	atgtggtagc	cctgggcttc	1020
ccctcaatg	ccttgatttt	tgtcttggtc	caaatgctac	agctgtacct	agagccagag	1080
ccctccagc	tcaggggagg	gggttactgg	ctctccctac	tctctacccc	tacttctacc	1140
aaggcctact	gcctaactga	cccctttttt	tgtatgacct	tttctacaaa	aaccataaat	1200
ctgttctacc	ttcagacacc	agagaaagga	ttccactcaa	gtataaattg	gtgaactgat	1260
ttcctggagt	tacttacaaa	agcacggtga	ctcttgggtg	ctcagtcact	gaaaagcctc	1320
actcagcata	gataacaatc	cccaaactgc	accgctagat	taccaatccc	cactaaactt	1380
ccacctcaca	cacacacttg	gacacctgac	ctgctccaga	caaaaatgtg	cctagggtgt	1440
gaggaagctg	tggctgogac	ccaagggtgtg	ctgacctctc	tcgctctgcc	aaggactact	1500
aacagcttca	tgatcatcag	cctattcgcc	acagccgtat	tttgettgtt	tactggcat	1560
gactgtaggc	cgagctgttc	tgtggatcag	agcagcgctt	ttcctgttca	ctgctgatga	1620
tcatectaag	ccagagaaat	ggcttctctg	ccacttggc	ccactctccc	tccagttctc	1680
acatcccctc	caccctctgt	tctgcagtat	tatctaaacc	ttcaccttgg	aaggaaggga	1740
tggtgtatct	atataatatc	aagatatagg	atccacaaaa	aaaaaaaaaa	aaaa	1800
						1854

<210> 30

<211> 2866

<212> DNA

<213> Mouse

<400> 30

ggtttcggag	agataaggcg	cttggccggt	actaactgga	ctacaaagag	ctggatcgga	60
ccggaaccac	atggctcaac	tcgcccagc	caccgcctcc	ccgtgtcat	ggctgctgct	120
gctgttctgc	tatgcaactc	ggaaagcggg	tggggatata	cgtgtgctgg	tgccctacaa	180
ttcgacaggc	gtcttgggag	ggtcgaccac	cttgcactgt	agtctgactt	ctaattgagaa	240
tgtgactatc	actcaaataa	cctggatgaa	gaaggattca	ggtggatccc	acgctcttgt	300
ggctgtcttc	caccccaga	aggggcccaa	catcaaagag	ccagagaggg	tgaaattctt	360
ggctgcccaa	caggatctga	ggaacgcac	tctggccatc	tcgaacttaa	gtgtagaaga	420
cgaaggcatc	tatgaatgtc	agattgccac	attccccaga	ggcagtagaa	gcaccaatgc	480
ctggctgaag	gtgcaagccc	gacctaagaa	cactgcagag	gccctggagc	cctctcccac	540
cttgatactg	caggatgtgg	ctaaatgcat	ctctgccaat	ggtcacccctc	ctggacgaat	600
ctcttggccc	tcgaatgtga	atggaagtca	ccgtgaaatg	aaggaaaccag	ggtcccagcc	660
gggcaccacc	acagttacca	gctacctctc	catggtacct	tctcgccagg	cagacggcaa	720
gaacatcacc	tgcacgggtg	agcatgaaag	cttacaggag	ctggaccagc	tgctggtgac	780
cctttcccaa	ccctatccac	ctgaaaacgt	gtccatctct	ggctatgacg	gcaactggta	840
tgttggcctc	actaacttga	ccctgacctg	tgaagctcac	agcaaaccag	cgctgacat	900
ggctggatat	aactggagca	cgaacacggg	tgactttccc	aactctgtta	agcgccaggg	960
caatatgctt	ctaactctca	ccgtagagga	tggcttcaat	aacacgggtca	ttgtgtgcga	1020
agtcaccaat	gccctagggt	ctgggcaggg	ccaagtgcac	atcattgtta	aagagaacc	1080
tgagaatatg	cagcaaaaata	caagattaca	cctaggctac	atctttctta	tcgtctttgt	1140

cctcgtctgta	gtcatcatca	tgcgagcact	atacactata	cgaagatgca	ggcatggctg	1200
tgctctgcag	tccaatccct	cagagagggg	gaacgtccag	tattcatctg	tgaacggcga	1260
ctgtagactg	aacatggagc	caaacagcac	aaggtgacgg	tgctgggtag	acagaactaa	1320
ggaacttgaa	ggcatagcaa	ctggaaccct	actctcataa	atgaagaagc	ctccagagag	1380
actggctgct	cagtgtgatg	agcatagcaa	gtttgggggg	tctcccagga	tgctgccgaa	1440
ttccacgttg	tcaaaaggac	ccatggaggc	cagtgtgttg	gctcactctt	gacatctcag	1500
caagctgggg	gggggggggg	gagcataaag	caaggttgag	tctagcttgg	gctatagagc	1560
aaagccctgt	ccatacacaa	acaagctaag	gggctttgag	acggtcagaa	actgaagtct	1620
tgctttgggt	aaggtaaata	ctctaccgca	tgtatgtgct	agacttgaaa	gacttccaca	1680
cagacctctt	tataagttga	ctccattggg	gctatcccct	cctctctgga	caaggtctct	1740
gtatgtagcc	aaggctaggc	tcaaaactcac	agagatatgt	ctgcttctac	ctccccagtg	1800
ctagagttga	aagtatttgt	gccactgcac	ttttctaggt	cttcttttaa	tgaagtaaag	1860
tatatattta	taaaaagcta	tttagttata	tatatatata	tttttgagac	tatttcatag	1920
agcccaagct	aacctcaaac	ttactatgta	gccaaagagt	atggtaaact	aattttatttt	1980
aattttatttg	tcttcaattt	taaccatcac	ccaacccctg	ctcccttcca	tatcttcttt	2040
caatccattt	cattgtcttt	ttcttcccag	acactattct	gacttacgtc	tccattacaa	2100
acattttatt	gaactacata	aaaatgtgtg	aaccacaaaa	aaaaaatgta	tttgtcaaaa	2160
ttgtagttgt	ctttctgagg	ctgacctgag	ttctctgata	ccattctctc	cagttgtatc	2220
cagtttcctg	taaacaatgt	gactttgttt	ttctcagtag	ctaaaacatc	ccaattatgt	2280
gagtgtacac	tttctttact	cattcctctg	tgggccacca	gctgggttgg	ttccatatct	2340
gagctattgt	gcatggaatt	gtctctgtgg	tgggtttagt	aaactcccag	gaatgcctgt	2400
acatgtttgt	agaggccaga	agaaggcaca	aaatcttgag	ccaggcttac	atgcacttgt	2460
gagtagcccc	acataggtgc	taagaaccca	gttcaggctc	tctgctgtgg	gatgggtggc	2520
tgtgcacaga	aagcctggtc	ccggtctagc	aaaggtctgg	aactccggag	ccggtgggct	2580
gtgatttaca	ccagcatggg	atggaaggag	ttggacctcg	cctcctgggc	acctggctcc	2640
tgtcacatag	ctacagcctc	ccacagcccc	cctataggga	ggatgacagc	atcaatcaca	2700
tagtagctgc	actaagccct	cccacatgca	aataaggttt	ccccaaactc	tcagtcocaa	2760
ccaatgaaaa	gtacctgctg	tcaaacccta	aatcatcccc	aaaactctgt	aagtcctatc	2820
aggggaataaa	atgtgtgtga	aaactaaaaa	aaaaaaaaaa	aaaaaa		2866

<210> 31

<211> 1093

<212> DNA

<213> Mouse

<400> 31

gcgaccactg	agaccttgag	actcagacac	caagagagat	gtttctagtt	gggagcctcg	60
ttgtcctctg	tgggctgctg	gcccacagca	cagcacagct	ggcaggcttg	ccattgcccc	120
tggggccagg	tcaccccttg	ccactgaacc	agggcccacc	gttgccactg	aaccaggggc	180
agctgttgcc	cctggctcag	ggtctgcctt	tggctgtaag	cccagcactg	ccttcaaatc	240
ccacagatct	tcttgctgga	aaattcacag	atgctctcag	cggtggcctg	ctgtctgggg	300
ggctgctggg	catttttgaa	aatatccac	tcttgatgt	tataaagtct	ggaggaggca	360
attctaattg	ccttgctggg	ggcctgctgg	gaaaactgac	gtcatcagtt	cctctcctga	420
acaacatcct	cgacataaaa	atcactgata	cgcagctgct	agaacttggg	cttgtgcaga	480
gtcctgatgg	ccatcgctct	tatgtcacca	tccctctggg	cttgacactc	aacgtaaaata	540
tgcccgtagt	tgggaagtct	ttgcaatttg	ctgtgaagct	gaacattact	gcagaagtct	600
tagccgtgaa	agacaatcag	gggaggattc	atctggttct	tgggtgactgc	accactccc	660
ctggcagcct	gaaaatcagc	ttgctcaatg	gagtcactcc	tgttcaaagc	tttttagaca	720
acctcacagg	gatattgact	aaagtccctc	ctgagctgat	ccaggggcaag	gtatgtcctc	780
tgggtcaatgg	gattctcagc	ggtttgatg	tcaccctggg	gcacaacatt	gctgaattac	840
tgatccatgg	actacagttt	gtcatcaaag	tttaggcata	ccaggaagga	aggctatctt	900
ggctgagctg	aatcatttct	tgctgctcag	tctcctgcct	cttgcccag	ctcccatggc	960
tcacagaaag	gggcccacat	cctggaaaat	tatgtcttcc	ttctcctcac	ggagcctgat	1020
ctcttcccat	caggcacgat	taatcctgtg	atcctcacta	aataaaaatag	ctcttcatct	1080
gcaaaaaaaaa	aaa					1093

<210> 32

<211> 1353
 <212> DNA
 <213> Mouse

<400> 32
 gaaacagtat gagcaaacac tgagctgagg ggagcttctg attaagagcg ctccccagcg 60
 agggccgagg ccgtgaacct tcccagcaag aggggtggtg ttgctcctgg aagcctgcgc 120
 ccagcagctg aagccatggc caccaccacg tgccaggtg tagggcttct cctgtccctc 180
 ctgggtctgg ccggctgcat agccgccact gggatggaca tgtggagcac tcaagacctg 240
 tatgacaacc cagtcaccgc cgtgttccag catgaagggc tctggaggag ttgcgtgcaa 300
 cagagctcgg ggttcaccga gtgccggcca tacttcacca tccctgggcct tccagccatg 360
 ctgcaagctg tacgagccct gatgatcgtg ggcatgttgc tgggggtcat cggatatcctc 420
 gtgtccatct tcgccctgaa gtgcattcgc attggtagca tggatgactc tgccaaggcc 480
 aagatgactc tgacttctgg gatcttggtc atcatctccg gcatctgtgc aatcattggt 540
 gtgtctgtgt ttgccaacat gctggtgacc aacttctgga tgtccacagc taacatgtac 600
 agcggcatgg gcggcatggg tggcatggtg cagaccgttc agaccaggta caccttcggt 660
 gcagctctgt tcgtgggctg ggttgctgga ggcctcacc tgattggggg agtgatgatg 720
 tgcacgcct gccgtggcct gacaccagat gacagcaact tcaaagctgt gtcttaccat 780
 gcctctggcc aaaatgttgc ctacaggcct ggaggcttta aggccagcac tggctttggg 840
 tccaacacca gaaacaagaa gatctacgat gggggtgccc gcacagaaga cgatgaacag 900
 tctcatccta ccaagtatga ctatgtgtag tgctctaaga ccgccaacc tgtgtgcagg 960
 aggaaccctt cccaagaag agctcaccac aaagcaacgg gagtctacct tgttcccttg 1020
 ttgatttcaa ctgacatctg aaagttggtg aagcctgatt ttcattcata gggaggctag 1080
 acagtcttgg ccacatgtgt ctgcctctaa atatcccatc aaaaaacagc tgagttatcg 1140
 tttatgagtt agaggccata acactcactt tagcccaacc ctctgctttt taccgtagac 1200
 tttcttttca tctggtgatg gaatggaatt tgactcacag actaatactt taatgggtta 1260
 gagaaacttt ccttcctcgt acttaataag cctgctgatg gtcgattttc cagcttgacc 1320
 accaagggaa atttttaaaaa aaaaaaaaaa aaa 1353

<210> 33
 <211> 1046
 <212> DNA
 <213> Mouse

<400> 33
 gcctcagtc acagctgtct cccagctgc ttccagtga cccccggca gtctaggctc 60
 ccacagcaat gagttggtgg agggacaact tctggatcat cttagctatg tccatcatct 120
 tcatctccct ggtcctgggt ctcatcctgt actgtgtctg caggtggcag cttagacaag 180
 gcaggaactg ggaaattgct aagccctcaa aacaggatgg aagagatgaa gaaaagatgt 240
 atgagaatgt tcttaattct tcaccaggcc agttacctgc tctgccacc aggggttcac 300
 cttttccagg agacctagcc ccacagggaag ctccaagaca accctcagct tggtagctat 360
 cagtgaagaa agttaggaac aagaaggtct ttgctatctc gggctccacc gagccagaaa 420
 atgattatga tgatgttgag attccagcaa ccaccgaaac ccagcactct aaaaccacac 480
 ctttttggca agctgaagtg ggtttacaca gctcgtttta gaatactcta gaatagccgg 540
 attataacac aagcacttcc taatccccag aggaagccac ctccagccatg tgaaagctac 600
 agcagaagac aggacagctt gatgttcccg aggctccaga tgtttctggt gctccagatg 660
 tttctgctgc tccagatggt tctgttgctc caaatatttc tgctgctcca gatgtttctg 720
 ttgctccaga tgtttctggt gctccagatg ctcctgttgc tccagatgct cctgatgttt 780
 ctgacactgc agaagctcta cccaagatt ctgaggatgt ggccttggca cctttgtgga 840
 ggaagtttcc ttagtgacga ccactgggcc tgtgagaact gactcatttc tcaacatttt 900
 ctttcgttcc ctgggtgaat gttagctgtaa ggcagtgact ctcaaccttc ctaatgcagg 960
 gatccttcaa tacaattcct tatttgtggt gatcctcaac cataaaaatta ttttgttgct 1020
 acttcaaaaa aaaaaaaaaa aaaaaa 1046

<210> 34
 <211> 1261
 <212> DNA

<213> Mouse

<400> 34

```

gcacagacgg gtaaaccgct tgggaacctc gaggaaaaag aggctacgaa aaccttttcc      60
taagaggcta caaatTTTgga agcagggaaa acccagacat gagatgtttt tagtttatTT 120
ctccagaagg gggcactgta tcaattatgt gaaggggacat gcagacagcc tagctccatg 180
gtgctgtggg gtaggactga ggagccctct ggccagaccc cagcacggcc atgtctctcc 240
caaggatcat gttcctggag gtcacgcccc tggctcttct cataagtggc tgtgcacagc 300
agctctctgg aggtatttgg aacattctgc tgtcacacat gggactgctc ttcctgaagc 360
ccacgctgtt cgtgggaaac atgggaagaa aggaagacgt gttgtgtgct gctcagtaga 420
cttcccacaa gccacctctc tcttctgaaa cgtcactgaa tggactggag aggactgcgg 480
gtttataaaa ctgcttttta tctgagaaca atgggtttgg aaactagtct cttttcttcc 540
cacttttaca gagcttctca aatcattcct ccaggccctg acttggacag gtaggggggc 600
agaccctggg tcccagggtg cactgtccag gcacactgcc cacattgcta agagaagagg 660
ccctgctgcc agtggaccct tcaccccaca cgagacacct gtcttgccct taggacaccc 720
tcctctagag agtgggtgtt gaaggagggg acctatgtaa ggagtggggg caggcatgaa 780
tctgccaaat actggatatg gatccaaggc tggcccaggc acctgcacct ccagtgagtg 840
gtcagcaggt ggcgctgctg cccgccaggc ttcacagagt ccctttaggg agtctgctcc 900
cagatccctt ctggtgcaca cttactggat gtcactgcaa gctctaccct ctgagcaggt 960
gttgcaccac agtggcgctg accctggccc cgcaacggca actgctgaag gcagccattg 1020
cctcagccat tctcaagacc cttcaatttt taaaagcagt tcgattctgt aatatttatt 1080
tttctttttg aggatgttcc gttgcccgcg agactgactg cagtgtgcac cattgcatga 1140
gccctgcctc agtgccctgt ggctccctgg gcactgctgc ccctctgtct aaagctgact 1200
gtggcagcac tgcccaacaa taaagctgac ctaaaagctg aaaaaaaaaa aaaaaaaaaa 1260
a                                                    1261

```

<210> 35

<211> 995

<212> DNA

<213> Mouse

<400> 35

```

gtcaccgccg gtcggggggc gcgcaggccc cgtctccttg ccttccaggc ctcatgcgct      60
cccgcgccct gctcccgcga ccgctgcccg gaggaggggg gcccgcgttg tctgcgcgtc 120
tacgcaggcc tcataggcac cgtggtcacc cccaactacc tggacaacgt gagcgcgccg 180
gttgcgccct ggtgcggctg tgcggccagt ggaaaccggc gcgaagaatg cgaagccttc 240
cgcaagctct ttacaaggaa ccctgcttg gatggtgcc aacaagcctt tgacagcttg 300
cagccatcag ttctgcagga ccagactgct ggggtgctgt tcccgcgggt gtccctggctg 360
tatgactca ctgccctggc tctccaggcc ctgctctgat taggaacatg aaccgtggac 420
gacacagctg actgccatgt ctcccgatga ctgctcactg agctgaaact cccttgccct 480
caggtctgct gccctttgca ggccctggacc cttgtgtggc tgtcctctgg attgggggct 540
ggaggctagg gtctgactga aaagcctgtg ttccctgtc agtaggcac ttgtccgttt 600
tcttccccat cctagagctg agcaccata gatgaggcct cattgggtcc cctgggctta 660
cagagcagga cagagactag ccccgcctcc tagaattcgg aactgtcctt ttccaagatg 720
acaaggcact aaggagatca tatgaacagg ctgacagaca aggctgccta aataccctcc 780
cagttagcca ttattcacca ttaagcttac ccgtgtcaca gcaactgacg ggcttgtcac 840
ctatgacaca gtgtgtagac attaaggaga gactgaggtc cctcctgctc agcaccacac 900
tggcttccca ggctttccct gccatggttt cccagcacc tgcaggggct caataaaccc 960
atgtgcactg agaaaaaaaa aaaaaaaaaa aaaaaa

```

<210> 36

<211> 747

<212> PRT

<213> Rat

<400> 36

Glu Ala Thr Val Ile Thr Thr Glu Lys Arg Glu Arg Pro Ala Pro Pro

1					5					10					15				
Arg	Glu	Leu	Leu	Val	Pro	Gln	Ala	Glu	Val	Thr	Ala	Arg	Ser	Leu	Arg				
			20							25				30					
Leu	Gln	Trp	Val	Pro	Gly	Ser	Asp	Gly	Ala	Ser	Pro	Ile	Arg	Tyr	Phe				
			35							40				45					
Thr	Val	Gln	Val	Arg	Glu	Leu	Pro	Gly	Gly	Glu	Trp	Gln	Thr	Tyr	Ser				
			50							55				60					
Ser	Ser	Ile	Ser	His	Glu	Ala	Thr	Leu	Cys	Ala	Val	Glu	Arg	Leu	Arg				
65							70				75				80				
Pro	Phe	Thr	Ser	Tyr	Lys	Leu	Arg	Leu	Lys	Ala	Thr	Asn	Asp	Ile	Gly				
						85				90				95					
Asp	Ser	Asp	Phe	Ser	Ala	Glu	Thr	Glu	Ala	Val	Thr	Thr	Leu	Gln	Asp				
						100				105				110					
Val	Pro	Gly	Glu	Pro	Pro	Gly	Ser	Val	Ser	Ala	Thr	Pro	His	Thr	Thr				
						115				120				125					
Ser	Ser	Val	Leu	Ile	Gln	Trp	Gln	Pro	Pro	Arg	Asp	Glu	Ser	Leu	Asn				
						130				135				140					
Gly	Leu	Leu	Gln	Gly	Tyr	Arg	Ile	Tyr	Tyr	Arg	Glu	Leu	Glu	Ser	Glu				
145							150				155				160				
Thr	Gly	Leu	Ser	Pro	Glu	Pro	Lys	Thr	Leu	Lys	Ser	Pro	Ser	Ala	Leu				
						165				170				175					
Arg	Ala	Glu	Leu	Thr	Ala	Gln	Ser	Ser	Phe	Lys	Thr	Val	Asn	Ser	Ser				
						180				185				190					
Ser	Thr	Leu	Thr	Thr	Tyr	Glu	Leu	Thr	His	Leu	Lys	Lys	Tyr	Arg	Arg				
						195				200				205					
Tyr	Glu	Val	Ile	Met	Thr	Ala	Tyr	Asn	Ile	Ile	Gly	Glu	Ser	Pro	Ala				
						210				215				220					
Ser	Val	Pro	Val	Glu	Val	Phe	Val	Gly	Glu	Ala	Ala	Pro	Ala	Met	Ala				
225							230				235				240				
Pro	Gln	Asn	Ile	Gln	Val	Thr	Pro	Leu	Thr	Ala	Ser	Gln	Leu	Glu	Val				
						245				250				255					
Thr	Trp	Asp	Pro	Pro	Pro	Pro	Glu	Ser	Gln	Asn	Gly	Asn	Ile	Gln	Gly				
						260				265				270					
Tyr	Lys	Val	Tyr	Tyr	Trp	Glu	Ala	Asp	Ser	Arg	Asn	Glu	Thr	Glu	Lys				
						275				280				285					
Met	Lys	Val	Leu	Phe	Leu	Pro	Glu	Pro	Val	Val	Lys	Ile	Lys	Asp	Leu				
						290				295				300					
Thr	Ser	His	Thr	Lys	Tyr	Leu	Val	Ser	Ile	Ser	Ala	Phe	Asn	Ala	Ala				
305							310				315				320				
Gly	Asp	Gly	Pro	Arg	Ser	Asp	Pro	Cys	Gln	Gly	Arg	Thr	His	Gln	Ala				
						325				330				335					
Ala	Pro	Gly	Pro	Pro	Ser	Phe	Leu	Glu	Phe	Ser	Glu	Ile	Thr	Ser	Thr				
						340				345				350					
Thr	Leu	Asn	Val	Ser	Trp	Gly	Glu	Pro	Ser	Ala	Ala	Asn	Gly	Ile	Leu				
						355				360				365					
Gln	Gly	Tyr	Arg	Val	Val	Tyr	Glu	Pro	Leu	Ala	Pro	Val	Gln	Gly	Val				
						370				375				380					
Ser	Lys	Val																	

Asn Thr Pro Thr Thr Gly Tyr Val Ile Glu Ala Arg Pro Ser Asp Glu
 465 470 475 480
 Gly Leu Trp Asp Met Phe Ala Lys Asp Ile Pro Arg Ser Ala Thr Ser
 485 490 495
 Tyr Thr Val Gly Leu Asp Lys Leu Arg Gln Gly Val Thr Tyr Glu Phe
 500 505 510
 Arg Val Val Ala Val Asn Lys Ala Gly Phe Gly Glu Pro Ser Arg Pro
 515 520 525
 Ser Ile Ala Val Ser Ala Gln Ala Glu Ala Pro Phe Tyr Glu Glu Trp
 530 535 540
 Trp Phe Leu Leu Val Ile Ala Leu Ser Ser Leu Leu Val Leu Leu
 545 550 555 560
 Val Val Phe Val Leu Val Leu His Gly Gln Ser Lys Lys Tyr Lys Asn
 565 570 575
 Cys Gly Ser Gly Lys Gly Ile Ser Asn Met Glu Glu Thr Val Thr Leu
 580 585 590
 Asp Asn Gly Gly Phe Ala Ala Leu Glu Leu Asn Ser Arg His Leu Asn
 595 600 605
 Val Lys Ser Thr Phe Ser Lys Lys Asn Gly Thr Arg Ser Pro Pro Arg
 610 615 620
 Pro Ser Pro Gly Gly Leu His Tyr Ser Asp Glu Asp Ile Cys Asn Lys
 625 630 635 640
 Tyr Asn Gly Ala Val Leu Thr Glu Ser Val Asn Leu Lys Glu Lys Ser
 645 650 655
 Val Asp Gly Ser Glu Ser Glu Ala Ser Asp Ser Asp Tyr Glu Glu Ala
 660 665 670
 Leu Pro Lys His Ser Phe Val Asn His Tyr Met Ser Asp Pro Thr Tyr
 675 680 685
 Tyr Asn Phe Trp Lys Arg Arg Pro Pro Ala Ala Ala Pro His Arg Tyr
 690 695 700
 Glu Ala Val Ala Gly Ala Glu Ala Gly Pro His Leu His Thr Val Ile
 705 710 715 720
 Thr Thr Gln Ser Ala Gly Gly Val Tyr Thr Pro Ala Gly Pro Gly Ala
 725 730 735
 Arg Ala Pro Leu Thr Gly Phe Ser Ser Phe Val
 740 745

<210> 37

<211> 205

<212> PRT

<213> Mouse

<400> 37

Met Leu Gly Thr Leu Val Trp Met Leu Ala Val Gly Phe Leu Leu Ala
 1 5 10 15
 Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro
 20 25 30
 Ala Arg Pro Arg Asp Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln
 35 40 45
 Leu Tyr Gly Arg Leu Ala Ala Gly Val Leu Ser Ala Phe His His Thr
 50 55 60
 Leu Gln Leu Gly Pro Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala
 65 70 75 80
 Gly Gly Arg Ala Ala Asp Arg Arg Phe Arg Pro Pro Thr Asn Leu Arg
 85 90 95
 Ser Val Ser Pro Trp Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Phe
 100 105 110

Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr
 115 120 125
 Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Thr Pro Val Phe
 130 135 140
 Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala Cys Ala Gly Gly Arg
 145 150 155 160
 Ser Val Tyr Ala Glu His Tyr Ile Thr Ile Pro Val Gly Cys Thr Cys
 165 170 175
 Val Pro Glu Pro Asp Lys Ser Ala Asp Ser Ala Asn Ser Ser Met Asp
 180 185 190
 Lys Leu Leu Leu Gly Pro Ala Asp Arg Pro Ala Gly Arg
 195 200 205

<210> 38
 <211> 238
 <212> PRT
 <213> Mouse

<400> 38
 Met Leu Cys Phe Leu Arg Gly Met Ala Phe Val Pro Phe Leu Leu Val
 1 5 10 15
 Thr Trp Ser Ser Ala Ala Phe Ile Ile Ser Tyr Val Val Ala Val Leu
 20 25 30
 Ser Gly His Val Asn Pro Phe Leu Pro Tyr Ile Ser Asp Thr Gly Thr
 35 40 45
 Thr Pro Pro Glu Ser Gly Ile Phe Gly Phe Met Ile Asn Phe Ser Ala
 50 55 60
 Phe Leu Gly Ala Ala Thr Met Tyr Thr Arg Tyr Lys Ile Val Glu Lys
 65 70 75 80
 Gln Asn Glu Thr Cys Tyr Phe Ser Thr Pro Val Phe Asn Leu Val Ser
 85 90 95
 Leu Ala Leu Gly Leu Val Gly Cys Ile Gly Met Gly Ile Val Ala Asn
 100 105 110
 Phe Gln Glu Leu Ala Val Pro Val Val His Asp Gly Gly Ala Leu Leu
 115 120 125
 Ala Phe Val Cys Gly Val Val Tyr Thr Leu Leu Gln Ser Ile Ile Ser
 130 135 140
 Tyr Lys Ser Cys Pro Gln Trp Asn Ser Leu Thr Thr Cys His Val Arg
 145 150 155 160
 Met Ala Ile Ser Ala Val Ser Cys Ala Ala Val Val Pro Met Ile Ala
 165 170 175
 Cys Ala Ser Leu Ile Ser Ile Thr Lys Leu Glu Trp Asn Pro Lys Glu
 180 185 190
 Lys Asp Tyr Ile Tyr His Val Val Ser Ala Ile Cys Glu Trp Thr Val
 195 200 205
 Ala Phe Gly Phe Ile Phe Tyr Phe Leu Thr Phe Ile Gln Asp Phe Gln
 210 215 220
 Ser Val Thr Leu Arg Ile Ser Thr Glu Ile Asn Asp Asp Phe
 225 230 235

<210> 39
 <211> 492
 <212> PRT
 <213> Mouse

<400> 39
 Leu Arg Leu Leu Leu Ala Trp Val Ala Ala Val Pro Ala Leu Gly Gln

1	5	10	15
Val Pro Trp Thr	Pro Glu Pro Arg	Ala Cys Gly Pro	Ser Ser Cys
	20	25	30
Tyr Ala Leu Phe	Pro Arg Arg Arg	Thr Phe Leu Glu	Ala Trp Arg Ala
	35	40	45
Cys Arg Glu Leu	Gly Gly Asn Leu	Ala Thr Pro Arg	Thr Pro Glu Glu
	50	55	60
Ala Gln Arg Val	Asp Ser Leu Val	Gly Val Gly Pro	Ala Asn Gly Leu
	65	70	75
Leu Trp Ile Gly	Leu Gln Arg Gln	Ala Arg Gln Cys	Gln Pro Gln Arg
	85	90	95
Pro Leu Arg Gly	Phe Ile Trp Thr	Thr Gly Asp Gln	Asp Thr Ala Phe
	100	105	110
Thr Asn Trp Ala	Gln Pro Ala Thr	Glu Gly Pro Cys	Pro Ala Gln Arg
	115	120	125
Cys Ala Ala Leu	Glu Ala Ser Gly	Glu His Arg Trp	Leu Glu Gly Ser
	130	135	140
Cys Thr Leu Ala	Val Asp Gly Tyr	Leu Cys Gln Phe	Gly Phe Glu Gly
	145	150	155
Ala Cys Pro Ala	Leu Pro Leu Glu	Val Gly Gln Ala	Gly Pro Ala Val
	165	170	175
Tyr Thr Thr Pro	Phe Asn Leu Val	Ser Ser Glu Phe	Glu Trp Leu Pro
	180	185	190
Phe Gly Ser Val	Ala Ala Val Gln	Cys Gln Ala Gly	Arg Gly Ala Ser
	195	200	205
Leu Leu Cys Val	Lys Gln Pro Ser	Gly Gly Val Gly	Trp Ser Gln Thr
	210	215	220
Gly Pro Leu Cys	Pro Gly Thr Gly	Cys Gly Pro Asp	Asn Gly Gly Cys
	225	230	235
Glu His Glu Cys	Val Glu Glu Val	Asp Gly Ala Val	Ser Cys Arg Cys
	245	250	255
Ser Glu Gly Phe	Arg Leu Ala Ala	Asp Gly His Ser	Cys Glu Asp Pro
	260	265	270
Cys Ala Gln Ala	Pro Cys Glu Gln	Gln Cys Glu Pro	Gly Gly Pro Gln
	275	280	285
Gly Tyr Ser Cys	His Cys Arg Leu	Gly Phe Arg Pro	Ala Glu Asp Asp
	290	295	300
Pro His Arg Cys	Val Asp Thr Asp	Glu Cys Gln Ile	Ala Gly Val Cys
	305	310	315
Gln Gln Met Cys	Val Asn Tyr Val	Gly Gly Phe Glu	Cys Tyr Cys Ser
	325	330	335
Glu Gly His Glu	Leu Glu Ala Asp	Gly Ile Ser Cys	Ser Pro Ala Gly
	340	345	350
Ala Met Gly Ala	Gln Ala Ser Gln	Asp Leu Arg Asp	Glu Leu Leu Asp
	355	360	365
Asp Gly Glu Glu	Gly Glu Asp Glu	Glu Glu Pro Trp	Glu Asp Phe Asp
	370	375	380
Gly Thr Trp Thr	Glu Glu Gln Gly	Ile Leu Trp Leu	Ala Pro Thr His
	385	390	395
Pro Pro Asp Phe	Gly Leu Pro Tyr	Arg Pro Asn Phe	Pro Gln Asp Gly
	405	410	415
Glu Pro Gln Arg	Leu His Leu Glu	Pro Thr Trp Pro	Pro Pro Leu Lys
	420	425	430
Ala Pro Lys Gly	Pro Gln Gln Pro	Pro Arg Gly Ala	Ala Lys Thr Pro
	435	440	445
Lys Gly Asn Pro	Ala Asn Pro Thr	His Thr Thr Phe	Cys Pro Gln Asp
	450	455	460

Leu Cys Tyr Phe Ser Tyr Thr Pro Thr Pro Glu Pro Cys Pro Pro Thr
 465 470 475 480
 Cys His Gly Pro Cys His Thr Ser Ser Cys Val Leu
 485 490

<210> 40
 <211> 464
 <212> PRT
 <213> Mouse

<400> 40
 Met Gly Arg Ala Trp Gly Leu Leu Val Gly Leu Leu Gly Val Val Trp
 1 5 10 15
 Leu Leu Arg Leu Gly His Gly Glu Glu Arg Arg Pro Glu Thr Ala Ala
 20 25 30
 Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys
 35 40 45
 Asp Val Glu Thr Ile Asp Lys Phe Asn Asn Tyr Arg Leu Phe Pro Arg
 50 55 60
 Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn
 65 70 75 80
 Leu Lys Lys Pro Cys Pro Phe Trp Asn Asp Ile Asn Gln Cys Gly Arg
 85 90 95
 Arg Asp Cys Ala Val Lys Pro Cys His Ser Asp Glu Val Pro Asp Gly
 100 105 110
 Ile Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Arg Ile Glu
 115 120 125
 Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu Ser
 130 135 140
 Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp Ser
 145 150 155 160
 Ser Asp Ser Phe Cys Glu Ile Asp Asp Ile Gln Ser Pro Asp Ala Glu
 165 170 175
 Tyr Val Asp Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly
 180 185 190
 Pro Asp Ala Trp Arg Ile Trp Ser Val Ile Tyr Glu Glu Asn Cys Phe
 195 200 205
 Lys Pro Gln Thr Ile Gln Arg Pro Leu Ala Ser Gly Arg Gly Lys Ser
 210 215 220
 Lys Glu Asn Thr Phe Tyr Asn Trp Leu Glu Gly Leu Cys Val Glu Lys
 225 230 235 240
 Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala Ser Ile Asn Val
 245 250 255
 His Leu Ser Ala Arg Tyr Leu Leu Gln Asp Thr Trp Leu Glu Lys Lys
 260 265 270
 Trp Gly His Asn Val Thr Glu Phe Gln Gln Arg Phe Asp Gly Ile Leu
 275 280 285
 Thr Glu Gly Glu Gly Pro Arg Arg Leu Arg Asn Leu Tyr Phe Leu Tyr
 290 295 300
 Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro Phe Phe Glu Arg
 305 310 315 320
 Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Val Gln Asp Ala Glu Asn
 325 330 335
 Lys Ala Leu Leu Leu Glu Ile Leu His Glu Ile Lys Ser Phe Pro Leu
 340 345 350
 His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys Asn Glu Ala His
 355 360 365

Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg Ile
 370 375 380
 Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln
 385 390 395 400
 Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu
 405 410 415
 Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe Gln Leu Thr
 420 425 430
 Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr
 435 440 445
 Ser Val Arg Glu Leu Glu Asn Phe Arg His Leu Leu Gln Asn Val His
 450 455 460

<210> 41
 <211> 148
 <212> PRT
 <213> Rat

<400> 41
 Leu Asn Trp Gln Ile Lys Lys Tyr Asp Thr Lys Ala Ala Tyr Cys Gln
 1 5 10 15
 Ser Lys Leu Ala Val Val Leu Phe Thr Lys Glu Leu Ser Arg Arg Leu
 20 25 30
 Gln Gly Thr Gly Val Thr Val Asn Ala Leu His Pro Gly Val Ala Arg
 35 40 45
 Thr Glu Leu Gly Arg His Thr Gly Met His Asn Ser Ala Phe Ser Gly
 50 55 60
 Phe Met Leu Gly Pro Phe Phe Trp Leu Leu Phe Lys Ser Pro Gln Leu
 65 70 75 80
 Ala Ala Gln Pro Ser Thr Tyr Leu Ala Val Ala Glu Glu Leu Glu Ser
 85 90 95
 Val Ser Gly Lys Tyr Phe Asp Gly Leu Arg Glu Lys Ala Pro Ser Pro
 100 105 110
 Glu Ala Glu Asp Glu Glu Val Ala Arg Arg Leu Trp Thr Glu Ser Ala
 115 120 125
 His Leu Val Gly Leu Asp Met Ala His Gly Ser Ser Gly Arg Gly His
 130 135 140
 Ser Ile Ser Arg
 145

<210> 42
 <211> 228
 <212> PRT
 <213> Mouse

<400> 42
 Met Gly Phe Leu Leu Leu Leu Leu His Ala Ala Ile Ala Gly His
 1 5 10 15
 Lys Asn Tyr Gly Thr His Asn His Cys Trp Leu Ser Leu His Arg Gly
 20 25 30
 Phe Ile Trp Ser Phe Leu Gly Pro Ala Ala Ala Ile Ile Leu Ile Asn
 35 40 45
 Leu Val Phe Tyr Phe Leu Ile Ile Trp Ile Leu Arg Ser Lys Leu Ser
 50 55 60
 Ser Leu Asn Lys Glu Val Ser Thr Leu Gln Asp Thr Lys Val Met Thr
 65 70 75 80
 Phe Lys Ala Ile Val Gln Leu Phe Val Leu Gly Cys Ser Trp Gly Ile

[illegible]

```
<210> 43
<211> 373
<212> PRT
<213> Mouse
```

<400> 43

Met 1	Lys	Glu	Tyr	Val 5	Met	Leu	Leu	Leu	Leu 10	Ala	Val	Cys	Ser	Ala 15	Lys
Pro	Phe	Phe	Ser 20	Pro	Ser	His	Thr	Ala 25	Leu	Lys	Asn	Met 30	Met	Leu	Lys
Asp	Met	Glu 35	Asp	Thr	Asp	Asp	Asp 40	Asp	Asn	Asp	Asp 45	Asp	Asn	Asn	Ser
Leu	Phe 50	Pro	Thr	Lys	Glu 55	Pro	Val	Asn	Pro	Phe 60	Phe	Pro	Phe	Asp	Leu
Phe 65	Pro	Thr	Cys	Pro	Phe 70	Gly	Cys	Gln	Cys 75	Tyr	Ser	Arg	Val	Val 80	His
Cys	Ser	Asp	Leu	Gly 85	Leu	Thr	Ser	Val	Pro 90	Asn	Asn	Ile	Pro	Phe 95	Asp
Thr	Arg	Met	Val 100	Asp	Leu	Gln	Asn	Asn 105	Lys	Ile	Lys	Glu 110	Ile	Lys	Glu
Asn	Asp	Phe 115	Lys	Gly	Leu	Thr	Ser 120	Leu	Tyr	Ala	Leu	Ile 125	Leu	Asn	Asn
Asn	Lys 130	Leu	Thr	Lys	Ile	His 135	Pro	Lys	Thr	Phe 140	Leu	Thr 145	Thr	Lys	Lys
Leu 145	Arg	Arg	Leu	Tyr 150	Leu	Ser	His	Asn	Gln 155	Leu	Ser	Glu 160	Ile	Pro	Leu
Asn	Leu	Pro	Lys 165	Ser	Leu	Ala	Glu	Leu 170	Arg	Ile	His	Asp 175	Asn	Lys	Val
Lys	Lys	Ile 180	Gln	Lys	Asp	Thr	Phe 185	Lys	Gly	Met	Asn	Ala 190	Leu	His	Val
Leu	Glu 195	Met	Ser	Ala	Asn	Pro	Leu 200	Glu	Asn	Asn	Gly 205	Ile	Glu	Pro	Gly
Ala	Phe 210	Glu	Gly	Val	Thr	Val 215	Phe	His	Ile	Arg	Ile 220	Ala	Glu	Ala	Lys
Leu 225	Thr	Ser	Ile	Pro 230	Lys	Gly	Leu	Pro	Pro 235	Thr	Leu	Leu	Glu	Leu	His
Leu	Asp	Phe	Asn	Lys	Ile	Ser	Thr	Val	Glu	Leu	Glu	Asp	Leu	Lys	Arg

```

                245                250                255
Tyr Arg Glu Leu Gln Arg Leu Gly Leu Gly Asn Asn Arg Ile Thr Asp
                260                265                270
Ile Glu Asn Gly Thr Phe Ala Asn Ile Pro Arg Val Arg Glu Ile His
                275                280                285
Leu Glu His Asn Lys Leu Lys Lys Ile Pro Ser Gly Leu Gln Glu Leu
                290                295                300
Lys Tyr Leu Gln Ile Ile Phe Leu His Tyr Asn Ser Ile Ala Lys Val
305                310                315                320
Gly Val Asn Asp Phe Cys Pro Thr Val Pro Lys Met Lys Lys Ser Leu
                325                330                335
Tyr Ser Ala Ile Ser Leu Phe Asn Asn Pro Met Lys Tyr Trp Glu Ile
                340                345                350
Gln Pro Ala Thr Phe Arg Cys Val Leu Gly Arg Met Ser Val Gln Leu
                355                360                365
Gly Asn Val Gly Lys
                370

```

<210> 44

<211> 466

<212> PRT

<213> Mouse

<400> 44

```

Met Trp Gly Cys Trp Leu Gly Leu Leu Leu Leu Leu Leu Ala Gly Gln
 1                5                10                15
Ala Ala Leu Glu Ala Arg Arg Ser Arg Trp Arg Arg Glu Leu Ala Pro
                20                25                30
Gly Leu His Leu Arg Gly Ile Arg Asp Ala Gly Gly Arg Tyr Cys Gln
                35                40                45
Glu Gln Asp Met Cys Cys Arg Gly Arg Ala Asp Glu Cys Ala Leu Pro
                50                55                60
Tyr Leu Gly Ala Thr Cys Tyr Cys Asp Leu Phe Cys Asn Arg Thr Val
65                70                75                80
Ser Asp Cys Cys Pro Asp Phe Trp Asp Phe Cys Leu Gly Ile Pro Pro
                85                90                95
Pro Phe Pro Pro Val Gln Gly Cys Met His Gly Gly Arg Ile Tyr Pro
                100                105                110
Val Phe Gly Thr Tyr Trp Asp Asn Cys Asn Arg Cys Thr Cys His Glu
                115                120                125
Gly Gly His Trp Glu Cys Asp Gln Glu Pro Cys Leu Val Asp Pro Asp
                130                135                140
Met Ile Lys Ala Ile Asn Arg Gly Asn Tyr Gly Trp Gln Ala Gly Asn
145                150                155                160
His Ser Ala Phe Trp Gly Met Thr Leu Asp Glu Gly Ile Arg Tyr Arg
                165                170                175
Leu Gly Thr Ile Arg Pro Ser Ser Thr Val Met Asn Met Asn Glu Ile
                180                185                190
Tyr Thr Val Leu Gly Gln Gly Glu Val Leu Pro Thr Ala Phe Glu Ala
                195                200                205
Ser Glu Lys Trp Pro Asn Leu Ile His Glu Pro Leu Asp Gln Gly Asn
                210                215                220
Cys Ala Gly Ser Trp Ala Phe Ser Thr Ala Ala Val Ala Ser Asp Arg
225                230                235                240
Val Ser Ile His Ser Leu Gly His Met Thr Pro Ile Leu Ser Pro Gln
                245                250                255
Asn Leu Leu Ser Cys Asp Thr His His Gln Gln Gly Cys Arg Gly Gly

```

[illegible]

```
<210> 45
<211> 422
<212> PRT
<213> Mouse
```

<400>	45															
Met	Asp	Phe	Trp	Leu	Trp	Leu	Leu	Tyr	Phe	Leu	Pro	Val	Ser	Gly	Ala	
1				5					10					15		
Leu	Arg	Val	Leu	Pro	Glu	Val	Gln	Leu	Asn	Val	Glu	Trp	Gly	Gly	Ser	
			20					25					30			
Ile	Ile	Ile	Glu	Cys	Pro	Leu	Pro	Gln	Leu	His	Val	Arg	Met	Tyr	Leu	
		35					40				45					
Cys	Arg	Gln	Met	Ala	Lys	Pro	Gly	Ile	Cys	Ser	Thr	Val	Val	Ser	Asn	
	50					55					60					
Thr	Phe	Val	Lys	Lys	Glu	Tyr	Glu	Arg	Arg	Val	Thr	Leu	Thr	Pro	Cys	
65				70						75				80		
Leu	Asp	Lys	Lys	Leu	Phe	Leu	Val	Glu	Met	Thr	Gln	Leu	Thr	Glu	Asn	
				85					90					95		
Asp	Asp	Gly	Ile	Tyr	Ala	Cys	Gly	Val	Gly	Met	Lys	Thr	Asp	Lys	Gly	
			100					105					110			
Lys	Thr	Gln	Lys	Ile	Thr	Leu	Asn	Val	His	Asn	Glu	Tyr	Pro	Glu	Pro	
		115					120					125				
Phe	Trp	Glu	Asp	Glu	Trp	Thr	Ser	Glu	Arg	Pro	Arg	Trp	Leu	His	Arg	
	130					135				140						
Phe	Leu	Gln	His	Gln	Met	Pro	Trp	Leu	His	Gly	Ser	Glu	His	Pro	Ser	
145				150						155				160		
Ser	Ser	Gly	Val	Ile	Ala	Lys	Val	Thr	Thr	Pro	Ala	Ser	Lys	Thr	Glu	
				165				170						175		
Ala	Pro	Pro	Val	His	Gln	Pro	Ser	Ser	Ile	Thr	Ser	Val	Thr	Gln	His	

```

      180      185      190
Pro Arg Val Tyr Arg Ala Phe Ser Val Ser Ala Thr Lys Ser Pro Ala
      195      200      205
Leu Leu Pro Ala Thr Thr Ala Ser Lys Thr Ser Thr Gln Gln Ala Ile
      210      215      220
Arg Pro Leu Glu Ala Ser Tyr Ser His His Thr Arg Leu His Glu Gln
      225      230      235      240
Arg Thr Arg His His Gly Pro His Tyr Gly Arg Glu Asp Arg Gly Leu
      245      250      255
His Ile Pro Ile Pro Glu Phe His Ile Leu Ile Pro Thr Phe Leu Gly
      260      265      270
Phe Leu Leu Leu Val Leu Leu Gly Leu Val Val Lys Arg Ala Ile Gln
      275      280      285
Arg Arg Arg Ala Ser Ser Arg Arg Ala Gly Arg Leu Ala Met Arg Arg
      290      295      300
Arg Gly Arg Gly Ala Ser Arg Pro Phe Pro Thr Gln Arg Arg Asp Ala
      305      310      315      320
Pro Gln Arg Pro Arg Ser Gln Asn Asn Val Tyr Ser Ala Cys Pro Arg
      325      330      335
Arg Ala Arg Gly Pro Asp Ser Leu Gly Pro Ala Glu Ala Pro Leu Leu
      340      345      350
Asn Ala Pro Ala Ser Ala Ser Pro Ala Ser Pro Gln Val Leu Glu Ala
      355      360      365
Pro Trp Pro His Thr Pro Ser Leu Lys Met Ser Cys Glu Tyr Val Ser
      370      375      380
Leu Gly Tyr Gln Pro Ala Val Asn Leu Glu Asp Pro Asp Ser Asp Asp
      385      390      395      400
Tyr Ile Asn Ile Pro Asp Pro Ser His Leu Pro Ser Tyr Ala Pro Gly
      405      410      415
Pro Arg Ser Ser Cys Gln
      420

```

<210> 46
 <211> 228
 <212> PRT
 <213> Mouse

```

<400> 46
Met Lys Ala Leu Arg Ala Val Leu Leu Ile Leu Leu Leu Ser Gly Gln
  1      5      10      15
Pro Gly Ser Gly Trp Ala Gln Glu Asp Gly Asp Ala Asp Pro Glu Pro
      20      25      30
Glu Asn Tyr Asn Tyr Asp Asp Asp Asp Glu Glu Glu Glu Glu Glu
      35      40      45
Thr Asn Met Ile Pro Gly Ser Arg Asp Arg Ala Pro Leu Gln Cys Tyr
      50      55      60
Phe Cys Gln Val Leu His Ser Gly Glu Ser Cys Asn Gln Thr Gln Ser
      65      70      75      80
Cys Ser Ser Ser Lys Pro Phe Cys Ile Thr Leu Val Ser His Ser Gly
      85      90      95
Thr Asp Lys Gly Tyr Leu Thr Thr Tyr Ser Met Trp Cys Thr Asp Thr
      100      105      110
Cys Gln Pro Ile Ile Lys Thr Val Gly Gly Thr Gln Met Thr Gln Thr
      115      120      125
Cys Cys Gln Ser Thr Leu Cys Asn Ile Pro Pro Trp Gln Asn Pro Gln
      130      135      140
Val Gln Asn Pro Leu Gly Gly Arg Ala Asp Ser Pro Leu Glu Ser Gly

```

145					150					155				160
Thr	Arg	His	Pro	Gln	Gly	Gly	Lys	Phe	Ser	His	Pro	Gln	Val	Val
				165					170					175
Ala	Ala	His	Pro	Gln	Ser	Asp	Gly	Ala	Asn	Leu	Pro	Lys	Ser	Gly
			180					185					190	
Ala	Asn	Gln	Pro	Gln	Gly	Ser	Gly	Ala	Gly	Tyr	Pro	Ser	Gly	Trp
		195					200				205			
Lys	Phe	Gly	Asn	Ile	Ala	Leu	Leu	Leu	Ser	Phe	Phe	Thr	Cys	Leu
	210					215					220			
Ala	Ser	Gly	Ala											
225														

<210> 47

<211> 269

<212> PRT

<213> Mouse

<400> 47

Gly	Cys	Ser	Asp	Gly	Glu	Asn	Gln	Arg	Ser	Gly	His	Leu	Ser	Val	Ser
1				5					10					15	
Leu	Gln	Leu	Ser	Leu	Lys	Val	Leu	Leu	Ile	Arg	Met	Ala	Ser	Gly	Trp
			20					25					30		
Phe	Tyr	Leu	Ser	Cys	Met	Val	Leu	Gly	Ser	Leu	Gly	Ser	Met	Cys	Ile
		35					40					45			
Leu	Phe	Thr	Ala	Tyr	Trp	Met	Gln	Tyr	Trp	Arg	Gly	Gly	Phe	Ala	Trp
	50					55					60				
Asp	Gly	Thr	Val	Leu	Met	Phe	Asn	Trp	His	Pro	Val	Leu	Met	Val	Ala
65					70					75					80
Gly	Met	Val	Val	Leu	Tyr	Gly	Ala	Ala	Ser	Leu	Val	Tyr	Arg	Leu	Pro
				85					90					95	
Ser	Ser	Trp	Val	Gly	Pro	Arg	Leu	Pro	Trp	Lys	Val	Leu	His	Ala	Ala
			100					105					110		
Leu	His	Leu	Leu	Ala	Phe	Thr	Cys	Thr	Val	Val	Gly	Leu	Ile	Ala	Val
		115					120					125			
Phe	Arg	Phe	His	Asn	His	Ser	Arg	Ile	Ala	His	Leu	Tyr	Ser	Leu	His
	130					135					140				
Ser	Trp	Leu	Gly	Ile	Thr	Thr	Val	Val	Leu	Phe	Ala	Cys	Gln	Trp	Phe
145					150					155					160
Leu	Gly	Phe	Ala	Val	Phe	Leu	Leu	Pro	Trp	Ala	Ser	Gln	Trp	Leu	Arg
			165						170					175	
Ser	Leu	Leu	Lys	Pro	Leu	His	Val	Phe	Phe	Gly	Ala	Cys	Ile	Leu	Ser
			180					185					190		
Leu	Ser	Ile	Thr	Ser	Val	Ile	Ser	Gly	Ile	Asn	Glu	Lys	Leu	Phe	Phe
		195					200					205			
Val	Leu	Lys	Asn	Ala	Thr	Lys	Pro	Tyr	Ser	Ser	Leu	Pro	Gly	Glu	Ala
	210					215					220				
Val	Phe	Ala	Asn	Ser	Thr	Gly	Leu	Leu	Val	Val	Ala	Phe	Gly	Leu	Leu
225					230					235					240
Val	Leu	Tyr	Val	Leu	Leu	Ala	Ser	Ser	Trp	Lys	Arg	Pro	Asp	Pro	Gly
			245						250					255	
Ala	Leu	Thr	Asp	Arg	Gln	Pro	Leu	Leu	His	Asp	Arg	Glu			
			260					265							

<210> 48

<211> 188

<212> PRT

<213> Mouse

<400> 48

```

Met Arg Leu Pro Leu Pro Leu Leu Leu Leu Phe Gly Cys Arg Ala Ile
 1          5          10          15
Leu Gly Ser Ala Gly Asp Arg Val Ser Leu Ser Ala Ser Ala Pro Thr
          20          25          30
Leu Asp Asp Glu Glu Lys Tyr Ser Ala His Met Pro Ala His Leu Arg
          35          40          45
Cys Asp Ala Cys Arg Ala Val Ala Phe Gln Met Gly Gln Arg Leu Ala
          50          55          60
Lys Ala Glu Ala Lys Ser His Thr Pro Asp Ala Ser Gly Leu Gln Glu
65          70          75          80
Leu Ser Glu Ser Thr Tyr Thr Asp Val Leu Asp Gln Thr Cys Ser Gln
          85          90          95
Asn Trp Gln Ser Tyr Gly Val His Glu Val Asn Gln Met Lys Arg Leu
          100          105          110
Thr Gly Pro Gly Leu Ser Lys Gly Pro Glu Pro Arg Ile Ser Val Met
          115          120          125
Ile Ser Gly Gly Pro Trp Pro Asn Arg Leu Ser Lys Thr Cys Phe His
          130          135          140
Tyr Leu Gly Glu Phe Gly Glu Asp Gln Ile Tyr Glu Ala Tyr Arg Gln
145          150          155          160
Gly Gln Ala Asn Leu Glu Ala Leu Leu Cys Gly Gly Thr His Gly Pro
          165          170          175
Cys Ser Gln Glu Ile Leu Ala Gln Arg Glu Glu Leu
          180          185

```

<210> 49

<211> 247

<212> PRT

<213> Mouse

<400> 49

```

Met Ile Pro Gln Val Val Thr Ser Glu Thr Val Thr Val Ile Ser Pro
 1          5          10          15
Asn Gly Ile Ser Phe Pro Gln Thr Asp Lys Pro Gln Pro Ser His Gln
          20          25          30
Ser Gln Asp Arg Leu Lys Lys His Leu Lys Ala Glu Ile Lys Val Met
          35          40          45
Ala Ala Ile Gln Ile Met Cys Ala Val Met Val Leu Ser Leu Gly Ile
          50          55          60
Ile Leu Ala Ser Val Pro Ser Asn Leu His Phe Thr Ser Val Phe Ser
65          70          75          80
Ile Leu Leu Glu Ser Gly Tyr Pro Phe Val Gly Ala Leu Phe Phe Ala
          85          90          95
Ile Ser Gly Ile Leu Ser Ile Val Thr Glu Lys Lys Met Thr Lys Pro
          100          105          110
Leu Val His Ser Ser Leu Ala Leu Ser Ile Leu Ser Val Leu Ser Ala
          115          120          125
Leu Thr Gly Ile Ala Ile Leu Ser Val Ser Leu Ala Ala Leu Glu Pro
          130          135          140
Ala Leu Gln Gln Cys Lys Leu Ala Phe Thr Gln Leu Asp Thr Thr Gln
145          150          155          160
Asp Ala Tyr His Phe Phe Ser Pro Glu Pro Leu Asn Ser Cys Phe Val
          165          170          175
Ala Lys Ala Ala Leu Thr Gly Val Phe Ser Leu Met Leu Ile Ser Ser
          180          185          190

```

Val Leu Glu Leu Gly Leu Ala Val Leu Thr Ala Thr Leu Trp Trp Lys
 195 200 205
 Gln Ser Ser Ser Ala Phe Ser Gly Asn Val Ile Phe Leu Ser Gln Asn
 210 215 220
 Ser Lys Asn Lys Ser Ser Val Ser Ser Glu Ser Leu Cys Asn Pro Thr
 225 230 235 240
 Tyr Glu Asn Ile Leu Thr Ser
 245

<210> 50
 <211> 182
 <212> PRT
 <213> Mouse

<400> 50
 Pro Phe His Cys His Val Trp Ser Leu Cys Leu Gln Gly Ser Lys Gln
 1 5 10 15
 Ser Gly Leu Cys Gln Val Gln Arg Asp Leu Gly Arg Asp Asp Arg Ser
 20 25 30
 Val Arg Gly Ser Lys Ala Ala Val Val Ala Gly Ala Val Val Gly Thr
 35 40 45
 Phe Val Gly Leu Val Leu Ile Ala Gly Leu Val Leu Leu Tyr Gln Arg
 50 55 60
 Arg Ser Lys Thr Leu Glu Glu Leu Ala Asn Asp Ile Lys Glu Asp Ala
 65 70 75 80
 Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser Asp Thr Ile Ser
 85 90 95
 Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg Pro
 100 105 110
 Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr Pro Thr Pro Ser
 115 120 125
 Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro Arg Val Asp Glu
 130 135 140
 Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly Val Ser Ser Ser
 145 150 155 160
 Ala Leu Ser Arg Met Gly Ala Val Pro Val Met Val Pro Ala Gln Ser
 165 170 175
 Gln Ala Gly Ser Leu Val
 180

<210> 51
 <211> 248
 <212> PRT
 <213> Mouse

<400> 51
 Met Ser Trp Ser Pro Ile Leu Pro Phe Leu Ser Leu Leu Leu Leu Leu
 1 5 10 15
 Phe Pro Leu Glu Val Pro Arg Ala Ala Thr Ala Ser Leu Ser Gln Ala
 20 25 30
 Ser Ser Glu Gly Thr Thr Thr Cys Lys Val His Asp Val Cys Leu Leu
 35 40 45
 Gly Pro Arg Pro Leu Pro Pro Ser Pro Pro Val Arg Val Ser Leu Tyr
 50 55 60
 Tyr Glu Ser Leu Cys Gly Ala Cys Arg Tyr Phe Leu Val Arg Asp Leu
 65 70 75 80
 Phe Pro Thr Trp Leu Met Val Met Glu Ile Met Asn Ile Thr Leu Val

[illegible]

[illegible]

```
<210> 53
<211> 409
<212> PRT
<213> Mouse
```

<400>	53														
Met	Lys	Leu	Lys	Gln	Arg	Val	Val	Leu	Leu	Ala	Ile	Leu	Leu	Val	Ile
1				5					10					15	
Phe	Ile	Phe	Thr	Lys	Val	Phe	Leu	Ile	Asp	Asn	Leu	Asp	Thr	Ser	Ala
			20					25					30		
Ala	Asn	Arg	Glu	Asp	Gln	Arg	Ala	Phe	His	Arg	Met	Met	Thr	Gly	Leu
		35					40					45			
Arg	Val	Glu	Leu	Val	Pro	Lys	Leu	Asp	His	Thr	Leu	Gln	Ser	Pro	Trp
	50					55					60				
Glu	Ile	Ala	Ala	Gln	Trp	Val	Val	Pro	Arg	Glu	Val	Tyr	Pro	Glu	Glu
65				70						75				80	
Thr	Pro	Glu	Leu	Gly	Ala	Ile	Met	His	Ala	Met	Ala	Thr	Lys	Lys	Ile
				85					90					95	
Ile	Lys	Ala	Asp	Val	Gly	Tyr	Lys	Gly	Thr	Gln	Leu	Lys	Ala	Leu	Leu
			100					105					110		
Ile	Leu	Glu	Gly	Gly	Gln	Lys	Val	Val	Phe	Lys	Pro	Lys	Arg	Tyr	Ser
		115					120					125			
Arg	Asp	Tyr	Val	Val	Glu	Gly	Glu	Pro	Tyr	Ala	Gly	Tyr	Asp	Arg	His
	130					135					140				
Asn	Ala	Glu	Val	Ala	Ala	Phe	His	Leu	Asp	Arg	Ile	Leu	Gly	Phe	Arg
145				150						155					160
Arg	Ala	Pro	Leu	Val	Val	Gly	Arg	Tyr	Val	Asn	Leu	Arg	Thr	Glu	Val
				165					170					175	
Lys	Pro	Val	Ala	Thr	Glu	Gln	Leu	Leu	Ser	Thr	Phe	Leu	Thr	Val	Gly
			180					185					190		
Asn	Asn	Thr	Cys	Phe	Tyr	Gly	Lys	Cys	Tyr	Tyr	Cys	Arg	Glu	Thr	Glu
	195					200						205			
Pro	Ala	Cys	Ala	Asp	Gly	Asp	Met	Met	Glu	Gly	Ser	Val	Thr	Leu	Trp
	210					215					220				
Leu	Pro	Asp	Val	Trp	Pro	Leu	Gln	Lys	His	Arg	His	Pro	Trp	Gly	Arg
225				230						235					240
Thr	Tyr	Arg	Glu	Gly	Lys	Leu	Ala	Arg	Trp	Glu	Tyr	Asp	Glu	Ser	Tyr
				245					250					255	
Cys	Asp	Ala	Val	Lys	Lys	Thr	Ser	Pro	Tyr	Asp	Ser	Gly	Pro	Arg	Leu
		260						265					270		
Leu	Asp	Ile	Ile	Asp	Thr	Ala	Val	Phe	Asp	Tyr	Leu	Ile	Gly	Asn	Ala
	275						280					285			
Asp	Arg	His	His	Tyr	Glu	Ser	Phe	Gln	Asp	Asp	Glu	Gly	Ala	Ser	Met
	290					295					300				
Leu	Ile	Leu	Leu	Asp	Asn	Ala	Lys	Ser	Phe	Gly	Asn	Pro	Ser	Leu	Asp
305				310						315					320
Glu	Arg	Ser	Ile	Leu	Ala	Pro	Leu	Tyr	Gln	Cys	Cys	Ile	Ile	Arg	Val
				325					330					335	
Ser	Thr	Trp	Asn	Arg	Leu	Asn	Tyr	Leu	Lys	Asn	Gly	Val	Leu	Lys	Ser

[illegible]

```
<210> 54
<211> 697
<212> PRT
<213> Mouse
```

<400>	54														
Met	Arg	Leu	Thr	Val	Gly	Ala	Leu	Leu	Ala	Cys	Ala	Ala	Leu	Gly	Leu
1				5					10					15	
Cys	Leu	Ala	Val	Pro	Asp	Lys	Thr	Val	Lys	Trp	Cys	Ala	Val	Ser	Glu
			20					25					30		
His	Glu	Asn	Thr	Lys	Cys	Ile	Ser	Phe	Arg	Asp	His	Met	Lys	Thr	Val
		35					40					45			
Leu	Pro	Pro	Asp	Gly	Pro	Arg	Leu	Ala	Cys	Val	Lys	Lys	Thr	Ser	Tyr
	50					55					60				
Pro	Asp	Cys	Ile	Lys	Ala	Ile	Ser	Ala	Ser	Glu	Ala	Asp	Ala	Met	Thr
65					70					75				80	
Leu	Asp	Gly	Gly	Trp	Val	Tyr	Asp	Ala	Gly	Leu	Thr	Pro	Asn	Asn	Leu
				85					90					95	
Lys	Pro	Val	Ala	Ala	Glu	Phe	Tyr	Gly	Ser	Val	Glu	His	Pro	Gln	Thr
			100					105					110		
Tyr	Tyr	Tyr	Ala	Val	Ala	Val	Val	Lys	Lys	Gly	Thr	Asp	Phe	Gln	Leu
		115					120					125			
Asn	Gln	Leu	Glu	Gly	Lys	Lys	Ser	Cys	His	Thr	Gly	Leu	Gly	Arg	Ser
	130					135					140				
Ala	Gly	Trp	Val	Ile	Pro	Ile	Gly	Leu	Leu	Phe	Cys	Lys	Leu	Ser	Glu
145					150					155				160	
Pro	Arg	Ser	Pro	Leu	Glu	Lys	Ala	Val	Ser	Ser	Phe	Phe	Ser	Gly	Ser
				165					170					175	
Cys	Val	Pro	Cys	Ala	Asp	Pro	Val	Ala	Phe	Pro	Lys	Leu	Cys	Gln	Leu
			180					185					190		
Cys	Pro	Gly	Cys	Gly	Cys	Ser	Ser	Thr	Gln	Pro	Phe	Phe	Gly	Tyr	Val
		195					200					205			
Gly	Ala	Phe	Lys	Cys	Leu	Lys	Asp	Gly	Gly	Gly	Asp	Val	Ala	Phe	Val
	210					215					220				
Lys	His	Thr	Thr	Ile	Phe	Glu	Val	Leu	Pro	Glu	Lys	Ala	Asp	Arg	Asp
225					230					235				240	
Gln	Tyr	Glu	Leu	Leu	Cys	Leu	Asp	Asn	Thr	Arg	Lys	Pro	Val	Asp	Gln
				245					250					255	
Tyr	Glu	Asp	Cys	Tyr	Leu	Ala	Arg	Ile	Pro	Ser	His	Ala	Val	Val	Ala
			260					265					270		
Arg	Lys	Asn	Asn	Gly	Lys	Glu	Asp	Leu	Ile	Trp	Glu	Ile	Leu	Lys	Val
		275					280					285			
Ala	Gln	Glu	His	Phe	Gly	Lys	Gly	Lys	Ser	Lys	Asp	Phe	Gln	Leu	Phe
	290					295					300				
Ser	Ser	Pro	Leu	Gly	Lys	Asp	Leu	Leu	Phe	Lys	Asp	Ser	Ala	Phe	Gly
305					310					315					320
Leu	Leu	Arg	Val	Pro	Pro	Arg	Met	Asp	Tyr	Arg	Leu	Tyr	Leu	Gly	His

				325							330			335		
Asn	Tyr	Val	Thr	Ala	Ile	Arg	Asn	Gln	Gln	Glu	Gly	Val	Cys	Pro	Glu	
				340								350				
Gly	Ser	Ile	Asp	Asn	Ser	Pro	Val	Lys	Trp	Cys	Ala	Leu	Ser	His	Leu	
				355								365				
Glu	Arg	Thr	Lys	Cys	Asp	Glu	Trp	Ser	Ile	Ile	Ser	Glu	Gly	Lys	Ile	
				370								380				
Glu	Cys	Glu	Ser	Ala	Glu	Thr	Thr	Glu	Asp	Cys	Ile	Glu	Lys	Ile	Val	
				385	390							395			400	
Asn	Gly	Glu	Ala	Asp	Ala	Met	Thr	Leu	Asp	Gly	Gly	His	Ala	Tyr	Ile	
				405								415				
Ala	Gly	Gln	Cys	Gly	Leu	Val	Pro	Val	Met	Ala	Glu	Tyr	Tyr	Glu	Ser	
				420								430				
Ser	Asn	Cys	Ala	Ile	Pro	Ser	Gln	Gln	Gly	Ile	Phe	Pro	Lys	Gly	Tyr	
				435								445				
Tyr	Ala	Val	Ala	Val	Val	Lys	Ala	Ser	Asp	Thr	Ser	Ile	Thr	Trp	Asn	
				450	455							460				
Asn	Leu	Lys	Gly	Lys	Lys	Ser	Cys	His	Thr	Gly	Val	Asp	Arg	Thr	Ala	
465				470							475			480		
Gly	Trp	Asn	Ile	Pro	Met	Gly	Met	Leu	Tyr	Asn	Arg	Ile	Asn	His	Cys	
				485								495				
Lys	Phe	Asp	Glu	Phe	Phe	Ser	Gln	Gly	Cys	Ala	Pro	Gly	Tyr	Glu	Lys	
				500				505				510				
Asn	Ser	Thr	Leu	Cys	Asp	Leu	Cys	Ile	Gly	Pro	Leu	Lys	Cys	Ala	Pro	
				515	520							525				
Asn	Asn	Lys	Glu	Glu	Tyr	Asn	Gly	Tyr	Thr	Gly	Ala	Phe	Arg	Cys	Leu	
				530	535							540				
Val	Glu	Lys	Gly	Asp	Val	Ala	Phe	Val	Lys	His	Gln	Thr	Val	Leu	Asp	
545				550							555			560		
Asn	Thr	Glu	Gly	Lys	Asn	Pro	Ala	Glu	Trp	Ala	Lys	Asn	Leu	Lys	Gln	
				565				570				575				
Glu	Asp	Phe	Glu	Leu	Leu	Cys	Pro	Asp	Gly	Thr	Arg	Lys	Pro	Val	Lys	
				580				585				590				
Asp	Phe	Ala	Ser	Cys	His	Leu	Ala	Gln	Ala	Pro	Asn	His	Val	Val	Val	
				595	600							605				
Ser	Arg	Lys	Glu	Lys	Ala	Ala	Arg	Val	Lys	Ala	Val	Leu	Thr	Ser	Gln	
				610	615							620				
Glu	Thr	Leu	Phe	Gly	Gly	Ser	Asp	Cys	Thr	Gly	Asn	Phe	Cys	Leu	Phe	
625				630							635			640		
Lys	Ser	Thr	Thr	Lys	Asp	Leu	Leu	Phe	Arg	Asp	Asp	Thr	Lys	Cys	Phe	
				645				650				655				
Val	Lys	Leu	Pro	Glu	Gly	Thr	Thr	Pro	Glu	Lys	Tyr	Leu	Gly	Ala	Glu	
				660	665							670				
Tyr	Met	Gln	Ser	Val	Gly	Asn	Met	Arg	Lys	Cys	Ser	Thr	Ser	Arg	Leu	
				675	680							685				
Leu	Glu	Ala	Cys	Thr	Phe	His	Lys	His								
				690	695											

```
<210> 55
<211> 400
<212> PRT
<213> Mouse
```

<400> 55
Gly Ala Pro Thr Pro Ala Tyr Val Arg Ser Ala Arg Arg Thr Glu Pro
1 5 10 15
Leu Ala Ser Gly Ala Arg Ser Arg Leu Cys Gln Cys Arg Arg Val Pro

<400> 56
Met Pro Ala Cys Arg Leu Cys Leu Leu Ala Ala Gly Leu Leu Leu Gly
1 5 10 15
Leu Leu Leu Phe Thr Pro Ile Ser Ala Thr Gly Thr Asp Ala Glu Lys

			20					25					30				
Pro	Gly	Glu	Cys	Pro	Gln	Leu	Glu	Pro	Ile	Thr	Asp	Cys	Val	Leu	Glu		
		35					40					45					
Cys	Thr	Leu	Asp	Lys	Asp	Cys	Ala	Asp	Asn	Arg	Lys	Cys	Cys	Gln	Ala		
	50					55					60						
Gly	Cys	Ser	Ser	Val	Cys	Ser	Lys	Pro	Asn	Gly	Pro	Ser	Glu	Gly	Glu		
65					70					75					80		
Leu	Ser	Gly	Thr	Asp	Thr	Lys	Leu	Ser	Glu	Thr	Gly	Thr	Thr	Thr	Gln		
			85						90					95			
Ser	Ala	Gly	Leu	Asp	His	Thr	Thr	Lys	Pro	Pro	Gly	Gly	Gln	Val	Ser		
			100					105					110				
Thr	Lys	Pro	Pro	Ala	Val	Thr	Arg	Glu	Gly	Leu	Gly	Val	Arg	Glu	Lys		
		115					120					125					
Gln	Gly	Thr	Cys	Pro	Ser	Val	Asp	Ile	Pro	Lys	Leu	Gly	Leu	Cys	Glu		
	130					135					140						
Asp	Gln	Cys	Gln	Val	Asp	Ser	Gln	Cys	Ser	Gly	Asn	Met	Lys	Cys	Cys		
145					150					155					160		
Arg	Asn	Gly	Cys	Gly	Lys	Met	Ala	Cys	Thr	Thr	Pro	Lys	Phe				
				165					170								

<210> 57
 <211> 173
 <212> PRT
 <213> Mouse

<400> 57																	
Val	Arg	Asn	Gly	Asp	Leu	Phe	Phe	Lys	Lys	Val	Gln	Val	Glu	Asp	Gly		
1				5					10					15			
Gly	Val	Tyr	Thr	Cys	Tyr	Ala	Met	Gly	Glu	Thr	Phe	Asn	Glu	Thr	Leu		
			20					25					30				
Ser	Val	Glu	Leu	Lys	Val	Tyr	Asn	Phe	Thr	Leu	His	Gly	His	His	Asp		
		35					40					45					
Thr	Leu	Asn	Thr	Ala	Tyr	Thr	Thr	Leu	Val	Gly	Cys	Ile	Leu	Ser	Val		
	50					55				60							
Val	Leu	Val	Leu	Ile	Tyr	Leu	Tyr	Leu	Thr	Pro	Cys	Arg	Cys	Trp	Cys		
65				70					75					80			
Arg	Gly	Val	Glu	Lys	Pro	Ser	Ser	His	Gln	Gly	Asp	Ser	Leu	Ser	Ser		
				85					90					95			
Ser	Met	Leu	Ser	Thr	Thr	Pro	Asn	His	Asp	Pro	Met	Ala	Gly	Gly	Asp		
			100				105						110				
Lys	Asp	Asp	Gly	Phe	Asp	Arg	Arg	Val	Ala	Phe	Leu	Glu	Pro	Ala	Gly		
		115					120					125					
Pro	Gly	Gln	Gly	Gln	Asn	Gly	Lys	Leu	Lys	Pro	Gly	Asn	Thr	Leu	Pro		
	130					135					140						
Val	Pro	Glu	Ala	Thr	Gly	Lys	Gly	Gln	Arg	Arg	Met	Ser	Asp	Pro	Glu		
145					150					155					160		
Ser	Val	Ser	Ser	Val	Phe	Ser	Asp	Thr	Pro	Ile	Val	Val					
				165					170								

<210> 58
 <211> 88
 <212> PRT
 <213> Mouse

<400> 58																	
Met	Glu	Glu	Ile	Thr	Cys	Ala	Phe	Leu	Leu	Leu	Leu	Ala	Gly	Leu	Pro		
1				5					10					15			

Ala Leu Glu Ala Ser Asp Pro Val Asp Lys Asp Ser Pro Phe Tyr Tyr
 20 25 30
 Asp Trp Glu Ser Leu Gln Leu Gly Gly Leu Ile Phe Gly Gly Leu Leu
 35 40 45
 Cys Ile Ala Gly Ile Ala Met Ala Leu Ser Gly Lys Cys Lys Cys Arg
 50 55 60
 Arg Thr His Lys Pro Ser Ser Leu Pro Gly Lys Ala Thr Pro Leu Ile
 65 70 75 80
 Ile Pro Gly Ser Ala Asn Thr Cys
 85

<210> 59
 <211> 171
 <212> PRT
 <213> Mouse

<400> 59
 Leu Ser Val Val Leu Gly Gly Thr Leu Tyr Ile Gly His Tyr Leu Ala
 1 5 10 15
 Met Tyr Ser Glu Gly Ala Pro Phe Trp Thr Gly Ile Val Ala Met Leu
 20 25 30
 Ala Gly Ala Val Ala Phe Leu His Lys Lys Arg Gly Gly Thr Cys Trp
 35 40 45
 Ala Leu Met Arg Thr Leu Leu Val Leu Ala Ser Phe Cys Thr Ala Val
 50 55 60
 Ala Ala Ile Val Ile Gly Ser Arg Glu Leu Asn Tyr Tyr Trp Tyr Phe
 65 70 75 80
 Leu Gly Asp Asp Val Cys Gln Arg Asp Ser Ser Tyr Gly Trp Ser Thr
 85 90 95
 Met Pro Arg Thr Thr Pro Val Pro Glu Glu Ala Asp Arg Ile Ala Leu
 100 105 110
 Cys Ile Tyr Tyr Thr Ser Met Leu Lys Thr Leu Leu Met Ser Leu Gln
 115 120 125
 Ala Met Leu Leu Gly Ile Trp Val Leu Leu Leu Ala Ser Leu Thr
 130 135 140
 Pro Val Cys Val Tyr Ile Trp Lys Arg Phe Phe Thr Lys Ala Glu Thr
 145 150 155 160
 Glu Glu Lys Lys Leu Leu Gly Ala Ala Val Ile
 165 170

<210> 60
 <211> 318
 <212> PRT
 <213> Mouse

<400> 60
 Met Leu Gln His Thr Ser Leu Val Leu Leu Leu Ala Ser Ile Trp Thr
 1 5 10 15
 Thr Arg His Pro Val Gln Gly Ala Asp Leu Val Gln Asp Leu Ser Ile
 20 25 30
 Ser Thr Cys Arg Ile Met Gly Val Ala Leu Val Gly Arg Asn Lys Asn
 35 40 45
 Pro Gln Met Asn Phe Thr Glu Ala Asn Glu Ala Cys Lys Met Leu Gly
 50 55 60
 Leu Thr Leu Ala Ser Arg Asp Gln Val Glu Ser Ala Gln Lys Ser Gly
 65 70 75 80
 Phe Glu Thr Cys Ser Tyr Gly Trp Val Gly Glu Gln Phe Ser Val Ile

```

      85              90              95
Pro Arg Ile Phe Ser Asn Pro Arg Cys Gly Lys Asn Gly Lys Gly Val
      100              105              110
Leu Ile Trp Asn Ala Pro Ser Ser Gln Lys Phe Lys Ala Tyr Cys His
      115              120              125
Asn Ser Ser Asp Thr Trp Val Asn Ser Cys Ile Pro Glu Ile Val Thr
      130              135              140
Thr Phe Tyr Pro Val Leu Asp Thr Gln Thr Pro Ala Thr Glu Phe Ser
145              150              155
Val Ser Ser Ser Ala Tyr Leu Ala Ser Ser Pro Asp Ser Thr Thr Pro
      165              170              175
Val Ser Ala Thr Thr Arg Ala Pro Pro Leu Thr Ser Met Ala Arg Lys
      180              185              190
Thr Lys Lys Ile Cys Ile Thr Glu Val Tyr Thr Glu Pro Ile Thr Met
      195              200              205
Ala Thr Glu Thr Glu Ala Phe Val Ala Ser Gly Ala Ala Phe Lys Asn
      210              215              220
Glu Ala Ala Gly Phe Gly Gly Val Pro Thr Ala Leu Leu Val Leu Ala
225              230              235
Leu Leu Phe Phe Gly Ala Ala Ala Val Leu Ala Val Cys Tyr Val Lys
      245              250              255
Arg Tyr Val Lys Ala Phe Pro Phe Thr Thr Lys Asn Gln Gln Lys Glu
      260              265              270
Met Ile Glu Thr Lys Val Val Lys Glu Glu Lys Ala Asp Asp Val Asn
      275              280              285
Ala Asn Glu Glu Ser Lys Lys Thr Ile Lys Asn Pro Glu Glu Ala Lys
      290              295              300
Ser Pro Pro Lys Thr Thr Val Arg Cys Leu Glu Ala Glu Val
305              310              315

```

<210> 61
 <211> 93
 <212> PRT
 <213> Mouse

```

<400> 61
Ala His Met Val Trp Ala Asn Leu Ala Val Phe Val Ile Cys Phe Leu
 1              5              10              15
Pro Leu His Val Val Leu Thr Val Gln Val Ser Leu Asn Leu Asn Thr
      20              25              30
Cys Ala Ala Arg Asp Thr Phe Ser Arg Ala Leu Ser Ile Thr Gly Lys
      35              40              45
Leu Ser Asp Thr Asn Cys Cys Leu Asp Ala Ile Cys Tyr Tyr Tyr Met
      50              55              60
Ala Arg Glu Phe Gln Glu Ala Ser Lys Pro Ala Thr Ser Ser Asn Thr
65              70              75              80
Pro His Lys Ser Gln Asp Ser Gln Ile Leu Ser Leu Thr
      85              90

```

<210> 62
 <211> 408
 <212> PRT
 <213> Mouse

```

<400> 62
Met Ala Gln Leu Ala Arg Ala Thr Arg Ser Pro Leu Ser Trp Leu Leu
 1              5              10              15

```

Leu Leu Phe Cys Tyr Ala Leu Arg Lys Ala Gly Gly Asp Ile Arg Val
 20 25 30
 Leu Val Pro Tyr Asn Ser Thr Gly Val Leu Gly Gly Ser Thr Thr Leu
 35 40 45
 His Cys Ser Leu Thr Ser Asn Glu Asn Val Thr Ile Thr Gln Ile Thr
 50 55 60
 Trp Met Lys Lys Asp Ser Gly Gly Ser His Ala Leu Val Ala Val Phe
 65 70 75 80
 His Pro Lys Lys Gly Pro Asn Ile Lys Glu Pro Glu Arg Val Lys Phe
 85 90 95
 Leu Ala Ala Gln Asp Leu Arg Asn Ala Ser Leu Ala Ile Ser Asn
 100 105 110
 Leu Ser Val Glu Asp Glu Gly Ile Tyr Glu Cys Gln Ile Ala Thr Phe
 115 120 125
 Pro Arg Gly Ser Arg Ser Thr Asn Ala Trp Leu Lys Val Gln Ala Arg
 130 135 140
 Pro Lys Asn Thr Ala Glu Ala Leu Glu Pro Ser Pro Thr Leu Ile Leu
 145 150 155 160
 Gln Asp Val Ala Lys Cys Ile Ser Ala Asn Gly His Pro Pro Gly Arg
 165 170 175
 Ile Ser Trp Pro Ser Asn Val Asn Gly Ser His Arg Glu Met Lys Glu
 180 185 190
 Pro Gly Ser Gln Pro Gly Thr Thr Thr Val Thr Ser Tyr Leu Ser Met
 195 200 205
 Val Pro Ser Arg Gln Ala Asp Gly Lys Asn Ile Thr Cys Thr Val Glu
 210 215 220
 His Glu Ser Leu Gln Glu Leu Asp Gln Leu Leu Val Thr Leu Ser Gln
 225 230 235 240
 Pro Tyr Pro Pro Glu Asn Val Ser Ile Ser Gly Tyr Asp Gly Asn Trp
 245 250 255
 Tyr Val Gly Leu Thr Asn Leu Thr Leu Thr Cys Glu Ala His Ser Lys
 260 265 270
 Pro Ala Pro Asp Met Ala Gly Tyr Asn Trp Ser Thr Asn Thr Gly Asp
 275 280 285
 Phe Pro Asn Ser Val Lys Arg Gln Gly Asn Met Leu Leu Ile Ser Thr
 290 295 300
 Val Glu Asp Gly Leu Asn Asn Thr Val Ile Val Cys Glu Val Thr Asn
 305 310 315 320
 Ala Leu Gly Ser Gly Gln Gly Gln Val His Ile Ile Val Lys Glu Lys
 325 330 335
 Pro Glu Asn Met Gln Gln Asn Thr Arg Leu His Leu Gly Tyr Ile Phe
 340 345 350
 Leu Ile Val Phe Val Leu Ala Val Val Ile Ile Ile Ala Ala Leu Tyr
 355 360 365
 Thr Ile Arg Arg Cys Arg His Gly Arg Ala Leu Gln Ser Asn Pro Ser
 370 375 380
 Glu Arg Glu Asn Val Gln Tyr Ser Ser Val Asn Gly Asp Cys Arg Leu
 385 390 395 400
 Asn Met Glu Pro Asn Ser Thr Arg
 405

<210> 63
 <211> 278
 <212> PRT
 <213> Mouse

<400> 63

```

Met Phe Leu Val Gly Ser Leu Val Val Leu Cys Gly Leu Leu Ala His
 1      5      10      15
Ser Thr Ala Gln Leu Ala Gly Leu Pro Leu Pro Leu Gly Gln Gly Pro
      20      25      30
Pro Leu Pro Leu Asn Gln Gly Pro Pro Leu Pro Leu Asn Gln Gly Gln
      35      40      45
Leu Leu Pro Leu Ala Gln Gly Leu Pro Leu Ala Val Ser Pro Ala Leu
      50      55      60
Pro Ser Asn Pro Thr Asp Leu Leu Ala Gly Lys Phe Thr Asp Ala Leu
65      70      75      80
Ser Gly Gly Leu Leu Ser Gly Gly Leu Leu Gly Ile Leu Glu Asn Ile
      85      90      95
Pro Leu Leu Asp Val Ile Lys Ser Gly Gly Gly Asn Ser Asn Gly Leu
      100      105      110
Val Gly Gly Leu Leu Gly Lys Leu Thr Ser Ser Val Pro Leu Leu Asn
      115      120      125
Asn Ile Leu Asp Ile Lys Ile Thr Asp Pro Gln Leu Leu Glu Leu Gly
130      135      140
Leu Val Gln Ser Pro Asp Gly His Arg Leu Tyr Val Thr Ile Pro Leu
145      150      155      160
Gly Leu Thr Leu Asn Val Asn Met Pro Val Val Gly Ser Leu Leu Gln
      165      170      175
Leu Ala Val Lys Leu Asn Ile Thr Ala Glu Val Leu Ala Val Lys Asp
      180      185      190
Asn Gln Gly Arg Ile His Leu Val Leu Gly Asp Cys Thr His Ser Pro
      195      200      205
Gly Ser Leu Lys Ile Ser Leu Leu Asn Gly Val Thr Pro Val Gln Ser
210      215      220
Phe Leu Asp Asn Leu Thr Gly Ile Leu Thr Lys Val Leu Pro Glu Leu
225      230      235      240
Ile Gln Gly Lys Val Cys Pro Leu Val Asn Gly Ile Leu Ser Gly Leu
      245      250      255
Asp Val Thr Leu Val His Asn Ile Ala Glu Leu Leu Ile His Gly Leu
      260      265      270
Gln Phe Val Ile Lys Val
      275

```

<210> 64

<211> 264

<212> PRT

<213> Mouse

<400> 64

```

Met Ala Thr Thr Thr Cys Gln Val Val Gly Leu Leu Leu Ser Leu Leu
 1      5      10      15
Gly Leu Ala Gly Cys Ile Ala Ala Thr Gly Met Asp Met Trp Ser Thr
      20      25      30
Gln Asp Leu Tyr Asp Asn Pro Val Thr Ala Val Phe Gln His Glu Gly
      35      40      45
Leu Trp Arg Ser Cys Val Gln Gln Ser Ser Gly Phe Thr Glu Cys Arg
      50      55      60
Pro Tyr Phe Thr Ile Leu Gly Leu Pro Ala Met Leu Gln Ala Val Arg
65      70      75      80
Ala Leu Met Ile Val Gly Ile Val Leu Gly Val Ile Gly Ile Leu Val
      85      90      95
Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Asp Asp Ser
      100      105      110

```

Ala Lys Ala Lys Met Thr Leu Thr Ser Gly Ile Leu Phe Ile Ile Ser
 115 120 125
 Gly Ile Cys Ala Ile Ile Gly Val Ser Val Phe Ala Asn Met Leu Val
 130 135 140
 Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Ser Gly Met Gly Gly
 145 150 155 160
 Met Gly Gly Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe Gly Ala
 165 170 175
 Ala Leu Phe Val Gly Trp Val Ala Gly Gly Leu Thr Leu Ile Gly Gly
 180 185 190
 Val Met Met Cys Ile Ala Cys Arg Gly Leu Thr Pro Asp Asp Ser Asn
 195 200 205
 Phe Lys Ala Val Ser Tyr His Ala Ser Gly Gln Asn Val Ala Tyr Arg
 210 215 220
 Pro Gly Gly Phe Lys Ala Ser Thr Gly Phe Gly Ser Asn Thr Arg Asn
 225 230 235 240
 Lys Lys Ile Tyr Asp Gly Gly Ala Arg Thr Glu Asp Asp Glu Gln Ser
 245 250 255
 His Pro Thr Lys Tyr Asp Tyr Val
 260

<210> 65
 <211> 132
 <212> PRT
 <213> Mouse

<400> 65
 Ala His Pro Arg Pro Gly Ala Arg Arg Pro Arg Leu Leu Ala Phe Gln
 1 5 10 15
 Ala Ser Cys Ala Pro Ala Pro Gly Ser Arg Asp Arg Cys Pro Glu Glu
 20 25 30
 Gly Gly Pro Arg Cys Leu Arg Val Tyr Ala Gly Leu Ile Gly Thr Val
 35 40 45
 Val Thr Pro Asn Tyr Leu Asp Asn Val Ser Ala Arg Val Ala Pro Trp
 50 55 60
 Cys Gly Cys Ala Ala Ser Gly Asn Arg Arg Glu Cys Glu Ala Phe
 65 70 75 80
 Arg Lys Leu Phe Thr Arg Asn Pro Cys Leu Asp Gly Ala Ile Gln Ala
 85 90 95
 Phe Asp Ser Leu Gln Pro Ser Val Leu Gln Asp Gln Thr Ala Gly Cys
 100 105 110
 Cys Phe Pro Arg Val Ser Trp Leu Tyr Ala Leu Thr Ala Leu Ala Leu
 115 120 125
 Gln Ala Leu Leu
 130

<210> 66
 <211> 764
 <212> DNA
 <213> Mouse

<400> 66
 gcagcaccce gcgccaagcg caccaggcac cgcgacagac ggcaggagca cccatcgacg 60
 ggcgtactgg agcgagccga gcagagcaga gagaggcgtg cttgaaaccg agaaccaagc 120
 cgggcggcgat ccccgggccg ccgcacgcac aggcgggcgc cctccttgcc tccctgctcc 180
 ccaccgcgcc cctccggcca gcatgaggct cctggcggcc gcgctgctcc tgctgctcct 240
 ggcgctgtgc gcctcgcgcg tggacgggtc caagtgtgtaag tgttcccggga aggggcccga 300

gatccgctac	agcgacgtga	agaagctgga	aatgaagcca	aagtaccac	actgcgagga	360
gaagatggtt	atcgtcacca	ccaagagcat	gtccaggtac	cggggccagg	agcactgcct	420
gcaccctaag	ctgcagagca	ccaaacgctt	catcaagtgg	tacaatgcct	ggaacgagaa	480
gcgcagggtc	tacgaagaat	aggggtggacg	atcatggaaa	gaaaaactcc	aggccagttg	540
agagacttca	gcagaggact	ttgcagatta	aaataaaagc	cctttctttc	tcacaagcat	600
aagacaaatt	atatattgct	atgaagctct	tcttaccagg	gtcagttttt	acattttata	660
gctgtgtgtg	aaaggcttcc	agatgtgaga	tccagctcgc	ctgcgcacca	gacttcatta	720
caagtggcctt	tttgctgggc	ggttggcggg	gggcgggggg	acct		764

<210> 67

<211> 288

<212> DNA

<213> Human

<400> 67

gcggccgcgc	tgctcctgct	gctgctggcg	ctgtacaccg	cgctgtgga	cggttccaaa	60
tgcaagtgct	cccgaaggg	acccaagatc	cgctacagcg	acgtgaagaa	gctggaaatg	120
aagccaaagt	accgcactg	cgaggagaag	atggttatca	tcaccaccaa	gagcgtgtcc	180
aggtaccgag	gtcaggagca	ctgcctgcac	cccaagctgc	agagcaccaa	gcgcttcac	240
aagtgggtaca	acgcctggaa	cgagaagcgc	aggtctctacg	aagaatag		288

<210> 68

<211> 95

<212> PRT

<213> Human

<400> 68

Ala	Ala	Ala	Leu	Leu	Leu	Leu	Leu	Ala	Leu	Tyr	Thr	Ala	Arg	Val
1			5					10				15		
Asp	Gly	Ser	Lys	Cys	Lys	Cys	Ser	Arg	Lys	Gly	Pro	Lys	Ile	Arg
			20					25				30		
Ser	Asp	Val	Lys	Lys	Leu	Glu	Met	Lys	Pro	Lys	Tyr	Pro	His	Cys
			35				40				45			
Glu	Lys	Met	Val	Ile	Ile	Thr	Thr	Lys	Ser	Val	Ser	Arg	Tyr	Arg
			50			55					60			
Gln	Glu	His	Cys	Leu	His	Pro	Lys	Leu	Gln	Ser	Thr	Lys	Arg	Phe
65					70				75					80
Lys	Trp	Tyr	Asn	Ala	Trp	Asn	Glu	Lys	Arg	Arg	Val	Tyr	Glu	Glu
			85					90					95	

<210> 69

<211> 234

<212> DNA

<213> Mouse

<400> 69

tccaagtgtg	agtgttcccg	gaagggggccc	aagatccgct	acagcgacgt	gaagaagctg	60
gaaatgaagc	caaagtaccc	acactgcgag	gagaagatgg	ttatcgtcac	caccaagagc	120
atgtccagg	accggggcca	ggagcactgc	ctgcacccta	agctgcagag	caccaaaccg	180
ttcatcaagt	ggtacaatgc	ctggaacgag	aagcgcagg	tctacgaaga	atag	234

<210> 70

<211> 77

<212> PRT

<213> Mouse

<400> 70

```

Ser Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp
 1          5          10          15
Val Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys
      20          25          30
Met Val Ile Val Thr Thr Lys Ser Met Ser Arg Tyr Arg Gly Gln Glu
      35          40          45
His Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp
      50          55          60
Tyr Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu
65          70          75

```

<210> 71
 <211> 234
 <212> DNA
 <213> Human

```

<400> 71
tccaaatgca agtgctcccg gaagggaccc aagatccgct acagcgacgt gaagaagctg      60
gaaatgaagc caaagtaccc gcactgcgag gagaagatgg ttatcatcac caccaagagc      120
gtgtccaggt accgaggtca ggagcactgc ctgcacccca agctgcagag caccaagcgc      180
ttcatcaagt ggtacaacgc ctggaacgag aagcgcaggg tctacgaaga atag          234

```

<210> 72
 <211> 77
 <212> PRT
 <213> Human

```

<400> 72
Ser Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp
 1          5          10          15
Val Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys
      20          25          30
Met Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu
      35          40          45
His Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp
      50          55          60
Tyr Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu
65          70          75

```

<210> 73
 <211> 1460
 <212> DNA
 <213> Pinus radiata

```

<400> 73
aaaacgtcca tagcttcctt gccaaactgca agcaatacag tacaagagcc agacgatcga      60
atcctgtgaa gtggttctga agtgatggga agcttggaat ctgaaaaaac tggttacagga      120
tatgcagctc gggactccag tggccacttg tccccttaca cttacaatct cagaaagaaa      180
ggacctgagg atgtaattgt aaaggtcatt tactgcggaa tctgccactc tgatttagtt      240
caaatgcgta atgaaatgga catgtctcat tacccaatgg tccctgggca tgaagtgggtg      300
gggattgtaa cagagattgg cagcgagggtg aagaaattca aagtgggaga gcatgtaggg      360
gttggttgca ttgttgggtc ctgtcgcagt tgcggtaatt gcaatcagag catggaacaa      420
tactgcagca agaggatttg gacctacaat gatgtgaacc atgacggcac acctactcag      480
ggcggatttg caagcagtat ggtggttgat cagatgtttg tggttcgaat cccggagaat      540
cttcctctgg aacaagcggc ccctctgtta tgtgcagggg ttacagtttt cagcccaatg      600
aagcattttc ccatgacaga gcccggaag aaatgtggga ttttgggttt aggaggcgtg      660
gggcacatgg gtgtcaagat tgccaaagcc tttggactcc acgtgacggt tatcagttcg      720

```

tctgataaaa	agaaagaaga	agccatggaa	gtcctcggcg	ccgatgctta	tcttgtttagc	780
aaggatactg	aaaagatgat	ggaagcagca	gagagcctag	attacataat	ggacaccatt	840
ccagttgctc	atcctctgga	accatatctt	gcccttctga	agacaaatgg	aaagctagtg	900
atgctgggcg	ttgttccaga	gccgttgcac	ttcgtgactc	ctctcttaat	acttgggaga	960
aggagcatag	ctggaagttt	cattggcagc	atggaggaaa	cacaggaaac	tctagatttc	1020
tgtgcagaga	agaaggtatc	atcgatgatt	gaggttgtgg	gcctggacta	catcaacacg	1080
gccatggaaa	ggttggagaa	gaacgatgtc	cgttacagat	ttgtgggtgga	tgttgctaga	1140
agcaagttgg	ataattagtc	tgcaatcaat	caatcagatc	aatgcctgca	tgcaagatga	1200
atagatctgg	actagtagct	taacatgaaa	gggaaattaa	atTTTTtattt	aggaactcga	1260
tactggtttt	tgttacttta	gttttagcttt	tgtgaggttg	aaacaattca	gatgtttttt	1320
taacttgtat	atgtaaagat	caatttctcg	tgacagtaaa	taataatcca	atgtcttctg	1380
ccaaattaat	atatgtattc	gtattttttat	atgaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1440
aaaaaaaaaa	aaaaaaaaaa					1460

<210> 74

<211> 363

<212> DNA

<213> *Eucalyptus grandis*

<400> 74

aaagcaacac	attgaactct	ctctctctct	ctctctctct	ctctctctct	ccccacccc	60
cccttcccaa	ccccaccac	atacagacaa	gtagatacgc	gcacacagaa	gaagaaaaga	120
tgggggtttc	aatgcagtca	atcgcactag	cgacggttct	ggccgtccta	acgacatggg	180
cgtggagggc	ggtgaactgg	gtgtggctga	ggccgaagag	gctcgagagg	cttctgagac	240
agcaaggtct	ctccggcaag	tcctacacct	tcctggctcg	cgacctcaag	gagaacctgc	300
ggatgctcaa	ggaagccaag	tccaagccca	tcgccgtctc	cgatgacatc	aagcctcgtc	360
tct						363

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ00/00256

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. 7: C12N 15/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

SEE ELECTRONIC DATA BASES

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SEE ELECTRONIC DATA BASES

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EMBL, GenBank, PIR, GenePept: Sequence IDs 1, 36, 2, 37, 3, 38, 4, 39, 5, 40

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenBank Accession No. AL034558 28 July 1999 Whole Sequence w.r.t. Sequence ID 3	1 - 14
X	GenPept Accession No. CAA29045 21 March 1995 Whole Sequence Frame +2 w.r.t. Sequence ID 4	1 - 14
X	GenBank Accession No. AR018857 5 December 1998 & US 5783182 Whole Sequence w.r.t. Sequence ID 5	1 - 14

☒ Further documents are listed in the continuation of Box C ☒ See patent family annex

<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	--	---

Date of the actual completion of the international search
28 March 2001

Date of mailing of the international search report
29.03.2001

Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaustalia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer

CRAIG ALLATT
Telephone No : (02) 6283 2414

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ00/00256

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenPept Accession No. CAB4Q181 14 December 1999 Whole Sequence w.r.t. Sequence ID 40	1 - 14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ00/00256

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Supplemental Box

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Claims 1 - 14 partially.(See Supplemental Box)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ00/00256

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

In the present application, the feature that all sequences come from "mammalian sources" does not provide a special technical feature. Genes and their expressed proteins from "mammalian sources" have been sequenced. Cells from "mammalian sources" comprise a variety of different animals and cell types. Moreover the applicant has provided no evidence that the nucleotide sequences of the present application, and the peptides they express, form a unique group of protein types. On the contrary, putative peptides derived from the nucleotide sequences of the application have functions assigned on the basis of their similarity to known proteins expressed by a variety of cell types.

The applicant has grouped the polynucleotides of the application into activity categories according to putative functions of the proteins they encode. However, most of the applicants' groupings do not form a homogenous set of proteins either in structure or function. Moreover, it is noted that most of the peptides encoded by the polynucleotides are assigned to more than one activity category.

The ISA considers that each nucleotide/peptide sequence pair (defined in Table 1 pages 8 - 19) comprises one invention and that there are 35 different inventions (the inventions being numbered sequentially).

However, as a service to the applicants, the ISA will search the first five inventions without inviting additional search fees.

Therefore the ISA has searched SEQ IDs 1, 36, 2, 37, 3, 38, 4, 39, 5, and 40.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/NZ00/00256

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	5783182	AU	11609/97	CA	2237929	EP	870057
		WO	9718454				
END OF ANNEX							